

Table of Contents

Section I: Patient Survival: Medicare Only

- I.1 Incident patient counts: ESRD patients
by age, gender, race, ethnicity, & primary diagnosis
- I.2 90-day survival probabilities: incident ESRD patients
by age, gender, race, ethnicity, & primary diagnosis
- I.3 One-year survival probabilities: incident ESRD patients
from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis
- I.4 Two-year survival probabilities: incident ESRD patients
from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis
- I.5 Three-year survival probabilities: incident ESRD patients
from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis
- I.6 Five-year survival probabilities: incident ESRD patients
from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis
- I.7 Ten-year survival probabilities: incident ESRD patients
from day 91 to ten years + 90 days, by age, gender, race, ethnicity, & primary diagnosis
- I.8 Incident patient counts: dialysis patients, unknowns dropped
dialysis patients alive on day 91, by age, gender, race, ethnicity, & primary diagnosis
- I.9 90-day survival probabilities: incident dialysis patients
censored at transplant, by age, gender, race, ethnicity, & primary diagnosis
- I.10 One-year survival probabilities: incident dialysis patients
censored at transplant, from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis
- I.11 Two-year survival probabilities: incident dialysis patients
censored at transplant, from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis
- I.12 Three-year survival probabilities: incident dialysis patients
censored at transplant, from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis
- I.13 Five-year survival probabilities: incident dialysis patients
censored at transplant, from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis
- I.14 Ten-year survival probabilities: incident dialysis patients
censored at transplant, from day 91 to ten years + 90 days, by age, gender, race, & primary diagnosis
- I.15 Incident patient counts: hemodialysis patients, unknowns dropped
dialysis patients alive on day 91, by age, gender, race, ethnicity, & primary diagnosis
- I.16 90-day survival probabilities: incident hemodialysis patients
censored at transplant, by age, gender, race, ethnicity, & primary diagnosis

- I.17 One-year survival probabilities: incident hemodialysis patients
censored at transplant, from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis
- I.18 Two-year survival probabilities: incident hemodialysis patients
censored at transplant, from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis
- I.19 Three-year survival probabilities: incident hemodialysis patients
censored at transplant, from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis
- I.20 Five-year survival probabilities: incident hemodialysis patients
censored at transplant, from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis
- I.21 Ten-year survival probabilities: incident hemodialysis patients
censored at transplant, from day 91 to ten years + 90 days, by age, gender, race, & primary diagnosis
- I.22 Incident patient counts: CAPD/CCPD patients, unknowns dropped
dialysis patients alive on day 91, by age, gender, race, ethnicity, & primary diagnosis
- I.23 90-day survival probabilities: incident CAPD/CCPD patients
censored at transplant, by age, gender, race, ethnicity, & primary diagnosis
- I.24 One-year survival probabilities: incident CAPD/CCPD patients
censored at transplant, from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis
- I.25 Two-year survival probabilities: incident CAPD/CCPD patients
censored at transplant, from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis
- I.26 Three-year survival probabilities: incident CAPD/CCPD patients
censored at transplant, from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis
- I.27 Five-year survival probabilities: incident CAPD/CCPD patients
censored at transplant, from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis
- I.28 Ten-year survival probabilities: incident CAPD/CCPD patients
censored at transplant, from day 91 to ten years + 90 days, by age, gender, race, & primary diagnosis
- I.29 90-day patient survival probabilities: first transplants, deceased donors
by age, gender, race/ethnicity, primary diagnosis, & transplant number
- I.30 One-year patient survival probabilities: first transplants, deceased donors
by age, gender, race/ethnicity, primary diagnosis, & transplant number
- I.31 Two-year patient survival probabilities: first transplants, deceased donors
by age, gender, race/ethnicity, primary diagnosis, & transplant number
- I.32 Three-year patient survival probabilities: first transplants, deceased donors
by age, gender, race/ethnicity, primary diagnosis, & transplant number
- I.33 Five-year patient survival probabilities: first transplants, deceased donors
by age, gender, race/ethnicity, primary diagnosis, & transplant number

- I.34 Ten-year patient survival probabilities: first transplants, deceased donors
by age, gender, race/ethnicity, primary diagnosis, & transplant number
- I.35 90-day patient survival probabilities: first transplants, living donors
by age, gender, race/ethnicity, primary diagnosis, & transplant number
- I.36 One-year patient survival probabilities: first transplants, living donors
by age, gender, race/ethnicity, primary diagnosis, & transplant number
- I.37 Two-year patient survival probabilities: first transplants, living donors
by age, gender, race/ethnicity, primary diagnosis, & transplant number
- I.38 Three-year patient survival probabilities: first transplants, living donors
by age, gender, race/ethnicity, primary diagnosis, & transplant number
- I.39 Five-year patient survival probabilities: first transplants, living donors
by age, gender, race/ethnicity, primary diagnosis, & transplant number
- I.40 Ten-year patient survival probabilities: first transplants, living donors
by age, gender, race/ethnicity, primary diagnosis, & transplant number

Table I.1
Incident patient counts: ESRD patients

by age, gender, race, ethnicity, & primary diagnosis

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	
0-4	40	62	89	95	98	123	121	112	116	120	100	135	121	126	97	118	124	108	91	89	118	107	121	109	
5-9	86	78	99	81	95	91	110	100	80	100	112	101	92	97	122	98	95	79	84	91	88	89	117	84	
10-14	161	164	200	180	210	190	186	187	185	166	178	202	195	198	206	204	203	187	177	175	195	176	223	203	
15-19	394	427	406	390	379	386	405	429	422	454	415	389	437	428	404	432	425	349	380	393	365	385	379	408	
20-29	1,392	1,543	1,727	1,670	1,797	1,867	1,934	1,918	2,033	2,171	2,184	2,224	2,286	2,266	2,190	2,094	2,099	1,959	1,985	1,868	1,927	1,962	1,805	1799	
30-39	2,042	2,299	2,538	2,612	2,812	2,996	3,335	3,382	3,698	4,000	4,165	4,346	4,627	4,580	4,710	4,547	4,514	4,248	4,234	4,331	4,192	4,224	4,296	4179	
40-49	2,279	2,541	2,658	2,950	3,106	3,371	3,656	4,077	4,408	5,018	5,415	6,103	6,498	6,767	6,961	7,287	7,666	7,401	7,947	7,945	8,189	8,203	8,483	8776	
50-59	3,464	4,024	4,304	4,394	4,669	4,973	5,254	5,635	6,297	6,783	7,282	7,872	8,658	8,992	9,943	9,920	10,303	11,013	11,775	12,514	12,899	13,568	14,180	14592	
60-64	1,906	2,191	2,451	2,852	3,144	3,495	3,619	4,085	4,421	4,778	5,214	5,780	6,012	6,251	6,459	6,690	6,976	7,144	7,502	7,657	7,939	8,216	8,397	8823	
65-69	1,939	2,016	2,287	2,993	3,091	3,474	4,006	4,566	5,098	5,879	6,543	7,258	7,829	8,155	8,694	8,679	9,471	9,773	10,023	10,102	10,155	10,411	10,665	10901	
70-79	2,152	2,355	2,905	4,081	4,237	4,939	5,703	6,536	7,203	8,517	9,530	11,216	12,527	13,163	14,631	15,044	16,932	18,119	19,093	20,249	20,619	20,720	21,793	21589	
80+	355	396	539	835	894	1,124	1,385	1,598	1,938	2,397	2,768	3,251	3,814	4,133	4,651	5,029	6,014	6,852	7,512	8,452	9,106	9,510	11,001	11248	
Unknown	.	*	*	*	*	*	*	*	*	*	*	.	*	*	*	*	*	.
Male	9,063	10,046	11,152	12,759	13,595	14,706	16,293	17,745	19,366	21,927	23,735	26,217	28,200	29,594	31,388	31,920	34,828	35,968	37,890	39,800	40,834	41,929	44,586	45112	
Female	7,147	8,051	9,054	10,378	10,942	12,335	13,425	14,885	16,535	18,463	20,174	22,660	24,897	25,563	27,683	28,225	29,994	31,264	32,913	34,064	34,958	35,642	36,875	37596	
Unknown	.	.	.	*	*	*	.	.	.	*	.
White	11,338	12,641	14,091	15,756	16,764	18,468	20,371	22,114	24,115	27,064	29,460	32,622	35,254	36,307	38,837	38,963	42,316	43,998	45,999	48,605	50,206	51,185	53,577	54370	
Black	4,439	4,981	5,640	6,785	7,098	7,781	8,404	9,460	10,524	12,042	12,910	14,521	15,861	16,625	17,679	18,094	19,045	19,795	21,082	21,277	21,467	22,168	23,365	23681	
Other race	378	426	461	584	662	779	917	1,041	1,241	1,278	1,536	1,730	1,972	2,210	2,505	3,027	3,426	3,417	3,697	3,957	4,096	4,200	4,501	4624	
Unknown	55	49	14	13	14	13	26	15	21	*	*	*	10	15	50	61	35	22	25	27	23	18	18	36	
†Hispanic	7,179	7,207	7,651	8,347	9,683	8,896	9,498	10046	
†Non-Hispanic	57,643	60,025	63,152	65,519	66,109	68,675	71,963	72665	.
Diabetes	2,461	3,698	4,810	5,592	6,786	7,832	9,122	10,324	11,657	14,043	16,022	18,440	20,366	21,543	23,796	25,713	28,645	30,319	32,187	33,713	35,019	35,989	37,309	37825	
Hypertension	2,857	4,076	5,200	5,667	6,353	7,262	7,929	9,107	10,385	12,095	13,265	14,776	16,482	16,987	18,184	16,239	17,210	18,181	19,101	20,078	20,398	21,012	22,438	23192	
Glomerulonephritis	2,589	3,356	3,930	4,122	4,426	4,648	4,857	5,245	5,561	5,846	6,173	6,430	6,589	6,730	7,117	7,123	7,381	7,079	7,090	7,064	6,858	6,770	7,017	6741	
Cystic kidney	724	887	1,021	1,053	1,074	1,152	1,253	1,290	1,309	1,316	1,451	1,522	1,587	1,637	1,655	1,701	1,595	1,609	1,708	1,749	1,735	1,795	1,841	1876	
Other urologic	420	611	775	868	866	1,061	1,091	1,185	1,176	1,212	1,104	1,301	1,348	1,170	1,198	1,662	1,917	1,887	1,883	2,191	2,074	2,150	2,277	2206	
Other cause	1,613	1,982	2,507	2,744	2,916	3,129	3,225	3,235	3,438	3,941	4,032	4,417	4,760	4,956	5,139	5,568	5,656	5,732	6,154	6,294	6,620	6,721	7,294	7355	
Missing cause	4,129	2,053	786	1,907	890	702	745	596	754	508	364	320	256	353	177	149	122	104	143	196	212	139	223	453	
Unknown cause	1,417	1,434	1,177	1,185	1,227	1,255	1,496	1,648	1,621	1,429	1,498	1,671	1,709	1,781	1,805	1,990	2,296	2,321	2,537	2,581	2,876	2,995	3,062	3063	
All	16,210	18,097	20,206	23,138	24,538	27,041	29,718	32,630	35,901	40,390	43,909	48,877	53,097	55,157	59,071	60,145	64,822	67,232	70,803	73,866	75,792	77,571	81,461	82711	

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with 10 or fewer patients are suppressed.

." Zero values in this cell.

Table I.1 (continued)

Incident patient counts: ESRD patients, unknowns dropped*by age, gender, race, ethnicity, & primary diagnosis*

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	35	54	80	93	95	122	108	105	109	116	98	130	116	120	89	115	121	103	90	86	112	105	115	106
5-9	76	69	93	77	92	85	105	92	79	99	111	99	86	88	113	91	94	78	79	87	82	86	109	80
10-14	147	147	187	171	200	180	175	182	177	152	168	192	184	182	197	193	196	173	162	165	180	152	207	185
15-19	354	394	378	382	365	371	384	408	400	430	401	369	420	411	377	412	393	338	355	369	334	356	343	377
20-29	1,277	1,444	1,632	1,588	1,741	1,783	1,857	1,820	1,926	2,106	2,101	2,137	2,186	2,164	2,097	2,011	1,996	1,844	1,871	1,775	1,808	1,833	1,699	1,688
30-39	1,888	2,164	2,426	2,501	2,703	2,877	3,178	3,247	3,552	3,861	4,026	4,193	4,486	4,434	4,544	4,375	4,328	4,089	4,042	4,157	4,002	4,038	4,102	3,991
40-49	2,109	2,384	2,534	2,835	2,983	3,256	3,513	3,913	4,281	4,875	5,246	5,908	6,303	6,548	6,766	7,091	7,402	7,169	7,660	7,676	7,889	7,873	8,147	8,434
50-59	3,146	3,745	4,100	4,205	4,460	4,778	5,014	5,394	6,062	6,572	7,051	7,639	8,409	8,745	9,671	9,655	10,010	10,737	11,440	12,155	12,534	13,139	13,732	14,100
60-64	1,729	2,010	2,305	2,709	2,976	3,321	3,441	3,891	4,235	4,635	5,046	5,606	5,822	6,065	6,294	6,510	6,752	6,948	7,294	7,451	7,710	7,977	8,151	8,562
65-69	1,719	1,800	2,105	2,772	2,901	3,298	3,790	4,298	4,845	5,669	6,308	7,019	7,611	7,890	8,446	8,375	9,199	9,472	9,724	9,810	9,825	10,079	10,334	10,533
70-79	1,891	2,033	2,633	3,768	3,914	4,587	5,288	6,086	6,716	8,112	9,123	10,748	12,032	12,670	14,081	14,400	16,207	17,380	18,351	19,415	19,733	19,836	20,896	20,740
80+	313	333	486	761	797	1,026	1,252	1,427	1,777	2,233	2,599	3,035	3,593	3,915	4,415	4,712	5,630	6,369	6,984	7,888	8,477	8,845	10,290	10,558
Male	8,189	9,179	10,399	12,031	12,850	13,907	15,357	16,739	18,367	21,055	22,758	25,170	27,093	28,486	30,226	30,630	33,410	34,470	36,282	38,166	38,997	40,055	42,648	43,166
Female	6,495	7,398	8,560	9,831	10,377	11,777	12,748	14,124	15,792	17,805	19,520	21,905	24,155	24,746	26,864	27,310	28,918	30,230	31,770	32,868	33,689	34,264	35,477	36,188
White	10,266	11,500	13,169	14,847	15,813	17,488	19,233	20,859	22,909	26,029	28,322	31,349	33,944	34,984	37,454	37,438	40,544	42,154	44,054	46,526	47,948	48,823	51,175	51,923
Black	4,083	4,681	5,365	6,466	6,795	7,459	8,007	9,029	10,073	11,618	12,475	14,073	15,413	16,120	17,214	17,577	18,480	19,247	20,430	20,667	20,780	21,465	22,607	22,956
Other race	335	396	425	549	619	737	865	975	1,177	1,213	1,481	1,653	1,891	2,128	2,422	2,925	3,304	3,299	3,568	3,841	3,958	4,031	4,343	4,475
†Hispanic																	6,913	6,970	7,369	8,064	9,350	8,609	9,213	9,735
†Non-Hispanic																	55,415	57,730	60,683	62,970	63,336	65,710	68,912	69,619
Diabetes	2,439	3,675	4,798	5,571	6,763	7,800	9,088	10,286	11,609	14,010	15,971	18,396	20,305	21,494	23,729	25,607	28,557	30,228	32,099	33,602	34,919	35,874	37,186	37,709
Hypertension	2,840	4,056	5,184	5,645	6,331	7,235	7,903	9,069	10,353	12,063	13,226	14,736	16,445	16,951	18,130	16,189	17,169	18,128	19,045	20,021	20,333	20,954	22,359	23,115
Glomerulonephritis	2,573	3,345	3,920	4,111	4,418	4,627	4,842	5,233	5,550	5,834	6,157	6,412	6,573	6,711	7,090	7,097	7,357	7,056	7,064	7,037	6,837	6,749	6,994	6,716
Cystic kidney	721	885	1,019	1,049	1,073	1,148	1,250	1,289	1,308	1,312	1,448	1,517	1,585	1,634	1,651	1,699	1,588	1,607	1,702	1,745	1,731	1,790	1,840	1,871
Other urologic	416	610	773	867	862	1,058	1,090	1,183	1,168	1,209	1,099	1,293	1,342	1,163	1,194	1,656	1,908	1,881	1,873	2,182	2,065	2,143	2,262	2,196
Other cause	1,606	1,973	2,493	2,725	2,902	3,121	3,211	3,215	3,428	3,927	4,015	4,402	4,742	4,934	5,121	5,546	5,630	5,696	6,127	6,255	6,590	6,674	7,269	7,318
Missing cause	4,089	2,033	772	1,894	878	695	721	588	743	505	362	319	256	345	175	146	119	104	142	192	211	135	215	429
All	14,684	16,577	18,959	21,862	23,227	25,684	28,105	30,863	34,159	38,860	42,278	47,075	51,248	53,232	57,090	57,940	62,328	64,700	68,052	71,034	72,686	74,319	78,125	79,354

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, race, or primary cause of ESRD are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.2
90-day survival probabilities: incident ESRD patients

by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	100.0	98.4	97.8	100.0	100.0	100.0	98.4	100.0	97.5	96.0	90.0	97.8	99.2	99.2	96.0	98.3	100.0	99.1	98.9	98.9	99.2	99.1	100.0	99.1
5-9	100.0	98.7	100.0	98.8	100.0	100.0	100.0	100.0	97.6	99.0	89.6	99.0	100.0	100.0	99.2	100.0	100.0	100.0	100.0	100.0	98.9	100.0	99.2	100.0
10-14	99.4	100.0	100.0	100.0	99.5	100.0	98.9	100.0	100.0	99.4	92.2	97.1	100.0	100.0	99.5	100.0	100.0	98.9	100.0	100.0	100.0	100.0	100.0	100.0
15-19	99.5	99.8	100.0	100.0	100.0	99.7	99.8	100.0	99.1	99.6	95.8	99.5	99.8	100.0	99.8	100.0	100.0	100.0	100.0	100.0	100.0	99.2	100.0	99.3
20-29	99.1	99.4	99.4	99.0	99.0	99.6	99.3	99.4	99.7	99.3	99.0	99.3	99.3	99.3	99.3	99.4	99.5	99.5	99.7	99.6	99.6	99.6	99.6	99.7
30-39	98.4	98.9	98.9	99.1	99.2	99.0	98.6	99.1	99.2	99.0	98.8	99.1	99.0	99.0	99.0	99.2	98.9	99.1	99.0	99.1	99.1	99.2	99.2	99.2
40-49	98.5	98.2	98.6	98.1	98.7	98.7	98.9	98.6	99.0	98.7	98.6	99.0	98.9	98.8	98.8	98.7	98.6	98.6	98.5	98.6	99.0	98.7	98.5	98.7
50-59	97.4	97.5	97.6	96.9	97.8	97.4	97.7	98.0	97.7	97.8	97.8	98.2	98.3	98.0	97.6	98.1	98.0	98.1	97.8	97.6	97.7	97.6	97.8	97.5
60-64	95.2	95.8	95.6	95.7	96.0	95.4	95.5	96.5	96.2	96.5	96.3	96.6	96.8	96.7	96.6	96.7	96.7	96.4	96.2	96.5	96.4	96.4	96.6	96.7
65-69	90.7	91.1	89.9	91.5	89.8	90.2	91.5	91.2	92.3	91.9	92.2	92.2	92.5	92.9	92.6	92.7	92.9	92.2	92.4	92.6	92.1	92.4	92.7	92.7
70-79	87.1	88.2	87.6	88.4	87.7	87.2	87.9	89.3	88.3	88.5	89.1	89.5	89.6	89.1	89.6	89.3	89.0	88.6	88.7	88.7	88.9	88.2	88.7	88.5
80+	83.5	84.3	84.6	83.0	83.3	82.6	84.5	83.7	85.9	83.9	83.8	84.9	85.3	84.7	84.0	83.7	84.4	83.0	82.3	82.5	82.8	82.4	83.0	82.6
Male	94.8	95.1	94.7	94.2	94.4	93.7	94.0	94.3	94.1	94.0	93.7	94.1	93.9	93.9	93.7	93.6	93.3	92.7	92.6	92.6	92.8	92.3	92.6	92.3
Female	95.2	95.7	95.4	94.7	94.5	94.3	94.6	94.8	94.8	94.2	94.2	94.5	94.7	94.1	93.9	93.8	93.6	92.9	92.8	92.5	92.4	92.4	92.2	92.4
White	94.4	94.9	94.1	93.4	93.6	93.0	93.2	93.4	93.4	92.9	92.8	93.2	93.1	92.8	92.6	92.5	92.2	91.5	91.4	91.3	91.4	91.2	91.2	91.0
Black	96.4	96.6	97.1	96.8	96.3	96.3	96.4	96.8	96.7	96.6	96.3	96.5	96.5	96.4	96.1	96.1	95.8	95.5	95.1	95.2	94.9	94.6	94.9	94.8
Other race	94.3	96.9	96.3	95.8	96.8	95.5	97.4	98.0	96.5	96.7	97.1	97.0	96.8	96.1	96.0	95.4	95.7	95.3	95.2	94.6	95.6	95.0	95.6	95.5
†Hispanic																	95.5	94.8	95.0	95.2	94.5	94.2	95.0	94.4
†Non-Hispanic																	93.2	92.6	92.4	92.2	92.3	92.1	92.1	92.1
Diabetes	96.7	95.9	95.5	95.0	95.4	95.0	95.4	95.3	95.4	95.2	95.1	95.4	95.5	95.0	95.0	94.6	94.5	94.1	93.8	93.7	93.5	93.5	93.7	93.7
Hypertension	96.0	95.0	93.6	93.4	93.1	92.9	93.0	92.8	92.9	92.5	92.0	92.2	92.3	92.3	92.0	91.9	92.1	91.1	91.0	90.9	91.0	90.4	90.8	90.9
Glomerulonephritis	98.4	98.0	97.5	97.3	96.9	96.9	96.7	96.4	97.1	96.2	96.1	96.8	96.7	96.5	96.0	96.8	96.0	95.6	95.4	95.6	96.1	96.0	96.1	96.1
Other cause	93.1	94.2	94.3	93.4	93.2	92.2	92.8	94.3	93.4	93.2	93.3	93.7	93.5	93.3	92.8	92.3	91.4	90.6	91.0	90.8	90.9	90.5	90.3	89.8
All	95.0	95.4	95.0	94.5	94.4	94.0	94.3	94.5	94.4	94.1	93.9	94.2	94.3	94.0	93.8	93.7	93.4	92.8	92.7	92.6	92.6	92.3	92.5	92.3
ADJUSTED																								
0-19	99.2	99.3	99.5	99.8	99.8	99.8	98.9	100.0	98.0	98.0	88.4	97.3	99.5	99.8	98.4	99.5	100.0	99.2	99.7	99.7	99.5	98.9	99.8	99.0
20-44	98.8	99.0	99.0	99.0	99.2	99.2	99.0	99.0	99.3	99.0	98.8	99.1	99.1	99.1	99.0	99.1	98.9	99.0	99.0	99.1	99.2	99.2	99.1	99.2
45-64	97.2	97.2	97.2	96.7	97.3	96.9	97.2	97.6	97.4	97.5	97.3	97.8	97.9	97.7	97.5	97.7	97.7	97.6	97.4	97.4	97.6	97.4	97.6	97.5
65-74	91.0	91.1	89.8	91.4	89.8	89.7	90.8	91.3	91.3	91.4	91.4	91.5	91.8	91.9	92.0	91.6	91.6	91.2	91.4	91.4	91.2	91.0	91.4	91.6
75+	87.4	87.8	87.8	86.9	87.1	86.3	87.0	87.4	87.5	86.4	87.1	87.8	87.7	86.9	86.7	86.7	86.9	85.8	85.5	85.7	86.0	85.5	85.9	85.4
Male	93.1	93.1	92.6	92.9	93.0	92.4	92.9	93.4	93.3	93.3	93.1	93.7	93.6	93.6	93.6	93.5	93.5	93.2	93.1	93.3	93.5	93.0	93.5	93.1
Female	93.5	93.8	93.5	93.6	93.1	93.1	93.8	94.1	94.2	93.8	93.9	94.2	94.6	94.1	94.0	94.0	94.0	93.5	93.5	93.4	93.4	93.4	93.4	93.5
White	92.7	92.9	92.1	92.2	92.3	91.9	92.4	92.9	93.0	92.7	92.7	93.3	93.4	93.2	93.1	93.1	93.2	92.7	92.7	92.8	92.9	92.8	92.9	92.8
Black	95.0	94.4	95.4	95.8	94.6	94.8	95.1	95.6	95.5	95.4	95.1	95.4	95.5	95.3	95.0	95.1	94.9	94.6	94.3	94.4	94.2	93.8	94.3	94.2
Other race	92.4	95.5	93.8	94.4	95.3	93.5	96.3	97.0	95.1	95.5	96.2	96.2	96.0	95.4	95.3	94.9	95.4	95.1	95.0	94.6	95.5	94.8	95.7	95.6
Diabetes	93.9	92.5	92.3	91.9	92.7	92.5	93.3	93.4	93.7	93.7	93.8	94.3	94.6	94.1	94.3	94.0	94.1	93.9	93.6	93.7	93.7	93.7	93.9	93.9
Hypertension	94.5	93.8	92.7	93.0	92.8	92.9	93.3	93.4	93.6	93.4	93.2	93.5	93.6	93.7	93.5	93.5	93.9	93.3	93.3	93.3	93.4	93.0	93.4	93.4
Glomerulonephritis	96.5	95.7	95.1	95.1	94.8	95.1	94.9	94.6	95.6	94.8	94.7	95.8	95.6	95.4	95.1	96.0	95.3	94.9	94.7	95.2	95.6	95.2	95.6	95.4
Other cause	90.9	91.6	91.9	92.4	91.9	90.8	91.6	93.4	92.3	92.3	92.3	92.8	92.8	92.4	92.0	91.9	91.3	90.9	91.3	91.3	91.4	91.1	90.9	90.5
All	93.3	93.4	93.0	93.3	93.1	92.7	93.3	93.7	93.7	93.5	93.5	93.9	94.1	93.9	93.7	93.7	93.4	93.3	93.4	93.4	93.2	93.4	93.3	93.3

Reference cohort is 1996 incident ESRD patients. Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, & age >110 are excluded. Includes U.S. & territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

." Zero values in this cell.

Table I.3

One-year survival probabilities: incident ESRD patients

from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	92.5	91.9	88.8	88.4	85.7	89.4	91.6	91.1	81.7	83.3	82.8	81.5	88.4	87.3	89.7	86.3	94.4	89.8	90.1	93.3	90.7	93.5	90.9	91.4
5-9	93.0	94.9	94.9	97.5	94.7	94.5	98.2	99.0	100.0	97.0	97.3	98.0	96.7	96.9	100.0	97.9	96.8	94.9	100.0	98.9	100.0	96.6	94.9	96.4
10-14	98.1	97.6	98.5	97.8	97.1	97.4	98.9	98.4	96.2	95.2	96.6	98.0	95.4	96.0	99.0	99.0	98.0	97.9	98.3	97.7	97.4	98.3	98.2	99.0
15-19	96.4	96.0	96.0	95.1	96.3	95.9	95.8	96.3	97.9	98.5	97.1	95.9	96.6	96.7	96.3	98.4	96.5	98.3	95.8	98.2	97.3	97.9	97.9	98.0
20-29	91.5	93.1	93.7	93.4	93.2	92.2	94.1	92.3	92.9	93.0	93.3	92.8	94.0	93.6	93.9	93.4	95.2	96.2	96.0	95.9	94.2	95.3	94.3	94.6
30-39	89.3	88.8	88.8	90.0	88.8	89.1	89.7	89.2	89.9	89.8	90.7	90.0	90.7	90.1	90.5	90.5	91.1	92.3	91.9	92.0	92.2	92.3	92.5	92.6
40-49	87.8	87.2	86.5	87.4	87.8	87.6	87.7	87.9	88.7	88.5	89.2	88.2	88.7	89.6	89.5	89.9	90.1	90.5	89.7	90.2	90.6	90.0	90.3	90.1
50-59	83.2	83.0	83.6	81.6	81.8	81.9	82.5	83.2	83.5	83.2	84.4	84.1	85.4	85.2	86.1	86.5	85.8	86.2	86.0	86.3	86.0	86.7	86.5	86.3
60-64	78.1	77.3	77.5	77.2	75.5	76.2	76.8	76.0	76.3	77.6	78.3	78.9	79.4	81.1	80.9	80.6	81.9	82.2	80.5	81.5	81.3	82.1	81.2	82.6
65-69	72.9	73.5	73.8	71.8	72.9	71.0	73.1	73.0	73.1	73.8	75.4	75.1	75.5	77.1	76.2	77.1	77.9	77.0	76.3	76.6	77.1	76.9	76.9	77.5
70-79	67.1	67.8	68.4	65.1	66.5	66.9	66.2	65.3	65.9	67.3	68.4	68.1	68.4	69.9	70.0	70.2	70.8	69.8	69.9	69.6	69.5	69.6	69.5	69.7
80+	57.7	53.3	62.1	55.3	56.1	58.2	58.6	55.2	55.2	57.8	59.3	59.1	58.1	60.8	61.0	60.4	60.1	59.5	57.6	58.3	57.8	57.8	58.8	59.0
Male	81.0	81.5	81.2	78.8	78.8	78.5	78.3	78.0	77.6	78.3	79.1	78.5	78.6	79.9	79.4	79.4	79.5	78.9	78.2	78.4	78.1	78.3	77.9	78.2
Female	81.7	81.1	81.5	79.0	79.5	78.8	79.6	78.0	78.8	78.5	79.1	78.4	78.8	79.0	79.2	79.3	78.9	78.2	77.4	77.1	77.0	77.1	76.8	77.1
White	80.0	79.9	79.9	77.1	77.0	76.8	76.9	75.6	75.6	76.1	76.6	75.8	75.8	77.0	76.9	77.0	76.8	75.8	75.3	75.3	75.2	75.1	74.9	75.4
Black	84.9	85.1	84.7	82.8	83.8	82.7	83.1	83.2	83.2	82.8	84.1	83.3	84.1	84.1	83.7	83.5	84.1	83.8	82.5	82.5	82.0	82.6	82.0	81.6
Other race	80.3	81.3	84.9	81.7	80.9	82.5	85.2	81.6	84.2	85.0	86.1	87.5	86.0	86.7	85.9	84.6	82.7	83.4	82.3	82.6	82.8	84.1	83.0	84.5
†Hispanic																	82.8	82.5	82.6	82.0	82.6	82.9	82.1	82.4
†Non-Hispanic																	78.8	78.1	77.2	77.2	76.8	77.1	76.8	77.0
Diabetes	75.7	74.5	74.0	74.3	74.5	73.8	75.5	75.0	76.3	76.8	77.0	77.2	77.4	79.0	78.8	78.7	78.6	78.0	77.2	77.7	77.7	77.9	77.6	78.3
Hypertension	84.1	82.0	80.5	78.5	77.8	78.6	77.6	76.2	76.1	76.6	77.7	76.5	76.8	77.1	77.3	78.0	77.9	76.6	76.1	75.8	75.9	75.7	75.8	75.6
Glomerulonephritis	91.1	89.4	89.0	88.3	87.8	88.0	86.8	86.4	86.8	86.4	87.1	85.8	87.3	88.3	86.7	87.3	87.8	87.5	87.5	86.8	87.1	87.3	87.4	87.7
Other cause	79.0	80.7	82.9	77.5	79.2	77.9	79.2	78.3	77.6	78.0	79.6	78.7	78.7	78.7	78.8	77.7	77.3	77.5	76.4	76.1	74.9	75.7	74.4	75.1
All	81.3	81.3	81.4	78.9	79.1	78.6	78.9	78.0	78.2	78.4	79.1	78.4	78.7	79.5	79.3	79.3	79.2	78.5	77.8	77.8	77.6	77.8	77.4	77.7
ADJUSTED																								
0-19	93.3	92.8	92.5	91.7	91.4	91.6	93.6	93.8	92.2	92.5	92.1	90.6	92.0	92.1	94.5	94.6	94.4	94.3	93.9	96.1	94.4	95.4	94.4	95.4
20-44	87.8	88.3	88.7	89.3	88.9	88.8	89.4	88.9	89.7	89.4	90.4	89.6	90.2	90.0	90.6	90.5	91.5	92.1	91.7	91.8	91.9	92.1	92.0	92.1
45-64	79.6	79.6	80.3	79.5	79.4	79.8	80.8	80.8	81.3	82.2	83.1	83.2	84.2	85.1	85.4	85.6	85.8	86.3	85.5	86.1	86.0	86.4	86.1	86.3
65-74	70.0	70.5	72.0	68.7	70.1	69.0	70.1	70.2	70.7	71.6	73.2	72.9	73.4	75.3	74.5	75.4	76.1	75.3	75.1	75.3	75.4	75.3	75.0	75.6
75+	61.1	61.7	62.0	58.6	60.8	62.3	61.9	59.2	59.6	62.2	63.2	63.1	62.6	63.9	64.9	64.5	64.7	63.9	63.1	63.2	63.0	63.1	63.6	63.7
Male	72.5	73.1	73.4	71.9	72.1	72.5	72.9	72.9	73.0	74.5	75.9	75.7	76.2	78.0	77.8	78.0	78.8	78.8	78.3	78.9	78.7	79.0	78.9	79.2
Female	74.0	73.6	75.3	73.8	74.7	74.5	76.0	75.0	76.1	76.6	77.7	77.4	78.2	78.6	79.2	79.6	79.7	79.5	78.8	78.8	78.9	79.0	79.0	79.3
White	70.5	70.7	71.9	70.3	70.7	71.1	71.9	71.4	72.1	73.5	74.5	74.4	75.0	76.5	76.9	77.3	77.8	77.5	77.3	77.6	77.7	77.7	77.7	78.2
Black	79.6	79.0	79.1	78.0	78.9	78.0	79.0	79.1	79.2	79.1	80.9	80.3	81.3	81.4	81.2	81.2	82.2	82.2	80.9	80.9	80.7	81.3	80.8	80.4
Other race	70.9	74.1	76.4	75.1	73.9	77.4	81.1	76.8	80.5	81.8	84.0	85.6	84.4	85.5	84.9	84.4	82.8	84.1	82.8	83.6	83.8	84.7	84.0	85.3
Diabetes	68.0	66.8	67.0	67.9	68.7	68.3	70.7	70.7	72.5	73.6	74.3	74.9	75.5	77.4	77.5	77.6	78.0	77.9	77.2	77.9	78.0	78.3	78.2	78.8
Hypertension	80.3	78.9	78.2	77.1	76.5	78.2	77.9	76.9	77.0	77.9	79.2	78.6	78.8	79.5	79.8	80.6	80.9	80.2	79.9	79.8	80.0	79.7	80.2	79.9
Glomerulonephritis	83.4	81.4	81.4	81.2	81.0	82.2	80.7	80.4	81.1	81.4	82.4	81.3	83.2	84.5	83.2	83.8	85.0	84.8	84.9	84.5	84.7	84.4	85.0	85.0
Other cause	73.8	74.4	77.4	74.1	75.1	73.5	75.3	74.6	73.8	74.5	76.1	75.3	75.6	75.4	76.0	75.5	75.5	76.3	75.3	75.4	74.3	74.9	73.9	74.5
All	73.2	73.4	74.3	72.8	73.3	73.5	74.4	73.9	74.5	75.5	76.8	76.6	77.2	78.3	78.5	78.8	79.3	79.1	78.6	78.9	78.8	79.0	78.9	79.2

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, & age >110 are excluded. Includes U.S. & territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.4
Two-year survival probabilities: incident ESRD patients

from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002
0-4	85.0	90.3	84.3	82.1	83.7	82.9	85.7	85.7	76.5	78.3	78.8	78.5	86.0	84.1	83.5	82.9	90.3	86.1	86.8	89.9	85.6	92.5	85.9
5-9	91.9	91.0	92.9	93.8	92.6	93.4	93.6	97.0	97.5	96.0	94.6	98.0	96.7	92.7	97.5	96.9	95.8	93.7	97.6	97.8	100.0	95.5	94.0
10-14	95.6	94.5	96.5	96.7	95.2	95.3	95.7	98.4	94.1	92.8	93.8	97.0	93.8	94.4	98.1	97.1	96.6	96.8	97.7	97.1	96.4	95.5	95.9
15-19	94.9	92.7	93.6	92.5	93.4	94.1	92.8	94.4	95.0	96.9	95.2	93.0	95.0	94.6	95.0	96.7	92.9	95.1	93.7	95.1	94.5	95.6	96.0
20-29	85.9	87.0	88.8	87.0	87.6	86.5	88.6	85.8	88.1	88.5	87.9	87.6	89.1	89.6	90.0	88.7	91.1	91.7	92.5	91.6	90.0	90.6	89.1
30-39	80.2	80.9	80.1	82.1	80.0	80.0	81.2	80.9	82.5	82.2	82.8	81.7	82.7	83.1	82.7	83.8	84.4	85.5	84.8	85.9	85.9	86.0	87.0
40-49	76.7	76.5	76.1	75.9	77.2	77.8	77.2	77.7	78.6	78.2	79.8	77.7	79.5	80.0	80.1	80.9	80.5	81.5	81.3	81.1	81.5	81.7	81.9
50-59	70.2	70.0	70.3	68.1	67.3	67.4	68.2	68.5	68.9	70.3	70.5	70.8	72.1	72.8	73.8	73.6	73.5	74.2	73.2	74.2	74.2	74.9	75.3
60-64	63.1	61.0	60.6	61.2	58.5	58.9	60.0	59.1	60.0	61.2	61.5	62.4	63.0	65.2	65.7	64.9	66.7	66.7	65.2	67.0	67.4	68.0	67.5
65-69	55.1	55.7	55.6	52.0	55.1	52.9	53.9	55.3	55.8	55.9	56.5	56.7	57.9	59.9	58.8	59.8	60.9	59.5	59.4	59.9	61.1	62.4	61.3
70-79	47.0	48.5	49.3	44.1	46.5	47.1	46.3	45.6	46.4	47.6	47.9	48.2	49.1	50.0	50.3	50.7	51.6	49.9	50.9	51.1	50.7	51.7	51.4
80+	30.7	33.5	37.7	30.6	36.1	35.6	34.9	32.6	32.9	37.7	36.7	35.8	36.5	37.4	38.5	38.4	38.2	37.1	37.0	37.2	37.2	37.3	38.3
Male	67.2	68.4	67.9	64.2	64.6	63.3	63.8	62.9	63.3	63.9	64.0	63.3	63.8	65.3	64.7	65.0	64.7	63.7	63.6	63.8	63.8	64.2	63.7
Female	69.3	68.3	68.2	64.4	65.2	65.1	64.4	63.6	64.1	64.1	63.8	63.0	63.9	63.9	64.1	63.9	63.9	62.6	62.1	62.1	61.8	62.9	62.3
White	66.3	66.6	66.1	62.0	62.3	61.8	61.4	60.4	60.1	60.7	60.3	59.5	59.9	60.7	60.6	60.7	60.4	59.0	59.2	59.4	59.4	59.8	59.4
Black	72.6	73.0	72.4	69.2	70.8	69.3	69.9	69.3	71.1	70.5	71.0	69.8	71.3	71.9	71.5	71.3	72.3	71.2	69.8	69.8	69.8	70.7	70.1
Other race	69.2	66.7	73.0	69.3	68.3	67.7	70.5	68.9	71.1	73.1	73.3	76.8	74.1	75.1	73.5	71.5	69.1	70.0	69.5	70.9	70.0	72.8	70.9
†Hispanic																	68.9	68.5	69.2	69.3	70.6	70.3	69.7
†Non-Hispanic																	63.8	62.5	62.1	62.2	61.8	62.7	62.2
Diabetes	58.1	57.1	55.7	57.1	55.5	55.6	56.7	56.8	58.3	59.4	58.7	59.3	60.0	61.6	61.4	61.3	61.4	60.6	60.4	61.2	61.4	62.2	61.7
Hypertension	71.7	68.7	67.0	63.3	64.3	63.4	62.3	60.8	61.6	61.9	61.6	60.7	61.6	61.7	62.3	63.0	62.9	61.0	60.8	60.5	60.7	61.0	60.9
Glomerulonephritis	82.8	80.9	80.4	78.8	78.8	77.5	76.4	76.3	77.3	76.3	77.3	75.3	77.2	78.5	76.9	77.5	77.9	77.2	78.0	77.0	77.7	78.6	78.5
Other cause	65.3	68.1	70.6	62.6	65.8	65.5	66.8	65.7	64.9	66.2	67.6	66.4	66.7	67.1	66.8	65.4	65.1	64.6	64.1	63.8	62.6	63.7	62.4
All	68.1	68.4	68.0	64.3	64.9	64.1	64.1	63.2	63.7	64.0	63.9	63.2	63.9	64.7	64.4	64.4	64.4	63.2	62.9	63.0	62.9	63.6	63.1
ADJUSTED																							
0-19	89.8	87.6	88.2	87.0	87.4	87.5	87.6	90.7	87.4	89.2	88.1	87.3	89.6	88.3	91.3	91.5	89.8	90.4	90.9	92.4	90.6	92.0	90.7
20-44	77.5	79.2	79.9	80.1	80.0	79.8	80.8	80.1	81.9	81.7	82.5	81.1	82.2	82.5	83.0	83.2	84.3	85.4	84.9	85.2	85.2	85.2	85.5
45-64	65.1	64.5	65.3	64.5	63.9	64.4	65.6	65.6	66.5	68.3	68.9	69.3	70.6	72.1	72.9	72.8	73.4	73.9	73.2	74.2	74.4	75.0	75.1
65-74	50.6	52.0	53.2	48.1	51.4	50.1	50.7	51.6	52.7	53.2	53.8	54.2	55.5	56.9	56.4	57.7	58.5	57.2	57.7	58.3	58.5	59.9	59.0
75+	39.0	41.3	40.3	36.0	39.9	40.8	40.0	37.9	38.5	41.8	41.4	41.3	41.8	42.9	43.6	43.2	44.2	42.7	43.2	43.3	43.3	43.7	44.0
Male	54.9	56.3	56.5	54.3	55.3	54.8	56.2	55.7	56.8	58.6	59.3	59.3	60.4	62.4	62.5	63.0	63.8	63.6	63.8	64.6	64.8	65.2	65.1
Female	58.2	57.7	59.0	57.0	58.4	59.0	59.1	59.4	60.3	61.4	61.8	61.8	63.1	63.5	64.2	64.4	65.2	64.6	64.4	64.7	64.8	65.8	65.7
White	53.1	53.9	54.7	52.5	53.6	54.0	54.4	54.6	55.2	57.3	57.5	57.7	58.9	60.2	60.8	61.4	62.1	61.7	62.2	62.9	63.1	63.6	63.7
Black	64.3	63.6	63.6	61.8	63.0	62.2	63.6	63.0	65.0	64.8	65.9	65.2	66.8	67.7	67.8	67.8	69.2	68.7	67.5	67.4	67.8	68.7	68.3
Other race	56.2	56.1	59.6	58.9	58.3	59.6	63.2	61.5	65.1	68.1	69.5	73.5	71.3	72.9	71.8	71.1	69.4	71.2	70.3	72.3	71.6	73.7	72.4
Diabetes	48.0	47.3	46.7	48.8	48.0	48.6	50.3	51.2	53.2	55.1	55.1	56.2	57.5	59.4	59.7	60.0	60.8	60.6	60.5	61.7	62.2	63.0	62.8
Hypertension	65.6	64.1	63.7	61.1	62.5	62.9	62.7	61.8	62.8	63.9	64.0	63.8	64.6	65.3	66.1	66.9	67.5	66.4	66.5	66.4	66.7	66.9	67.4
Glomerulonephritis	69.1	67.8	68.1	67.3	68.1	67.6	66.6	66.7	68.3	68.2	69.6	68.1	70.2	71.9	71.2	71.6	73.1	72.6	73.5	73.2	73.7	73.9	74.5
Other cause	58.1	59.3	62.2	57.6	59.8	59.3	61.1	60.3	59.6	61.4	62.6	61.5	62.4	62.5	62.7	62.3	62.5	62.8	62.5	62.6	61.6	62.6	61.6
All	56.4	57.0	57.7	55.6	56.7	56.8	57.6	57.5	58.5	60.0	60.5	60.5	61.7	63.0	63.3	63.7	64.5	64.1	64.1	64.7	64.8	65.5	65.4

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, & age >110 are excluded. Includes U.S. & territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.5
Three-year survival probabilities: incident ESRD patients

from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
0-4	82.5	88.7	83.1	78.9	81.6	82.1	81.5	81.3	73.9	77.5	77.8	77.8	82.6	79.4	82.5	81.2	87.1	82.4	85.7	87.6	83.1	91.5
5-9	91.9	89.7	91.9	91.4	90.5	91.2	93.6	95.0	96.3	96.0	92.9	98.0	95.7	91.7	95.9	95.9	92.6	93.7	97.6	97.8	96.6	93.3
10-14	94.3	89.0	93.5	95.0	93.3	93.2	94.1	96.3	92.5	92.2	93.3	94.6	91.8	91.9	95.1	96.1	95.1	95.7	97.7	96.6	95.9	94.3
15-19	92.6	90.4	92.1	92.0	91.6	91.2	90.6	92.3	92.9	94.3	93.0	92.0	93.6	93.2	93.8	94.0	91.3	92.0	91.9	92.8	92.3	92.9
20-29	81.5	82.5	84.3	83.2	83.3	82.6	84.1	82.0	84.8	84.8	84.2	84.1	85.6	86.1	86.5	84.8	87.8	88.8	89.2	87.7	86.3	86.4
30-39	75.1	74.8	72.7	75.4	73.7	74.1	75.5	74.1	76.5	76.4	77.0	75.5	76.2	77.4	77.1	78.0	79.2	79.7	79.7	80.4	80.7	80.6
40-49	68.4	68.5	68.2	67.0	68.9	69.4	68.8	69.9	70.8	69.7	71.1	69.9	71.1	71.8	72.2	73.0	72.7	73.5	73.2	73.5	73.2	74.2
50-59	59.6	58.8	58.3	56.5	56.3	55.3	56.5	57.7	57.9	59.1	59.5	59.7	60.1	61.8	62.4	62.4	62.4	63.4	62.8	63.7	64.0	65.0
60-64	51.0	48.6	47.1	48.2	45.7	46.0	45.9	46.3	47.8	48.4	48.4	49.7	49.7	51.7	52.8	52.2	53.4	54.6	53.4	54.3	55.3	55.8
65-69	40.4	42.7	41.9	38.0	41.4	39.6	40.1	41.4	42.5	41.8	42.1	42.7	43.5	45.4	44.9	46.2	46.5	46.1	46.2	46.7	48.1	49.1
70-79	33.6	33.7	34.7	29.6	32.2	32.5	31.7	31.8	32.7	33.7	33.1	34.0	34.0	35.6	35.3	35.9	36.8	35.7	36.4	36.8	37.2	38.1
80+	18.3	20.8	18.6	18.3	21.1	21.9	20.7	21.2	19.8	22.9	22.1	21.7	22.6	22.8	23.2	23.1	24.2	22.9	22.4	22.9	23.6	23.6
Male	57.6	58.3	57.3	53.5	54.2	52.4	52.5	52.4	52.8	53.3	52.7	52.3	52.0	53.8	53.1	53.5	53.2	52.0	52.1	52.2	52.5	52.9
Female	59.3	58.4	57.1	53.5	54.4	54.4	53.5	52.7	53.5	52.4	52.0	51.3	52.0	52.1	52.1	51.7	51.7	51.0	50.3	50.2	50.5	51.6
White	56.6	56.4	55.5	51.1	51.9	50.9	50.2	49.5	49.1	49.3	48.3	47.7	47.5	48.6	48.2	48.4	47.9	46.9	47.1	47.0	47.4	47.9
Black	62.8	63.6	61.2	58.4	59.7	58.5	58.9	59.0	61.4	60.0	60.4	59.3	60.4	61.1	60.8	60.6	61.7	60.7	59.1	59.4	59.8	60.4
Other race	60.4	54.3	62.1	59.9	57.2	57.4	59.7	58.2	60.8	62.7	63.0	66.3	63.4	64.0	63.6	60.0	57.8	57.8	58.3	60.1	59.7	62.1
†Hispanic																	57.5	57.4	58.3	57.9	60.5	59.9
†Non-Hispanic																	51.9	50.8	50.4	50.4	50.3	51.3
Diabetes	45.6	45.0	42.7	43.5	43.0	42.9	43.9	44.1	45.4	45.8	45.4	45.7	46.3	47.6	47.9	47.6	47.8	47.4	47.1	47.8	48.5	49.7
Hypertension	62.3	58.2	55.1	52.4	52.3	52.2	50.6	49.6	50.6	50.6	49.8	49.0	49.4	49.8	49.7	50.9	50.9	49.1	49.0	48.7	49.2	49.1
Glomerulonephritis	76.6	73.5	72.7	71.8	71.1	68.3	67.7	68.1	69.6	67.9	68.6	67.4	68.6	70.3	68.8	69.2	69.0	69.4	69.6	68.3	70.1	70.9
Other cause	55.1	58.1	60.5	51.7	56.5	56.0	56.6	56.5	56.0	57.5	57.8	57.7	57.0	58.4	57.5	56.3	55.8	55.3	55.0	54.8	53.6	54.6
All	58.4	58.3	57.2	53.5	54.3	53.3	53.0	52.5	53.1	52.9	52.4	51.8	52.0	53.0	52.6	52.7	52.5	51.5	51.3	51.3	51.6	52.3
ADJUSTED																						
0-19	86.9	83.0	85.3	84.8	84.3	83.9	84.3	86.8	84.3	86.6	85.5	85.4	86.8	85.0	88.6	88.3	86.7	86.7	89.2	89.9	87.6	88.8
20-44	71.2	72.4	72.4	73.3	73.7	73.4	74.7	73.6	75.7	75.8	76.2	75.0	75.9	76.5	77.0	77.1	78.7	79.5	79.4	79.3	79.2	79.5
45-64	53.6	52.8	52.9	52.3	52.0	52.3	53.2	54.3	55.4	56.8	57.3	58.1	58.8	60.8	61.8	61.9	62.3	63.4	62.9	63.7	64.3	65.0
65-74	36.5	38.2	38.4	33.7	37.7	36.5	36.2	37.6	39.2	39.1	39.3	39.9	41.0	42.5	42.0	43.6	44.3	43.4	44.0	44.9	45.6	47.0
75+	25.5	27.2	25.6	22.7	24.7	26.2	26.2	25.4	24.9	27.7	26.4	27.4	27.0	28.3	28.5	28.2	29.4	28.6	28.6	28.9	29.7	29.8
Male	43.8	44.5	44.3	42.4	43.7	43.0	43.9	44.4	45.5	47.3	47.3	47.9	48.1	50.5	50.5	51.2	52.1	51.9	52.5	53.2	53.7	54.1
Female	46.8	46.5	46.6	45.2	46.7	47.6	47.6	48.0	49.2	49.4	49.7	50.0	51.2	51.7	52.3	52.5	53.3	53.5	53.1	53.4	54.1	55.1
White	42.0	42.2	42.7	40.6	42.3	42.4	42.5	43.3	43.8	45.5	45.3	45.9	46.5	48.1	48.5	49.3	50.1	50.1	50.7	51.2	51.9	52.5
Black	52.8	52.4	50.6	49.7	50.6	50.1	51.5	51.6	54.1	53.2	54.2	53.9	55.0	56.1	56.3	56.4	57.9	57.6	56.3	56.6	57.4	58.1
Other race	45.9	42.6	45.6	47.5	45.3	48.1	50.6	49.3	53.4	56.4	58.1	62.0	59.9	61.1	61.4	59.4	58.1	59.5	59.3	61.9	61.8	63.2
Diabetes	35.4	35.2	33.9	35.2	35.5	36.1	37.4	38.6	40.2	41.5	41.8	42.8	43.8	45.6	46.3	46.5	47.5	47.7	47.6	48.8	49.7	50.9
Hypertension	54.9	52.7	51.3	50.0	50.4	51.6	51.2	50.9	52.1	53.0	52.7	52.8	53.0	54.1	54.3	55.5	56.4	55.4	55.7	55.7	56.3	56.1
Glomerulonephritis	59.3	57.1	57.2	57.6	57.8	55.6	55.6	56.3	58.5	57.7	58.6	58.5	59.7	61.7	61.5	61.7	62.7	63.3	63.6	63.2	65.0	64.8
Other cause	47.1	48.1	50.6	46.0	49.5	48.8	50.0	50.2	49.9	51.9	51.8	51.9	51.8	53.0	52.7	52.6	52.7	53.1	52.9	53.3	52.4	53.1
All	45.2	45.4	45.4	43.7	45.1	45.1	45.6	46.1	47.2	48.3	48.5	48.9	49.6	51.1	51.4	51.9	52.7	52.7	52.8	53.3	53.9	54.6

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, & age >110 are excluded. Includes U.S. & territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.6
Five-year survival probabilities: incident ESRD patients

from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-4	77.5	79.0	78.7	75.8	76.5	79.7	76.5	75.9	73.0	76.7	73.7	76.3	81.0	76.2	80.4	76.9	84.7	80.6	80.2	85.4
5-9	87.2	88.5	85.9	88.9	88.4	89.0	90.0	95.0	93.8	92.0	91.1	95.0	92.4	88.5	94.3	94.8	91.6	93.7	96.4	95.6
10-14	87.4	84.1	90.5	91.1	91.0	90.6	91.9	95.2	89.8	88.6	88.8	91.6	88.7	90.4	91.7	94.6	93.1	92.5	93.8	93.1
15-19	89.6	87.1	88.4	88.9	86.5	84.8	87.4	87.9	87.9	89.4	89.4	87.6	90.8	89.7	90.3	90.7	87.5	89.1	87.9	88.7
20-29	76.7	75.1	78.3	75.1	75.7	75.6	78.5	76.3	78.5	78.0	78.5	78.5	79.0	80.5	81.0	79.4	81.8	83.0	82.5	83.2
30-39	64.2	65.2	63.8	64.8	64.7	64.0	66.3	63.1	67.2	68.0	67.7	66.3	67.1	68.3	67.8	69.1	69.5	70.6	70.3	71.2
40-49	54.9	54.5	54.8	52.8	56.2	55.9	56.8	57.5	58.1	56.8	57.3	57.0	58.7	59.2	58.8	60.5	58.8	60.0	59.7	60.2
50-59	41.2	41.6	40.7	39.7	39.3	38.7	40.9	42.4	41.0	41.7	41.4	43.0	42.9	44.7	45.1	45.1	44.6	45.9	45.7	46.6
60-64	30.8	30.7	28.8	29.0	27.0	27.8	29.2	28.0	30.1	29.8	30.3	30.2	31.4	32.4	33.0	32.8	33.9	35.1	34.8	35.5
65-69	23.4	24.7	24.0	20.6	22.5	22.5	22.1	23.2	23.3	23.5	23.5	22.7	24.3	24.8	25.5	25.6	26.4	25.9	26.9	27.4
70-79	16.0	15.7	17.1	13.5	15.2	15.6	14.8	15.5	15.6	16.1	15.8	16.1	15.9	16.7	16.6	17.3	17.9	17.2	18.1	18.4
80+	7.0	6.6	5.9	6.4	7.3	7.9	7.4	7.5	6.7	8.9	8.7	7.6	7.5	7.9	8.2	8.7	8.6	8.2	8.2	8.2
Male	43.4	43.2	43.0	38.9	39.4	38.4	39.1	38.3	38.5	38.6	37.8	37.0	36.9	38.2	37.2	37.9	36.9	35.8	36.2	36.2
Female	43.8	44.4	42.7	38.5	39.6	38.9	38.6	37.7	37.7	36.6	35.9	35.0	35.5	35.2	35.3	34.7	34.2	33.9	33.6	33.5
White	42.4	41.8	41.4	36.9	37.6	37.0	36.9	35.4	34.7	34.5	33.5	32.6	32.4	32.9	32.4	32.3	31.4	30.5	31.0	30.6
Black	46.7	48.6	45.7	42.1	43.6	41.9	42.9	43.0	44.9	43.6	43.8	42.5	43.5	43.8	43.4	44.3	44.2	43.6	42.6	43.0
Other race	43.3	42.5	50.2	46.6	43.3	44.0	48.0	47.1	47.5	49.1	45.9	48.8	46.4	47.5	47.0	42.0	40.5	41.5	41.5	44.4
†Hispanic																	40.5	40.3	41.6	40.7
†Non-Hispanic																	35.0	34.3	34.2	34.2
Diabetes	31.0	28.8	26.8	27.1	26.8	26.6	28.7	27.7	28.8	28.6	27.8	28.1	28.6	29.2	29.4	28.8	28.7	28.5	28.9	29.5
Hypertension	47.8	42.2	39.6	36.6	36.7	36.3	35.2	34.1	35.0	34.4	34.3	32.4	33.1	33.0	32.9	34.4	33.7	32.6	32.3	32.4
Glomerulonephritis	65.3	62.7	61.2	58.4	57.7	55.4	56.1	55.9	57.1	56.3	56.1	54.7	55.9	57.4	56.2	56.8	55.8	55.7	56.6	56.0
Other cause	39.1	43.4	46.3	38.1	42.8	43.1	43.9	44.0	42.5	44.6	44.5	45.1	44.4	45.8	44.9	43.9	42.9	42.4	42.6	41.6
All	43.6	43.7	42.8	38.7	39.5	38.6	38.9	38.0	38.1	37.7	36.9	36.1	36.3	36.8	36.3	36.4	35.6	34.9	35.0	34.9
ADJUSTED																				
0-19	80.2	76.9	79.2	79.8	78.2	77.1	79.3	81.7	78.9	80.7	80.0	80.3	82.7	80.6	83.9	84.1	82.4	83.0	83.5	84.5
20-44	60.6	61.5	62.4	61.5	63.6	63.0	65.4	63.4	65.7	66.5	66.7	65.6	66.4	67.3	67.6	67.9	68.3	69.5	69.2	69.6
45-64	35.2	35.5	35.4	34.9	34.7	35.1	37.5	38.0	38.7	39.4	39.4	40.9	41.9	43.5	44.2	44.7	44.8	46.2	46.1	47.0
65-74	19.5	20.4	20.6	17.1	19.1	19.4	18.8	20.2	20.6	21.0	21.2	20.7	22.1	22.6	23.0	23.4	24.4	23.7	24.9	25.7
75+	10.8	10.7	10.8	8.7	10.4	11.1	10.9	10.6	10.1	11.8	10.9	11.3	10.4	11.2	11.1	12.0	12.4	12.0	12.5	12.5
Male	29.3	29.0	29.6	27.7	28.8	29.0	30.3	30.3	31.0	32.4	32.1	32.5	32.8	34.5	34.4	35.4	35.8	35.7	36.5	37.4
Female	31.0	32.1	31.8	30.2	31.7	31.9	32.6	32.9	33.2	33.5	33.6	33.8	34.7	34.9	35.7	35.7	36.2	36.7	36.8	37.0
White	27.8	27.5	28.4	26.6	27.9	28.4	29.1	29.2	29.4	30.7	30.3	30.7	31.4	32.4	32.8	33.3	33.9	33.9	34.9	35.3
Black	35.6	36.4	34.3	32.8	33.9	33.2	35.0	35.3	36.8	36.2	37.0	36.8	37.5	38.3	38.4	39.6	39.9	40.1	39.4	39.9
Other race	28.4	30.8	32.2	32.9	30.7	34.0	37.3	37.1	39.0	41.4	39.8	43.5	42.2	43.7	44.1	41.3	40.8	43.4	42.8	46.5
Diabetes	22.4	20.7	19.9	20.6	20.9	21.3	23.3	23.4	24.6	25.1	25.0	26.0	26.9	27.9	28.5	28.6	29.2	29.5	30.1	31.1
Hypertension	39.7	36.4	35.9	34.5	35.0	35.9	35.7	35.8	36.5	37.0	37.4	36.5	37.0	37.6	37.8	39.2	39.6	39.4	39.5	39.8
Glomerulonephritis	43.7	43.1	42.4	41.2	41.7	40.2	41.8	42.0	43.5	44.0	43.6	44.0	44.7	46.3	46.5	47.0	47.5	47.6	48.6	49.2
Other cause	31.0	33.0	35.5	31.6	35.0	35.2	36.4	36.7	35.6	38.1	37.4	38.3	38.3	39.4	39.3	39.3	39.1	39.6	39.9	39.5
All	30.1	30.4	30.6	28.9	30.1	30.4	31.4	31.5	32.0	32.9	32.8	33.1	33.8	34.7	35.1	35.6	36.0	36.2	36.7	37.2

Reference cohort is 1996 incident ESRD patients. Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, & age >110 are excluded. Includes U.S. & territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.7

Ten-year survival probabilities: incident ESRD patients

from day 91 to ten years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994
0-4	72.5	67.7	74.2	70.5	72.4	73.2	74.8	74.1	63.5	75.0	68.7	72.6	76.0	74.6	75.3
5-9	79.1	79.5	78.8	81.5	84.2	81.3	85.5	83.0	88.8	85.0	85.7	90.1	88.0	79.2	87.7
10-14	79.2	75.6	76.5	82.8	83.3	82.2	84.9	88.8	81.2	79.5	80.3	86.1	83.0	84.3	81.5
15-19	80.5	79.1	80.0	81.0	78.6	76.2	78.5	78.8	79.9	83.5	82.7	78.4	81.0	79.4	82.4
20-29	63.4	61.3	64.8	62.8	63.1	64.0	65.1	64.1	66.6	64.7	66.5	64.8	66.3	69.9	69.9
30-39	46.3	46.8	47.4	48.6	48.4	46.8	49.6	47.2	49.1	49.7	50.9	49.2	51.2	51.4	50.7
40-49	32.8	31.7	33.0	32.8	35.0	35.1	36.0	35.6	36.2	34.3	35.1	34.9	36.9	37.8	37.2
50-59	15.9	17.2	17.2	15.9	16.6	17.3	18.3	19.3	17.5	17.9	18.0	19.0	19.0	19.3	20.4
60-64	8.0	7.8	6.1	8.0	8.2	9.0	8.7	8.3	8.8	8.3	8.3	8.6	9.6	9.7	10.2
65-69	4.6	5.5	4.2	4.8	5.2	6.1	5.2	4.7	5.0	4.8	5.1	4.7	4.8	5.4	5.2
70-79	2.7	2.0	2.8	1.9	2.8	2.7	2.3	2.5	2.3	2.0	2.0	1.8	2.0	2.2	2.1
80+	1.4	1.0	1.3	0.2	1.2	0.8	0.7	0.6	0.4	0.6	0.3	0.6	0.5	0.5	0.5
Male	24.3	24.3	24.7	22.5	23.0	22.5	22.9	21.7	21.1	20.6	20.7	19.3	19.8	20.2	19.3
Female	24.6	24.4	23.5	20.8	21.9	21.2	20.7	19.6	19.5	18.2	17.3	17.0	17.1	16.8	16.7
White	25.0	24.4	24.5	22.0	22.6	21.9	21.7	20.5	19.3	18.4	18.2	17.2	17.2	17.4	16.6
Black	23.0	24.2	22.7	20.6	21.7	21.2	21.3	20.5	21.8	21.1	20.2	19.6	20.6	20.4	20.2
Other race	24.1	25.5	32.8	28.9	28.9	27.9	31.9	27.4	28.5	27.7	27.1	27.0	25.6	26.0	24.7
Diabetes	13.7	12.1	11.8	11.3	11.7	12.0	12.4	11.8	11.4	11.2	10.4	10.0	10.4	10.7	10.7
Hypertension	25.4	21.1	18.6	17.5	17.7	16.6	16.8	14.8	15.7	15.0	15.0	14.2	15.0	14.7	14.5
Glomerulonephritis	46.9	42.6	41.7	39.7	39.8	39.1	39.4	38.1	38.9	37.6	37.9	35.9	38.6	38.7	37.6
Other cause	20.3	24.0	27.4	22.8	26.4	26.9	27.3	27.6	26.5	27.3	28.4	29.1	28.0	29.1	28.1
All	24.5	24.4	24.2	21.7	22.5	21.9	21.9	20.7	20.4	19.5	19.1	18.3	18.5	18.6	18.0
ADJUSTED															
0-19	67.9	64.9	65.9	68.5	68.3	65.7	69.4	70.3	67.5	72.0	70.4	70.5	71.8	69.4	72.2
20-44	42.9	42.7	44.8	44.9	46.3	46.2	47.8	46.3	47.8	48.1	49.0	47.9	49.4	50.5	50.3
45-64	12.7	13.1	13.5	13.5	14.4	15.0	16.2	16.5	16.3	16.6	16.5	17.5	18.7	19.3	20.3
65-74	3.6	3.9	3.5	3.4	4.1	4.7	4.0	3.9	3.9	3.9	4.1	3.7	4.1	4.5	4.4
75+	1.8	1.4	1.8	0.8	1.7	1.4	1.3	1.5	1.3	1.0	0.8	1.0	0.9	1.1	1.0
Male	13.5	13.3	14.0	13.6	14.4	15.0	15.4	15.2	15.0	15.3	15.7	15.4	16.1	16.7	16.80
Female	14.7	15.0	15.0	14.5	15.7	15.7	15.7	15.7	15.8	15.5	15.4	15.8	16.2	16.5	16.8
White	13.6	13.3	13.9	13.6	14.6	14.9	15.0	15.1	14.8	15.0	15.2	15.2	15.9	16.4	16.6
Black	14.4	14.8	14.0	13.6	14.4	14.7	15.0	14.7	15.4	15.0	15.0	15.0	15.6	15.9	16.1
Other race	12.3	15.3	16.9	16.1	17.5	18.2	20.7	17.7	20.0	19.8	20.5	21.1	21.1	21.3	20.9
Diabetes	8.9	8.1	8.2	8.1	8.8	9.4	9.6	9.7	9.5	9.6	9.5	9.5	10.1	10.7	11.1
Hypertension	19.0	17.1	16.4	16.5	16.7	16.8	17.2	16.6	16.9	16.9	17.2	16.9	17.6	17.9	18.2
Glomerulonephritis	23.8	22.3	22.4	22.2	23.4	23.6	24.4	23.6	24.6	24.1	24.1	24.3	26.0	26.1	26
Other cause	14.3	15.6	17.6	16.5	18.8	19.2	19.5	20.0	19.4	20.2	20.8	21.5	21.3	22.1	21.6
All	14.1	14.1	14.5	14.0	15.0	15.3	15.6	15.4	15.4	15.4	15.6	15.6	16.2	16.6	16.8

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, & age >110 are excluded. Includes U.S. & territories; no unknown or foreign states.

Table I.8

Incident patient counts: dialysis patients, unknowns dropped*dialysis patients alive on day 91, by age, gender, race, ethnicity, & primary diagnosis*

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992
0-4	21	40	53	72	75	97	90	82	89	94	77	110	97
5-9	57	44	64	60	68	50	75	66	57	66	81	58	50
10-14	119	121	155	137	145	132	118	116	121	97	125	135	141
15-19	305	339	312	327	305	308	297	310	333	367	324	303	363
20-29	1,127	1,294	1,460	1,421	1,569	1,590	1,641	1,615	1,707	1,842	1,868	1,929	1,996
30-39	1,753	1,976	2,242	2,310	2,500	2,648	2,835	2,922	3,218	3,543	3,690	3,831	4,124
40-49	2,012	2,297	2,427	2,722	2,846	3,108	3,310	3,677	4,025	4,623	4,951	5,577	5,979
50-59	3,104	3,707	4,033	4,149	4,399	4,715	4,903	5,243	5,925	6,451	6,896	7,471	8,211
60-64	1,728	2,002	2,302	2,699	2,970	3,306	3,422	3,859	4,216	4,598	5,015	5,570	5,775
65-69	1,717	1,799	2,105	2,771	2,896	3,289	3,784	4,287	4,837	5,656	6,290	6,999	7,588
70-79	1,891	2,032	2,633	3,766	3,907	4,583	5,282	6,080	6,708	8,105	9,115	10,743	12,024
80+	312	333	486	761	796	1,024	1,250	1,426	1,777	2,233	2,597	3,033	3,593
Male	7,848	8,797	9,964	11,600	12,393	13,410	14,666	16,013	17,669	20,330	22,020	24,404	26,362
Female	6,298	7,187	8,308	9,595	10,083	11,440	12,341	13,670	15,344	17,345	19,009	21,355	23,579
White	9,799	10,987	12,581	14,270	15,155	16,749	18,261	19,825	21,897	24,981	27,201	30,180	32,791
Black	4,024	4,610	5,281	6,391	6,714	7,383	7,905	8,919	9,961	11,512	12,377	13,965	15,283
Other race	323	387	410	534	607	718	841	939	1,155	1,182	1,451	1,614	1,867
†Hispanic													
†Non-Hispanic													
Diabetes	2,337	3,521	4,610	5,389	6,546	7,568	8,752	9,933	11,268	13,645	15,601	17,997	19,954
Hypertension	2,801	4,006	5,118	5,602	6,274	7,173	7,809	8,971	10,239	11,975	13,131	14,625	16,302
Glomerulonephritis	2,444	3,209	3,720	3,916	4,210	4,381	4,587	4,932	5,268	5,523	5,835	6,113	6,246
Cystic kidney	707	854	993	1,012	1,030	1,096	1,152	1,193	1,207	1,209	1,305	1,372	1,431
Other urologic	388	571	742	836	815	1,012	1,020	1,121	1,120	1,149	1,047	1,220	1,284
Other cause	1,518	1,884	2,386	2,620	2,782	2,983	3,057	3,030	3,269	3,747	3,829	4,184	4,546
Missing cause	3,951	1,939	703	1,820	819	637	630	503	642	427	281	248	178
All	14,146	15,984	18,272	21,195	22,476	24,850	27,007	29,683	33,013	37,675	41,029	45,759	49,941

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90 day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, race, or primary cause of ESRD are excluded.

Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.8

Incident patient counts: dialysis patients, unknowns dropped*dialysis patients alive on day 91, by age, gender, race, ethnicity, & primary diagnosis*

	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	94	80	92	96	87	81	72	95	86	103	92
5-9	56	85	62	65	55	57	67	61	63	77	54
10-14	143	150	142	156	134	124	125	140	121	172	148
15-19	340	295	339	326	283	309	315	290	304	285	306
20-29	1,952	1,923	1,844	1,854	1,708	1,740	1,641	1,683	1,691	1,600	1,557
30-39	4,088	4,216	4,024	4,035	3,857	3,760	3,953	3,776	3,806	3,828	3,761
40-49	6,271	6,480	6,758	7,083	6,893	7,392	7,384	7,570	7,492	7,768	8,014
50-59	8,570	9,483	9,455	9,783	10,514	11,207	11,937	12,238	12,783	13,345	13,665
60-64	6,016	6,252	6,458	6,683	6,879	7,236	7,371	7,608	7,858	7,996	8,408
65-69	7,859	8,424	8,341	9,161	9,415	9,665	9,744	9,745	9,986	10,223	10,393
70-79	12,658	14,069	14,385	16,198	17,368	18,341	19,386	19,694	19,782	20,837	20,684
80+	3,915	4,415	4,712	5,630	6,369	6,983	7,887	8,477	8,844	10,290	10,555
Male	27,730	29,552	29,856	32,648	33,808	35,631	37,498	38,269	39,192	41,727	42,176
Female	24,232	26,320	26,756	28,422	29,754	31,264	32,384	33,108	33,624	34,797	35,461
White	33,842	36,359	36,271	39,422	41,132	43,013	45,509	46,800	47,486	49,783	50,419
Black	16,029	17,122	17,453	18,397	19,153	20,350	20,563	20,666	21,346	22,454	22,810
Other race	2,091	2,391	2,888	3,251	3,277	3,532	3,810	3,911	3,984	4,287	4,408
†Hispanic				6,843	6,918	7,289	8,002	9,252	8,518	9,109	9,628
†Non-Hispanic				54,227	56,644	59,606	61,880	62,125	64,298	67,415	68,009
Diabetes	21,137	23,383	25,248	28,169	29,908	31,786	33,321	34,595	35,494	36,781	37,336
Hypertension	16,849	18,034	16,078	17,078	18,035	18,948	19,926	20,222	20,804	22,183	22,952
Glomerulonephritis	6,386	6,797	6,752	7,056	6,784	6,791	6,756	6,540	6,409	6,620	6,333
Cystic kidney	1,491	1,539	1,532	1,440	1,490	1,543	1,599	1,563	1,574	1,597	1,566
Other urologic	1,089	1,122	1,564	1,832	1,793	1,806	2,128	1,985	2,052	2,158	2,090
Other cause	4,723	4,907	5,348	5,430	5,495	5,960	6,069	6,384	6,411	7,029	7,048
Missing cause	287	90	90	65	57	61	83	88	72	156	312
All	51,962	55,872	56,612	61,070	63,562	66,895	69,882	71,377	72,816	76,524	77,637

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90 day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, race, or primary cause of ESRD are excluded.

Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.9

90-day survival probabilities: incident dialysis patients*censored at transplant, by age, gender, race, ethnicity, & primary diagnosis*

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992
0-4	100.0	100.0	100.0	100.0	100.0	100.0	98.1	100.0	98.0	95.2	90.2	98.3	99.0
5-9	100.0	98.2	100.0	98.5	100.0	100.0	100.0	100.0	97.0	100.0	92.7	98.6	100.0
10-14	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	94.6	97.4	100.0
15-19	99.7	100.0	100.0	100.0	100.0	99.7	99.7	100.0	98.9	99.7	98.1	99.4	100.0
20-29	99.2	99.4	99.7	99.3	99.1	99.7	99.4	99.5	99.8	99.5	99.1	99.2	99.3
30-39	98.5	99.0	99.1	99.3	99.2	99.1	98.6	99.0	99.2	99.0	98.9	99.1	99.0
40-49	98.7	98.3	98.8	98.2	98.8	98.7	98.9	98.6	99.0	98.6	98.7	99.1	99.0
50-59	97.6	97.5	97.6	96.9	97.8	97.4	97.7	98.0	97.8	97.8	97.8	98.2	98.3
60-64	95.2	95.8	95.6	95.7	96.0	95.4	95.5	96.5	96.2	96.5	96.3	96.6	96.8
65-69	90.7	91.1	89.9	91.5	89.8	90.1	91.6	91.2	92.3	91.9	92.2	92.2	92.5
70-79	87.1	88.2	87.6	88.4	87.7	87.2	87.9	89.3	88.3	88.5	89.1	89.5	89.6
80+	83.7	84.4	84.7	83.0	83.3	82.5	84.5	83.7	85.9	83.9	83.8	84.9	85.3
Male	94.8	95.1	94.6	94.1	94.3	93.6	93.8	94.1	94.0	93.8	93.6	94.0	93.8
Female	95.2	95.8	95.4	94.7	94.4	94.2	94.5	94.7	94.7	94.1	94.2	94.4	94.6
White	94.4	94.8	94.1	93.3	93.4	92.8	93.1	93.2	93.2	92.7	92.7	93.0	93.0
Black	96.5	96.6	97.1	96.8	96.3	96.3	96.4	96.8	96.7	96.6	96.4	96.5	96.5
Other race	94.4	96.9	96.2	95.7	96.8	95.8	97.4	97.9	96.5	96.8	97.2	96.9	96.8
†Hispanic													
†Non-Hispanic													
Diabetes	96.7	95.7	95.5	94.9	95.3	95.0	95.3	95.2	95.3	95.1	95.0	95.3	95.4
Hypertension	96.0	95.0	93.6	93.4	93.1	92.8	92.9	92.7	92.9	92.4	92.0	92.2	92.3
Glomerulonephritis	98.4	97.9	97.4	97.2	96.9	96.8	96.6	96.3	97.0	96.1	96.1	96.7	96.6
Other cause	93.1	94.3	94.3	93.4	93.0	92.0	92.6	94.0	93.2	93.0	93.3	93.4	93.3
All	95.0	95.4	95.0	94.4	94.3	93.9	94.1	94.4	94.3	94.0	93.9	94.2	94.2
<hr/>													
ADJUSTED													
0-19	99.6	99.6	100.0	99.6	100.0	99.6	98.9	100.0	97.2	97.9	90.1	96.7	99.6
20-44	98.9	99.1	99.3	99.1	99.2	99.2	99.0	99.0	99.3	99.0	99.0	99.1	99.1
45-64	97.4	97.3	97.2	96.7	97.3	96.9	97.1	97.6	97.4	97.5	97.3	97.8	97.8
65-74	91.0	91.1	89.8	91.4	89.8	89.7	90.9	91.3	91.3	91.4	91.4	91.5	91.8
75+	87.5	87.9	87.8	86.9	87.0	86.3	87.0	87.4	87.5	86.4	87.1	87.8	87.7
Male	93.3	93.2	92.7	93.0	93.0	92.4	92.9	93.3	93.4	93.3	93.2	93.7	93.6
Female	93.6	93.9	93.6	93.7	93.1	93.2	93.8	94.1	94.2	93.8	93.9	94.2	94.6
White	92.8	93.0	92.2	92.3	92.3	91.9	92.5	92.9	93.0	92.7	92.8	93.3	93.4
Black	95.1	94.5	95.4	95.8	94.7	94.8	95.1	95.6	95.5	95.4	95.1	95.4	95.5
Other race	92.6	95.5	93.7	94.4	95.3	93.8	96.3	96.9	95.2	95.6	96.4	96.2	96.0
Diabetes	94.0	92.4	92.5	91.9	92.7	92.5	93.2	93.4	93.7	93.7	93.8	94.3	94.6
Hypertension	94.4	93.8	92.7	92.9	92.8	92.9	93.3	93.4	93.6	93.4	93.2	93.5	93.6
Glomerulonephritis	96.5	95.8	95.2	95.1	94.8	95.1	95.0	94.6	95.6	94.8	94.9	95.8	95.6
Other cause	91.1	91.8	92.1	92.5	91.8	90.8	91.6	93.3	92.4	92.3	92.6	92.8	92.8
All	93.4	93.5	93.1	93.3	93.1	92.8	93.3	93.7	93.7	93.5	93.5	93.9	94.1

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age >110 are excluded.

Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

" " Zero values in this cell.

Table I.9

90-day survival probabilities: incident dialysis patients*censored at transplant, by age, gender, race, ethnicity, & primary diagnosis*

UNADJUSTED	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	100.0	96.7	98.0	100.0	99.0	98.8	98.7	99.0	98.9	100.0	99.0
5-9	100.0	100.0	100.0	100.0	100.0	100.0	100.0	98.6	100.0	98.8	100.0
10-14	100.0	99.4	100.0	100.0	98.7	100.0	100.0	100.0	100.0	100.0	100.0
15-19	100.0	99.7	100.0	100.0	100.0	100.0	100.0	100.0	99.1	100.0	99.1
20-29	99.4	99.3	99.4	99.4	99.6	99.7	99.5	99.6	99.6	99.6	99.7
30-39	99.0	98.9	99.1	98.9	99.1	99.0	99.1	99.1	99.2	99.2	99.2
40-49	98.8	98.8	98.6	98.6	98.5	98.4	98.5	99.0	98.7	98.5	98.7
50-59	98.0	97.6	98.1	98.0	98.1	97.8	97.6	97.7	97.6	97.8	97.5
60-64	96.7	96.5	96.6	96.6	96.3	96.1	96.5	96.4	96.3	96.5	96.6
65-69	92.8	92.6	92.7	92.9	92.2	92.4	92.6	92.1	92.3	92.6	92.7
70-79	89.1	89.6	89.2	89.0	88.6	88.7	88.7	88.9	88.2	88.7	88.5
80+	84.7	84.0	83.7	84.4	83.0	82.3	82.5	82.8	82.4	83.0	82.6
Male	93.8	93.6	93.5	93.2	92.7	92.5	92.5	92.7	92.1	92.5	92.1
Female	94.0	93.8	93.7	93.5	92.8	92.7	92.5	92.3	92.3	92.1	92.3
White	92.7	92.5	92.3	92.1	91.3	91.2	91.2	91.3	91.0	91.0	90.9
Black	96.4	96.1	96.1	95.8	95.4	95.1	95.2	94.9	94.5	94.9	94.8
Other race	96.1	96.0	95.3	95.7	95.3	95.2	94.6	95.6	94.9	95.5	95.5
†Hispanic				95.5	94.8	94.9	95.2	94.5	94.2	94.9	94.4
†Non-Hispanic				93.1	92.5	92.3	92.1	92.2	92.0	92.0	91.9
Diabetes	94.9	95.0	94.6	94.4	94.1	93.7	93.7	93.5	93.5	93.6	93.6
Hypertension	92.2	91.9	91.9	92.1	91.0	90.9	90.9	91.0	90.4	90.7	90.8
Glomerulonephritis	96.4	95.9	96.7	95.9	95.5	95.3	95.5	96.0	95.8	96.0	95.9
Other cause	93.1	92.5	92.0	91.1	90.3	90.7	90.5	90.6	90.1	89.9	89.4
All	93.9	93.7	93.6	93.4	92.7	92.6	92.5	92.5	92.2	92.3	92.2
ADJUSTED											
0-19	100.0	98.2	99.2	100.0	98.7	99.6	99.6	99.2	98.2	99.6	98.4
20-44	99.1	98.9	99.0	98.9	99.0	99.0	99.1	99.1	99.2	99.1	99.2
45-64	97.7	97.5	97.7	97.6	97.6	97.3	97.4	97.6	97.4	97.5	97.4
65-74	91.8	92.0	91.6	91.6	91.2	91.4	91.4	91.2	91.0	91.3	91.5
75+	86.9	86.7	86.7	86.9	85.8	85.5	85.7	86.0	85.5	85.9	85.4
Male	93.6	93.5	93.5	93.5	93.2	93.1	93.3	93.4	93.0	93.4	93.1
Female	94.1	93.9	94.0	93.9	93.5	93.5	93.4	93.3	93.4	93.4	93.5
White	93.2	93.1	93.1	93.1	92.7	92.7	92.8	92.9	92.7	92.9	92.8
Black	95.3	95.0	95.1	94.9	94.6	94.3	94.4	94.2	93.8	94.3	94.2
Other race	95.4	95.3	94.8	95.4	95.1	94.9	94.6	95.5	94.8	95.6	95.6
Diabetes	94.1	94.3	94.0	94.1	93.9	93.6	93.7	93.7	93.7	93.9	93.9
Hypertension	93.7	93.5	93.5	93.9	93.3	93.2	93.3	93.4	93.0	93.4	93.3
Glomerulonephritis	95.4	95.1	96.0	95.3	94.9	94.7	95.1	95.6	95.1	95.5	95.4
Other cause	92.4	92.0	91.8	91.3	90.9	91.3	91.2	91.3	90.9	90.8	90.3
All	93.8	93.7	93.7	93.7	93.3	93.3	93.3	93.4	93.2	93.4	93.3

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age >110 are excluded.

Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

" " Zero values in this cell.

Table I.10

One-year survival probabilities: incident dialysis patients*censored at transplant, from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis*

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992
0-4	95.2	91.9	87.9	88.2	83.8	84.8	89.0	93.6	78.8	81.6	77.1	77.6	84.9
5-9	91.9	92.7	95.5	98.0	88.5	88.5	100.0	100.0	100.0	98.3	94.7	94.8	92.0
10-14	97.1	98.3	97.4	98.1	96.6	97.3	98.8	98.8	95.5	96.4	95.4	97.3	94.0
15-19	96.0	94.6	94.6	94.7	96.4	93.6	94.3	95.2	97.6	98.2	96.5	95.7	96.8
20-29	90.5	92.1	92.3	92.3	92.0	90.5	93.0	90.2	91.6	91.5	91.8	91.6	92.9
30-39	88.9	88.7	88.0	89.2	87.1	87.7	88.0	87.7	88.3	88.2	89.3	88.3	89.5
40-49	87.5	87.2	86.0	87.1	87.0	86.6	86.7	86.9	87.7	87.8	88.7	87.0	87.7
50-59	83.2	83.1	83.6	81.3	81.7	81.7	82.0	82.7	83.2	82.7	83.9	83.6	85.0
60-64	78.1	77.2	77.5	77.1	75.3	76.0	76.6	75.7	76.1	77.3	78.1	78.7	79.1
65-69	73.0	73.5	73.8	71.8	72.9	70.9	73.0	73.0	73.1	73.7	75.4	75.0	75.4
70-79	67.1	67.8	68.4	65.1	66.5	66.9	66.2	65.3	65.9	67.2	68.4	68.1	68.4
80+	57.9	53.3	62.1	55.3	56.2	58.2	58.6	55.2	55.2	57.8	59.4	59.1	58.1
Male	79.9	80.4	79.9	77.3	77.2	76.8	76.4	76.3	76.0	77.0	77.9	77.3	77.5
Female	80.9	80.4	80.6	78.0	78.5	77.7	78.4	76.7	77.9	77.5	78.2	77.4	77.9
White	78.6	78.5	78.3	75.3	75.1	74.7	74.6	73.4	73.7	74.4	75.0	74.2	74.3
Black	84.6	84.8	84.4	82.4	83.4	82.3	82.6	82.7	82.9	82.5	83.9	83.0	83.8
Other race	79.9	80.9	83.4	80.5	80.3	81.1	84.1	80.0	83.7	84.0	85.4	86.8	85.6
†Hispanic													
†Non-Hispanic													
Diabetes	74.3	73.5	72.8	72.6	73.0	72.4	73.9	73.7	75.1	75.8	76.2	76.4	76.7
Hypertension	83.5	81.6	80.0	78.1	77.3	78.1	77.0	75.6	75.6	76.2	77.2	76.1	76.4
Glomerulonephritis	90.2	88.3	87.5	87.0	86.6	86.5	85.1	84.7	85.3	84.9	85.8	84.3	86.0
Other cause	78.1	79.7	81.9	76.2	77.6	75.9	77.2	76.3	75.7	76.2	77.7	76.6	76.8
All	80.4	80.4	80.2	77.6	77.8	77.2	77.3	76.5	76.9	77.2	78.1	77.3	77.7
ADJUSTED													
0-19	92.3	90.8	90.2	90.5	88.5	86.7	90.6	92.8	89.6	91.7	88.2	86.9	89.1
20-44	87.3	88.2	88.0	88.4	87.5	87.4	88.0	87.3	88.3	87.9	89.2	88.0	88.8
45-64	80.5	80.1	80.5	79.5	79.3	79.5	80.3	80.2	80.8	81.6	82.6	82.5	83.5
65-74	70.3	70.6	72.1	68.9	70.2	69.1	70.2	70.2	70.7	71.5	73.2	72.8	73.4
75+	61.1	61.7	62.0	58.6	60.9	62.3	61.9	59.2	59.6	62.2	63.2	63.2	62.6
Male	74.1	74.6	74.6	72.6	72.7	72.9	73.1	73.1	73.0	74.6	75.9	75.6	76.1
Female	75.2	74.9	76.0	74.2	75.0	74.6	76.0	74.7	76.0	76.3	77.4	76.9	77.7
White	72.1	72.3	73.0	70.8	71.1	71.3	71.8	71.1	71.8	73.2	74.2	73.8	74.4
Black	80.2	79.7	79.6	78.4	79.1	78.2	79.1	79.2	79.3	79.1	81.0	80.3	81.2
Other race	73.1	75.6	77.1	75.6	75.1	77.3	81.2	76.6	81.0	81.7	83.9	85.5	84.3
Diabetes	69.1	68.2	67.9	68.1	68.8	68.4	70.5	70.5	72.3	73.4	74.1	74.6	75.1
Hypertension	80.2	79.0	78.1	76.8	76.2	77.8	77.4	76.3	76.4	77.4	78.7	78.0	78.2
Glomerulonephritis	85.2	83.2	82.7	82.5	82.4	83.0	81.5	81.1	81.8	81.9	83.0	81.7	83.5
Other cause	74.8	75.7	78.4	74.4	75.3	73.6	75.3	74.5	73.8	74.5	76.0	75.0	75.4
All	74.6	74.8	75.2	73.4	73.8	73.7	74.4	73.8	74.4	75.4	76.6	76.3	76.8

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age >110 are excluded.

Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.10

One-year survival probabilities: incident dialysis patients*censored at transplant, from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis*

UNADJUSTED	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	82.6	87.0	82.2	91.1	85.3	87.3	90.1	88.9	91.0	90.0	88.8
5-9	96.1	100.0	98.4	93.7	95.8	100.0	98.5	100.0	95.1	91.4	96.1
10-14	93.2	98.4	98.1	97.4	96.0	98.1	95.9	95.9	97.6	96.9	100.0
15-19	95.7	95.5	98.0	96.2	97.9	94.6	97.9	96.2	97.0	97.1	97.1
20-29	92.1	92.9	92.2	94.3	95.7	95.3	95.2	93.3	94.6	93.4	93.7
30-39	88.8	89.3	89.3	90.0	91.5	90.8	91.2	91.4	91.5	91.7	91.9
40-49	88.8	88.8	89.2	89.6	89.9	89.0	89.6	89.9	89.4	89.6	89.3
50-59	84.8	85.8	86.1	85.4	85.7	85.5	85.9	85.5	86.1	85.9	85.7
60-64	80.9	80.7	80.2	81.7	81.9	80.1	81.2	81.0	81.7	80.8	82.1
65-69	77.0	76.1	77.0	77.7	76.8	76.2	76.4	76.8	76.6	76.5	77.1
70-79	69.8	70.0	70.2	70.8	69.8	69.8	69.5	69.4	69.5	69.4	69.6
80+	60.8	61.0	60.4	60.1	59.5	57.5	58.3	57.8	57.8	58.8	59.0
Male	78.9	78.6	78.4	78.7	78.1	77.4	77.7	77.4	77.6	77.1	77.4
Female	78.3	78.4	78.6	78.4	77.6	76.7	76.5	76.3	76.4	76.1	76.4
White	75.6	75.6	75.7	75.7	74.7	74.3	74.4	74.2	74.1	73.8	74.3
Black	83.8	83.5	83.2	83.9	83.6	82.3	82.3	81.8	82.4	81.8	81.4
Other race	86.2	85.4	84.2	82.2	83.2	81.9	82.3	82.4	83.7	82.6	84.0
†Hispanic				82.5	82.0	82.2	81.7	82.2	82.4	81.7	82.1
†Non-Hispanic				78.0	77.3	76.5	76.6	76.1	76.3	75.9	76.2
Diabetes	78.4	78.2	78.1	78.1	77.6	76.8	77.4	77.3	77.6	77.2	77.9
Hypertension	76.8	77.0	77.7	77.6	76.4	75.8	75.5	75.6	75.4	75.4	75.2
Glomerulonephritis	87.1	85.6	86.0	86.7	86.4	86.5	85.8	86.1	86.1	86.3	86.4
Other cause	76.8	77.1	75.8	75.9	75.9	74.8	74.5	73.2	73.8	72.5	73.0
All	78.6	78.5	78.5	78.5	77.8	77.1	77.1	76.9	77.0	76.6	76.9
ADJUSTED											
0-19	87.9	91.8	91.9	92.0	91.4	90.6	93.8	91.5	92.8	91.7	93.6
20-44	88.4	89.3	89.2	90.3	91.1	90.6	90.9	90.9	91.0	90.9	91.0
45-64	84.5	84.8	85.0	85.2	85.6	84.8	85.5	85.4	85.7	85.4	85.6
65-74	75.2	74.4	75.2	76.0	75.1	74.9	75.1	75.1	75.0	74.7	75.3
75+	63.9	64.9	64.4	64.7	63.9	63.1	63.2	63.0	63.1	63.6	63.7
Male	77.8	77.7	77.7	78.6	78.5	78.0	78.6	78.4	78.6	78.4	78.6
Female	78.2	78.6	79.1	79.2	78.8	78.1	78.1	78.2	78.3	78.2	78.5
White	75.9	76.2	76.6	77.1	76.6	76.4	76.8	76.8	76.7	76.7	77.2
Black	81.4	81.2	81.2	82.1	82.2	80.8	80.8	80.6	81.1	80.6	80.2
Other race	85.3	84.7	84.1	82.5	83.8	82.5	83.2	83.4	84.3	83.6	84.9
Diabetes	77.0	77.1	77.1	77.4	77.3	76.5	77.3	77.4	77.7	77.5	78.2
Hypertension	79.0	79.2	80.0	80.4	79.6	79.2	79.2	79.3	79.1	79.5	79.2
Glomerulonephritis	84.8	83.6	83.9	85.2	84.9	85.0	84.7	84.7	84.5	85.0	84.9
Other cause	75.2	75.8	75.1	75.3	75.8	74.8	74.8	73.7	74.2	73.1	73.6
All	78.0	78.1	78.4	78.9	78.6	78.0	78.4	78.3	78.4	78.3	78.6

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age >110 are excluded.

Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.11

Two-year survival probabilities: incident dialysis patients*censored at transplant, from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis*

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992
0-4	80.6	88.9	83.9	78.8	81.4	77.9	78.1	80.7	69.9	73.7	71.4	74.2	80.8
5-9	87.6	92.7	90.2	87.6	83.0	88.5	82.5	100.0	100.0	94.2	89.4	94.8	92.0
10-14	95.5	93.8	93.0	95.9	90.0	95.6	94.8	98.8	88.5	96.4	89.0	95.9	91.0
15-19	94.0	89.5	92.0	89.2	92.5	91.0	88.9	93.0	94.1	95.7	94.0	91.6	94.4
20-29	82.1	83.5	84.4	82.2	83.2	80.0	84.0	80.7	84.6	84.5	83.6	83.8	85.8
30-39	78.2	79.1	76.9	79.4	75.4	74.6	75.6	76.3	78.4	77.8	79.0	77.3	78.9
40-49	75.9	75.2	74.7	74.3	74.4	74.9	74.0	73.7	75.6	75.5	77.9	74.3	76.8
50-59	70.0	69.7	69.7	67.4	66.3	66.0	66.3	66.5	67.3	68.8	69.0	69.0	70.4
60-64	63.2	60.7	60.5	60.9	58.1	58.3	59.5	58.4	59.3	60.2	60.6	61.7	62.1
65-69	55.1	55.7	55.6	51.9	55.0	52.7	53.7	55.1	55.6	55.7	56.3	56.4	57.7
70-79	47.0	48.5	49.3	44.1	46.5	47.0	46.3	45.5	46.4	47.6	47.8	48.1	49.0
80+	30.8	33.7	37.7	30.6	36.2	35.7	34.8	32.6	32.9	37.7	36.7	35.9	36.5
Male	64.4	65.2	64.1	60.3	60.5	58.6	59.1	58.6	59.5	60.5	60.7	60.2	61.0
Female	67.1	66.1	65.7	61.9	62.3	62.1	61.3	60.5	61.5	61.5	61.5	60.5	61.7
White	63.0	62.9	61.9	57.5	57.5	56.5	55.9	55.2	55.4	56.3	56.1	55.4	56.3
Black	71.8	72.0	71.2	68.1	69.3	68.0	68.5	67.8	70.0	69.5	70.3	68.9	70.4
Other race	66.8	65.1	69.1	65.3	65.1	63.2	67.0	65.3	69.0	70.1	71.2	74.5	72.6
†Hispanic													
†Non-Hispanic													
Diabetes	55.4	53.8	52.3	53.8	51.5	51.5	52.5	53.2	55.3	56.6	56.4	57.0	58.0
Hypertension	70.2	67.4	65.5	61.9	62.8	61.6	60.5	59.0	60.0	60.6	60.3	59.5	60.5
Glomerulonephritis	79.7	77.4	76.1	74.6	74.9	72.5	71.5	71.5	73.1	71.8	73.5	71.1	73.4
Other cause	63.0	65.6	67.7	59.1	61.7	61.3	62.3	61.1	60.7	62.1	63.5	61.8	62.7
All	65.6	65.6	64.8	61.0	61.4	60.3	60.1	59.5	60.4	61.0	61.1	60.3	61.3
ADJUSTED													
0-19	87.4	83.1	84.5	80.7	80.8	81.8	78.7	87.7	81.9	86.8	81.4	81.8	84.8
20-44	75.1	77.3	76.6	76.8	75.1	74.2	75.7	75.2	77.7	77.3	78.7	76.5	78.3
45-64	66.1	64.7	65.1	64.1	62.9	63.0	63.9	63.5	64.7	66.5	67.2	67.3	68.6
65-74	51.0	52.3	53.4	48.3	51.5	50.2	50.7	51.6	52.6	53.1	53.6	54.0	55.3
75+	39.0	41.3	40.3	36.0	40.0	40.8	40.0	37.9	38.5	41.8	41.4	41.4	41.8
Male	56.3	57.3	56.9	54.2	54.9	54.0	55.1	54.6	55.9	57.7	58.2	58.3	59.4
Female	59.4	58.7	59.5	57.0	57.9	58.3	58.3	58.2	59.4	60.3	60.7	60.4	61.8
White	54.3	54.7	54.9	52.1	52.8	52.7	52.9	53.0	53.6	55.6	55.8	55.8	57.0
Black	65.1	64.2	64.0	62.1	63.0	62.1	63.3	62.6	64.8	64.6	65.8	64.9	66.5
Other race	57.7	57.9	59.9	58.3	58.2	58.3	62.7	60.8	65.2	67.1	69.0	72.7	70.9
Diabetes	48.8	47.3	46.4	48.2	46.6	47.0	48.4	49.4	51.8	53.7	53.7	54.7	56.0
Hypertension	65.4	63.8	63.1	60.3	61.7	61.8	61.6	60.6	61.6	62.8	62.9	62.6	63.5
Glomerulonephritis	71.2	69.5	69.0	68.0	68.9	67.6	66.7	66.6	68.3	67.8	69.5	67.5	69.9
Other cause	58.7	60.3	63.0	57.1	59.1	58.7	60.2	59.2	58.6	60.4	61.5	60.1	61.2
All	57.7	57.9	58.1	55.5	56.3	56.0	56.6	56.3	57.5	58.9	59.4	59.3	60.5

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age >110 are excluded.

Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.11

Two-year survival probabilities: incident dialysis patients*censored at transplant, from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis*

UNADJUSTED	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002
0-4	76.7	77.1	76.2	84.2	78.0	83.3	88.0	76.7	89.2	83.3
5-9	92.9	96.8	98.4	90.7	95.8	93.5	95.2	100.0	92.6	89.0
10-14	89.9	95.4	95.2	93.6	93.4	96.6	95.9	94.4	91.1	93.7
15-19	91.7	93.6	95.6	90.0	92.0	90.8	92.4	91.2	93.2	95.1
20-29	86.3	87.4	85.4	88.4	89.5	90.6	89.6	87.8	88.7	86.9
30-39	79.6	79.3	80.6	81.6	83.3	82.0	83.7	83.7	83.8	85.0
40-49	77.2	77.8	78.9	78.5	79.5	79.5	79.5	79.8	79.9	80.1
50-59	71.3	72.5	72.1	72.2	72.6	71.7	72.9	72.8	73.4	73.8
60-64	64.6	65.0	64.0	65.9	65.9	64.2	66.1	66.4	67.0	66.2
65-69	59.7	58.5	59.3	60.5	58.9	58.9	59.3	60.4	61.7	60.5
70-79	49.9	50.2	50.6	51.5	49.8	50.8	50.9	50.4	51.5	51.2
80+	37.4	38.5	38.4	38.2	37.1	37.0	37.1	37.2	37.3	38.3
Male	62.6	62.3	62.4	62.6	61.6	61.6	62.0	62.1	62.3	61.8
Female	61.8	62.2	62.0	62.3	61.0	60.6	60.5	60.2	61.4	60.8
White	57.2	57.4	57.5	57.6	56.2	56.6	57.0	57.0	57.3	56.9
Black	71.1	70.8	70.6	71.7	70.6	69.2	69.2	69.2	70.1	69.5
Other race	73.3	72.0	70.3	67.7	69.0	68.3	69.8	68.9	71.8	69.8
†Hispanic				67.6	67.1	67.9	68.2	69.4	69.2	68.5
†Non-Hispanic				61.8	60.6	60.3	60.5	60.0	60.9	60.4
Diabetes	59.8	59.7	59.8	60.1	59.4	59.1	60.2	60.4	61.2	60.6
Hypertension	60.6	61.3	62.0	62.0	60.1	60.1	59.7	59.8	60.2	60.1
Glomerulonephritis	74.8	73.7	74.3	74.8	74.1	75.2	74.3	74.8	75.7	75.6
Other cause	63.0	62.9	61.5	61.9	61.1	60.7	60.5	59.1	60.2	59.0
All	62.2	62.3	62.3	62.4	61.3	61.1	61.3	61.2	61.9	61.4
ADJUSTED										
0-19	81.0	85.9	86.9	82.7	82.9	84.5	87.1	83.3	86.0	86.6
20-44	78.4	79.5	79.8	81.0	82.6	81.9	82.6	82.7	82.5	82.8
45-64	70.4	71.2	71.0	71.7	72.1	71.3	72.6	72.8	73.2	73.3
65-74	56.6	56.1	57.3	58.1	56.7	57.3	57.8	58.0	59.3	58.4
75+	42.9	43.6	43.1	44.2	42.6	43.2	43.3	43.3	43.6	44.0
Male	61.4	61.5	61.8	62.8	62.4	62.7	63.6	63.8	64.0	63.9
Female	62.1	62.9	63.1	63.9	63.2	63.0	63.3	63.3	64.4	64.2
White	58.3	59.0	59.4	60.3	59.6	60.2	61.0	61.1	61.5	61.5
Black	67.4	67.5	67.5	69.0	68.4	67.1	67.0	67.4	68.3	67.9
Other race	72.2	71.1	70.4	68.5	70.4	69.4	71.4	70.7	72.9	71.6
Diabetes	58.1	58.3	58.5	59.3	59.1	58.9	60.3	60.8	61.5	61.2
Hypertension	64.1	65.0	65.7	66.4	65.1	65.3	65.2	65.4	65.7	66.1
Glomerulonephritis	71.4	70.9	71.2	72.6	72.0	73.0	72.8	73.0	73.3	73.8
Other cause	61.2	61.5	60.8	61.4	61.3	61.0	61.2	59.9	60.9	60.0
All	61.7	62.2	62.5	63.3	62.8	62.8	63.4	63.5	64.2	64.0

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age >110 are excluded.

Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.12
Three-year survival probabilities: incident dialysis patients

censored at transplant, from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992
0-4	80.6	84.2	83.9	66.5	74.0	77.9	74.8	67.4	63.8	73.7	68.0	70.5	75.4
5-9	87.6	92.7	90.2	76.6	83.0	78.6	82.5	83.3	91.7	94.2	80.8	94.8	86.6
10-14	95.5	82.7	93.0	92.6	90.0	88.5	86.9	87.2	85.1	93.9	86.8	87.1	86.7
15-19	90.2	85.4	91.0	88.4	90.4	86.2	82.5	88.8	89.9	89.5	89.5	89.4	92.6
20-29	76.1	77.3	77.5	75.7	75.5	72.4	75.7	74.4	78.6	77.9	77.1	77.8	79.6
30-39	72.0	71.0	65.9	70.8	66.2	65.5	66.1	66.0	69.7	69.0	70.1	68.1	69.4
40-49	66.5	65.8	65.1	62.9	63.4	64.1	63.0	63.4	65.4	64.0	66.6	64.0	65.6
50-59	58.9	57.9	57.0	54.8	54.1	52.5	53.0	54.3	54.7	56.1	56.4	56.5	56.9
60-64	51.0	48.3	46.8	47.6	44.9	44.9	44.8	44.9	46.4	46.8	46.9	48.1	48.0
65-69	40.4	42.5	41.9	38.0	41.1	39.4	39.8	41.0	42.2	41.3	41.4	42.0	43.0
70-79	33.6	33.6	34.7	29.6	32.1	32.5	31.6	31.6	32.6	33.6	33.0	33.9	34.0
80+	18.2	20.9	18.6	18.3	21.2	21.9	20.6	21.2	19.8	22.9	22.0	21.7	22.6
Male	52.8	52.7	50.9	47.0	47.3	44.6	44.9	45.6	46.5	47.4	47.1	47.0	46.9
Female	55.8	54.7	52.8	49.2	49.5	49.5	48.2	47.6	49.1	48.0	48.0	47.2	48.1
White	51.2	50.2	48.6	44.0	44.2	42.6	41.5	41.6	41.7	42.2	41.5	41.2	41.4
Black	61.1	61.8	58.8	55.8	56.9	56.0	56.3	56.3	59.2	57.9	58.7	57.5	58.5
Other race	56.4	50.1	55.4	54.1	51.6	49.8	52.5	52.1	56.6	57.0	59.0	61.9	60.1
†Hispanic													
†Non-Hispanic													
Diabetes	41.0	40.3	37.5	38.2	36.8	36.5	37.7	38.7	40.5	41.2	41.5	42.0	42.6
Hypertension	59.6	55.8	52.2	49.9	49.2	49.1	47.4	46.7	48.0	48.2	47.4	46.8	47.1
Glomerulonephritis	71.3	67.2	65.4	64.8	64.2	58.9	59.0	60.0	62.1	59.7	61.4	60.3	61.6
Other cause	51.5	53.7	55.3	45.9	50.0	49.4	49.1	49.4	49.5	51.0	50.9	50.5	50.6
All	54.2	53.7	51.8	48.0	48.3	47.0	46.5	46.6	47.7	47.7	47.5	47.1	47.5
<hr/>													
ADJUSTED													
0-19	83.0	74.3	83.4	76.0	77.7	74.2	70.1	76.2	74.9	80.1	74.4	76.4	80.0
20-44	67.3	68.4	66.2	67.4	65.6	63.9	65.9	65.3	68.5	68.1	69.1	67.2	68.6
45-64	54.3	52.5	51.9	50.8	49.8	49.6	49.9	50.7	52.0	53.4	54.2	54.6	55.0
65-74	36.9	38.3	38.6	33.9	37.6	36.5	36.1	37.5	39.0	38.8	38.9	39.5	40.6
75+	25.5	27.2	25.7	22.7	24.8	26.2	26.1	25.3	24.9	27.7	26.4	27.4	27.0
Male	44.3	44.5	43.6	41.1	41.9	40.5	41.4	42.1	43.1	45.0	44.9	45.6	45.6
Female	47.4	46.7	46.2	44.3	45.2	46.0	45.5	45.8	47.2	47.3	47.6	47.6	48.8
White	42.0	41.8	41.6	38.9	40.0	39.5	39.3	40.1	40.6	42.3	42.0	42.5	43.1
Black	53.4	52.9	50.5	49.2	49.8	49.5	50.7	50.7	53.4	52.5	53.5	53.1	54.1
Other race	46.8	43.2	45.1	46.6	44.4	45.4	48.3	47.3	52.5	54.2	56.8	60.2	58.6
Diabetes	34.8	34.1	32.1	33.1	32.6	32.8	34.0	35.4	37.3	38.6	39.1	40.0	40.9
Hypertension	54.2	52.0	50.1	48.6	48.7	49.9	49.3	49.0	50.2	51.2	50.8	50.9	51.1
Glomerulonephritis	60.9	58.0	57.5	57.5	57.6	53.8	54.0	54.9	57.1	55.6	57.0	56.7	57.8
Other cause	47.0	48.3	50.3	44.3	47.7	47.0	47.5	47.8	47.6	49.6	49.2	49.1	49.4
All	45.7	45.5	44.8	42.6	43.5	43.1	43.3	43.8	45.1	46.0	46.2	46.5	47.2

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age >110 are excluded.

Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.12

Three-year survival probabilities: incident dialysis patients*censored at transplant, from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis*

UNADJUSTED	1993	1994	1995	1996	1997	1998	1999	2000	2001
0-4	64.6	74.3	73.3	78.2	67.8	83.3	88.0	76.7	84.0
5-9	86.7	88.4	98.4	85.9	95.8	93.5	95.2	95.7	85.4
10-14	82.3	85.5	91.0	90.7	90.6	96.6	93.0	94.4	91.1
15-19	89.7	90.6	91.0	87.8	88.6	87.4	88.1	87.4	87.6
20-29	80.7	81.3	80.2	83.2	84.9	85.2	84.2	82.8	82.6
30-39	71.3	71.3	72.4	74.6	75.5	75.4	76.4	76.9	76.8
40-49	66.9	67.8	69.0	69.1	69.9	69.7	70.3	69.8	70.7
50-59	58.9	59.4	59.5	59.8	60.5	60.1	61.2	61.4	62.4
60-64	50.1	51.5	50.3	51.7	52.9	51.7	52.7	53.4	53.7
65-69	44.8	44.3	45.4	45.7	45.2	45.3	45.6	46.9	47.7
70-79	35.4	35.2	35.7	36.7	35.5	36.2	36.5	36.8	37.8
80+	22.8	23.2	23.1	24.2	22.9	22.4	22.8	23.6	23.6
Male	49.0	48.8	49.3	49.4	48.4	48.8	49.1	49.4	49.7
Female	48.6	48.6	48.5	48.9	48.2	47.6	47.6	47.8	49.0
White	42.8	42.7	43.1	43.2	42.3	42.8	43.0	43.4	43.8
Black	59.5	59.3	59.1	60.4	59.6	57.9	58.3	58.6	59.4
Other race	60.4	60.7	57.4	55.2	55.8	56.0	58.1	57.6	60.0
†Hispanic				54.8	54.8	55.7	55.8	58.2	57.7
†Non-Hispanic				48.4	47.6	47.3	47.4	47.3	48.3
Diabetes	44.5	44.9	44.9	45.3	45.1	45.0	45.9	46.6	47.8
Hypertension	47.6	47.8	49.1	49.3	47.5	47.6	47.3	47.7	47.7
Glomerulonephritis	63.8	62.9	63.4	63.4	64.0	64.3	63.1	65.1	65.6
Other cause	52.1	51.3	50.3	50.7	50.0	49.7	49.7	48.4	49.3
All	48.8	48.7	48.9	49.1	48.3	48.2	48.4	48.7	49.4
ADJUSTED									
0-19	74.0	78.0	80.2	78.2	76.6	80.7	81.7	78.8	78.5
20-44	69.4	70.5	71.1	73.3	74.5	74.3	74.8	74.5	74.9
45-64	57.5	58.5	58.5	59.1	60.3	59.8	60.8	61.4	61.9
65-74	42.0	41.5	43.0	43.7	42.7	43.3	44.0	44.7	46.0
75+	28.3	28.5	28.1	29.4	28.5	28.6	28.9	29.6	29.7
Male	48.2	48.3	49.0	50.0	49.8	50.3	51.2	51.7	51.9
Female	49.4	50.0	50.3	51.2	51.2	50.8	51.1	51.8	52.8
White	44.9	45.3	46.0	47.0	46.8	47.5	48.1	48.7	49.2
Black	55.3	55.4	55.6	57.2	56.9	55.5	55.8	56.6	57.3
Other race	59.5	60.1	57.9	56.5	58.0	57.8	60.4	60.2	61.7
Diabetes	43.0	43.7	43.9	44.8	45.1	45.1	46.4	47.4	48.5
Hypertension	52.1	52.4	53.7	54.7	53.6	53.9	53.9	54.4	54.3
Glomerulonephritis	60.0	60.0	60.0	61.0	61.7	61.8	61.5	63.2	62.8
Other cause	50.6	50.2	49.9	50.5	50.6	50.4	50.8	49.7	50.3
All	48.8	49.1	49.6	50.6	50.4	50.5	51.2	51.7	52.4

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age >110 are excluded.

Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.13

Five-year survival probabilities: incident dialysis patients*censored at transplant, from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis*

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-4	80.6	77.2	83.9	66.5	64.7	64.2	68.0	67.4	63.8	73.7	55.6	61.5	66.5	53.1	64.3	62.7	69.5	67.8	70.5	88.0
5-9	87.6	92.7	68.7	76.6	83.0	62.9	74.3	83.3	91.7	75.3	80.8	94.8	77.0	78.0	84.2	87.5	85.9	95.8	93.5	88.4
10-14	79.9	74.2	84.1	92.6	86.5	88.5	80.2	82.1	70.8	86.9	79.6	78.4	79.9	79.1	74.2	84.6	86.2	86.1	86.0	83.2
15-19	87.7	79.5	77.5	84.1	84.0	70.5	75.5	81.2	76.0	78.3	84.1	82.1	85.6	79.1	80.0	85.0	80.5	82.9	79.1	78.0
20-29	72.0	65.7	67.1	62.4	61.2	58.6	65.2	62.1	67.5	63.9	66.3	66.0	68.1	69.8	71.4	71.5	73.3	74.8	74.0	76.9
30-39	58.7	58.2	51.9	54.6	52.7	50.6	51.0	48.4	54.7	55.4	54.5	53.6	55.7	57.7	57.0	59.0	60.2	62.1	61.6	63.0
40-49	51.9	49.3	48.8	45.5	47.4	46.7	46.8	46.8	48.4	46.0	47.4	47.1	48.3	49.5	50.2	52.4	51.1	52.3	51.9	53.3
50-59	39.5	39.1	38.3	36.1	34.8	33.6	35.1	36.3	35.0	35.5	35.0	36.7	36.9	38.8	39.1	39.5	39.0	40.0	40.3	41.3
60-64	30.8	30.0	28.0	28.1	25.5	26.0	27.2	25.6	27.6	27.0	27.4	27.6	28.4	29.6	30.3	29.1	30.6	31.8	31.6	32.3
65-69	23.4	24.6	23.9	20.4	22.1	22.0	21.7	22.5	22.5	22.5	22.5	21.5	23.4	23.6	24.3	24.0	24.9	24.1	25.3	25.3
70-79	16.0	15.7	17.1	13.5	15.0	15.5	14.7	15.3	15.4	16.0	15.7	15.9	15.8	16.5	16.4	17.0	17.6	17.0	17.7	17.9
80+	7.1	6.6	5.9	6.4	7.2	7.9	7.3	7.6	6.7	8.9	8.7	7.6	7.5	7.9	8.2	8.7	8.6	8.2	8.2	8.2
Male	35.9	33.9	32.5	28.7	28.4	27.1	27.7	27.6	28.5	28.8	28.3	28.1	28.4	29.8	29.6	30.5	30.1	29.4	30.1	30.5
Female	37.9	38.0	35.2	31.4	31.4	30.8	30.2	29.6	30.1	29.0	29.0	28.2	28.9	29.0	29.2	29.1	28.9	28.8	28.8	28.6
White	34.2	31.7	30.2	26.0	25.7	24.6	24.2	23.5	23.2	23.3	22.6	22.3	22.6	23.2	23.4	23.4	23.4	22.7	23.6	23.6
Black	43.2	45.0	41.2	37.4	38.2	37.2	38.0	38.1	40.4	39.1	39.8	38.7	39.5	40.1	40.0	41.0	41.2	40.9	39.9	40.4
Other race	34.0	34.4	41.3	37.8	33.4	31.8	36.5	38.1	39.2	38.6	37.3	39.6	39.8	40.4	40.7	36.5	35.0	36.9	37.2	40.1
†Hispanic																	35.0	34.4	36.2	35.5
†Non-Hispanic																	28.9	28.5	28.6	28.9
Diabetes	24.9	22.2	19.1	19.8	18.5	17.8	20.1	19.9	21.6	21.2	21.3	22.0	22.7	23.7	24.2	24.1	24.3	24.3	25.0	25.8
Hypertension	43.4	37.6	34.5	32.2	31.1	31.3	29.7	29.1	30.2	29.9	29.8	28.2	28.9	28.9	29.3	30.8	30.5	29.6	29.4	29.5
Glomerulonephritis	55.4	51.6	48.2	44.6	43.8	39.6	40.7	41.5	42.7	41.7	42.7	42.3	42.9	44.7	44.2	45.7	45.0	44.7	46.3	45.9
Other cause	33.1	35.6	37.4	29.1	32.3	32.7	32.7	32.8	31.7	33.7	33.1	33.4	33.8	35.4	34.8	34.0	34.0	33.7	33.9	33.1
All	36.8	35.8	33.8	30.0	29.8	28.8	28.9	28.6	29.2	28.9	28.6	28.2	28.6	29.4	29.5	29.8	29.6	29.1	29.5	29.6
ADJUSTED																				
0-19	75.1	65.0	65.4	71.8	69.2	56.9	60.5	68.0	60.7	66.6	66.0	65.9	69.3	60.7	63.9	69.9	68.7	70.0	67.9	68.1
20-44	55.2	53.9	51.4	50.0	50.6	47.9	51.2	49.1	52.7	52.6	53.2	52.1	53.8	54.8	55.9	57.1	57.6	59.2	59.0	60.5
45-64	34.9	33.7	33.2	31.7	30.5	30.4	32.1	31.9	32.7	33.1	33.3	34.8	35.3	37.3	38.0	38.3	38.6	40.1	40.1	41.3
65-74	19.8	20.6	20.7	17.1	19.0	19.2	18.6	19.8	20.1	20.4	20.6	20.0	21.5	21.7	22.2	22.4	23.3	22.5	23.7	24.2
75+	10.9	10.7	10.8	8.7	10.4	11.0	10.8	10.5	10.1	11.8	10.9	11.3	10.4	11.2	11.1	12.0	12.3	11.9	12.4	12.4
Male	28.3	26.9	26.8	24.3	24.7	24.7	25.7	25.6	26.3	27.7	27.3	27.9	28.2	29.9	30.0	30.9	31.6	31.4	32.3	33.4
Female	30.3	30.7	29.7	27.8	28.5	28.5	28.8	29.0	29.4	29.4	29.7	29.7	30.6	30.9	31.6	31.7	32.3	32.6	32.9	33.0
White	26.2	24.9	25.0	22.8	23.3	23.5	23.7	23.7	23.8	25.1	24.6	24.9	25.6	26.7	27.2	27.6	28.4	28.3	29.4	29.8
Black	35.3	35.9	33.2	31.2	31.9	31.4	33.0	33.1	34.8	34.0	35.0	34.8	35.3	36.2	36.4	37.7	38.1	38.3	37.6	38.1
Other race	26.3	29.1	31.4	31.2	28.0	29.4	33.1	33.8	35.8	37.1	36.0	39.5	39.4	40.4	41.1	38.0	37.4	40.3	40.2	43.5
Diabetes	20.3	17.9	16.0	16.7	16.3	16.2	18.1	18.2	19.7	20.0	20.1	21.1	22.0	23.2	23.9	24.0	24.7	25.0	25.8	26.9
Hypertension	38.4	34.4	33.7	32.0	31.8	33.1	32.5	32.7	33.3	33.8	34.1	33.3	33.7	34.3	34.7	36.1	36.7	36.3	36.5	36.7
Glomerulonephritis	43.8	41.9	40.6	38.0	38.2	35.8	37.0	37.4	38.7	38.7	38.9	39.7	39.9	41.5	41.8	42.5	43.1	42.8	44.1	44.5
Other cause	29.5	31.2	33.2	28.3	31.1	31.4	32.0	32.0	30.8	33.4	32.4	32.9	33.4	34.5	34.4	34.1	34.5	34.9	35.1	34.7
All	29.2	28.7	28.1	25.9	26.5	26.5	27.1	27.2	27.8	28.5	28.4	28.7	29.4	30.3	30.8	31.3	31.9	32.0	32.6	33.2

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age >110 are excluded.

Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

" " Zero values in this cell.

Table I.14

Ten-year survival probabilities: incident dialysis patients*censored at transplant, from day 91 to ten years + 90 days, by age, gender, race, & primary diagnosis*

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994
0-4	64.5	66.2	55.9	39.9	53.9	25.7	68.0	57.8	39.0	73.7	38.1	54.7	54.4	46.5	55.1
5-9	87.6	61.8	51.5	76.6	83.0	31.5	74.3	83.3	91.7	62.8	67.4	35.5	66.0	29.3	56.8
10-14	61.3	49.4	54.5	80.1	69.4	75.8	59.4	82.1	50.4	57.9	57.1	69.7	65.9	71.9	49.1
15-19	79.0	61.1	63.9	68.1	64.1	52.9	57.6	57.7	63.5	66.5	62.6	63.5	61.5	62.1	66.2
20-29	52.1	44.2	44.9	42.2	42.0	40.7	42.8	40.1	44.9	40.7	44.6	42.1	45.5	50.8	50.8
30-39	37.1	34.2	29.9	32.0	30.8	29.1	28.3	27.5	28.8	30.7	31.0	30.0	32.2	32.9	30.7
40-49	25.4	22.3	22.2	21.0	22.6	20.7	20.5	20.9	22.6	19.0	19.7	19.4	20.8	21.5	21.9
50-59	12.8	13.3	13.0	11.0	10.8	11.6	10.7	11.2	10.3	10.3	10.1	10.8	10.5	10.4	11.4
60-64	7.6	7.1	5.4	6.8	6.6	7.1	6.8	5.7	6.5	5.5	5.4	5.6	6.1	6.5	6.8
65-69	4.5	5.3	4.0	4.7	4.9	5.7	4.6	4.1	4.3	4.0	4.3	3.8	4.0	4.4	4.1
70-79	2.7	2.1	2.7	1.9	2.8	2.6	2.2	2.4	2.2	1.9	1.9	1.7	2.0	2.1	1.9
80+	1.4	1.0	1.3	0.2	1.1	0.8	0.6	0.6	0.4	0.6	0.3	0.6	0.5	0.5	0.5
Male	13.2	11.6	10.4	9.4	9.7	9.4	9.2	8.9	8.8	8.3	8.8	8.0	8.6	8.8	8.7
Female	15.1	14.3	12.3	10.9	10.9	10.5	9.4	8.9	9.5	8.4	7.9	7.9	7.9	8.1	8.0
White	13.0	10.6	9.6	8.0	8.3	7.7	7.0	6.6	6.2	5.5	5.6	5.2	5.3	5.6	5.4
Black	16.6	17.6	14.7	14.0	14.0	14.2	13.6	12.9	14.5	13.7	13.3	13.0	13.5	13.6	13.5
Other race	12.2	14.6	15.0	13.6	13.8	11.4	15.7	13.8	14.0	11.4	12.7	12.2	12.4	12.9	12.3
Diabetes	7.4	5.3	4.4	4.1	4.2	4.2	4.0	4.2	4.4	3.8	4.1	3.8	4.0	4.3	4.6
Hypertension	17.4	14.1	10.7	11.0	10.5	10.1	9.6	8.2	9.2	9.0	8.5	8.2	8.7	8.6	8.8
Glomerulonephritis	29.9	23.4	19.1	18.2	18.6	17.3	17.4	16.8	16.9	15.6	17.4	16.2	18.1	18.4	16.8
Other cause	11.2	12.2	13.7	10.6	12.0	12.6	11.9	12.3	12.4	12.1	12.2	12.6	12.7	13.7	12.7
All	14.1	12.9	11.3	10.1	10.3	9.9	9.3	8.9	9.1	8.4	8.3	7.9	8.2	8.5	8.3
ADJUSTED															
0-19	59.7	41.8	42.4	52.0	47.4	36.4	41.9	48.1	45.1	51.0	43.1	44.9	45.4	43.0	44.0
20-44	33.4	29.3	27.3	27.5	28.1	26.5	27.2	26.1	27.6	27.4	28.1	27.2	29.0	29.9	29.4
45-64	10.7	10.1	9.9	9.1	9.2	9.5	9.5	9.3	9.5	9.0	9.2	9.7	10.1	10.5	11.4
65-74	3.7	3.8	3.4	3.4	4.0	4.5	3.7	3.5	3.5	3.4	3.6	3.1	3.6	3.8	3.5
75+	1.8	1.5	1.8	0.8	1.7	1.4	1.3	1.5	1.3	1.0	0.7	1.0	0.9	1.0	1.0
Male	10.1	9.1	9.0	8.4	9.0	9.6	9.5	9.1	8.8	8.9	9.2	9.0	9.4	9.8	9.9
Female	11.6	11.3	10.7	10.1	10.8	10.7	10.0	10.1	10.5	10.0	9.7	9.9	10.3	10.6	10.6
White	9.6	8.4	8.5	7.8	8.6	8.8	8.3	8.3	7.9	7.8	8.0	7.9	8.4	8.7	8.7
Black	12.3	12.6	11.1	11.0	11.2	11.7	11.3	11.2	12.0	11.4	11.4	11.5	11.7	12.1	12.1
Other race	8.6	12.2	12.2	11.1	12.2	11.6	14.7	12.5	13.4	12.9	13.1	14.2	14.3	14.8	14.4
Diabetes	5.9	4.3	3.9	3.8	4.2	4.5	4.1	4.3	4.4	4.0	4.4	4.3	4.5	4.9	5.3
Hypertension	15.4	13.7	12.3	12.5	12.6	12.9	12.8	12.3	12.3	12.5	12.2	12.1	12.6	12.9	13.1
Glomerulonephritis	20.5	17.2	16.1	15.2	16.6	16.6	16.3	15.5	16.2	15.2	15.9	15.9	17.1	17.3	16.3
Other cause	10.5	11.1	12.5	11.0	12.5	13.0	12.5	12.8	12.5	12.8	12.7	13.3	13.4	13.9	13.2
All	10.8	10.1	9.8	9.2	9.8	10.1	9.7	9.5	9.6	9.3	9.4	9.4	9.8	10.2	10.2

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age >110 are excluded.

Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories.

Table I.15
Incident patient counts: hemodialysis patients, unknowns dropped

dialysis patients alive on day 91, by age, gender, race, ethnicity, & primary diagnosis

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	*	12	*	12	*	19	22	13	15	21	19	17	15	16	11	14	*	21	*	15	12	16	17	16
5-9	33	29	30	20	17	*	18	20	12	16	26	15	*	13	22	20	20	16	21	25	20	22	30	16
10-14	95	83	80	67	60	71	54	52	48	49	52	40	64	58	66	57	59	59	62	59	70	66	87	74
15-19	281	301	239	246	226	219	205	210	244	256	213	213	232	223	188	226	224	193	230	243	208	228	218	237
20-29	1,010	1,107	1,205	1,150	1,215	1,260	1,252	1,217	1,254	1,392	1,380	1,404	1,441	1,434	1,398	1,404	1,427	1,358	1,436	1,377	1,412	1,443	1,379	1,359
30-39	1,503	1,650	1,783	1,764	1,939	1,988	2,135	2,185	2,428	2,610	2,682	2,707	2,969	2,954	3,002	2,968	3,157	3,095	3,100	3,275	3,193	3,265	3,291	3,269
40-49	1,767	1,990	1,940	2,167	2,251	2,395	2,515	2,818	3,110	3,483	3,754	4,051	4,466	4,675	4,879	5,178	5,632	5,706	6,311	6,330	6,526	6,569	6,925	7,075
50-59	2,709	3,170	3,325	3,374	3,526	3,745	3,879	4,168	4,783	5,136	5,390	5,834	6,324	6,747	7,423	7,542	7,974	8,874	9,642	10,390	10,790	11,276	11,893	12,276
60-64	1,561	1,697	1,915	2,225	2,461	2,671	2,779	3,109	3,426	3,762	4,038	4,450	4,570	4,886	5,036	5,253	5,644	5,963	6,386	6,510	6,754	7,081	7,221	7,624
65-69	1,526	1,540	1,800	2,376	2,374	2,573	2,987	3,404	3,931	4,649	5,139	5,576	6,112	6,302	6,800	6,820	7,719	8,145	8,495	8,586	8,623	8,985	9,203	9,385
70-79	1,657	1,784	2,253	3,227	3,312	3,721	4,328	4,941	5,577	6,868	7,642	8,781	9,833	10,545	11,421	12,216	13,884	15,343	16,449	17,376	17,747	18,149	19,177	19,080
80+	271	285	413	650	664	821	1,034	1,212	1,518	1,939	2,273	2,612	3,083	3,391	3,760	4,149	5,008	5,764	6,451	7,290	7,841	8,279	9,694	9,956
Male	6,952	7,607	8,272	9,522	9,942	10,555	11,534	12,588	14,133	16,249	17,490	18,874	20,565	21,985	23,234	24,086	27,090	29,039	31,252	33,045	33,964	35,258	37,717	38,252
Female	5,470	6,041	6,721	7,756	8,111	8,937	9,674	10,761	12,213	13,932	15,118	16,826	18,554	19,259	20,772	21,761	23,666	25,498	27,341	28,431	29,232	30,121	31,418	32,115
White	8,494	9,211	10,157	11,369	11,874	12,671	13,923	15,130	16,910	19,353	20,871	22,627	24,655	25,883	27,637	28,430	31,698	34,329	36,877	39,209	40,732	41,981	44,393	45,144
Black	3,645	4,078	4,474	5,439	5,676	6,195	6,575	7,419	8,439	9,824	10,484	11,739	12,927	13,627	14,431	15,057	16,344	17,383	18,648	18,868	19,032	19,846	20,929	21,272
Other race	283	359	362	470	503	626	710	800	997	1,004	1,253	1,334	1,537	1,734	1,938	2,360	2,714	2,825	3,068	3,399	3,432	3,552	3,813	3,951
†Hispanic																	5,778	6,005	6,451	7,137	8,292	7,783	8,265	8,809
†Non-Hispanic																	44,978	48,532	52,142	54,339	54,904	57,596	60,870	61,558
Diabetes	1,909	2,843	3,579	4,151	5,081	5,798	6,735	7,671	8,895	10,834	12,298	13,954	15,436	16,729	18,371	20,397	23,342	25,654	27,849	29,335	30,673	32,039	33,284	34,026
Hypertension	2,465	3,485	4,311	4,698	5,245	5,852	6,377	7,393	8,510	9,973	10,847	11,925	13,445	13,956	14,791	13,545	14,780	15,941	17,028	17,946	18,290	19,064	20,439	21,158
Glomerulonephritis	2,114	2,758	3,051	3,157	3,345	3,397	3,540	3,775	4,014	4,189	4,409	4,482	4,568	4,757	4,982	5,098	5,457	5,461	5,573	5,653	5,474	5,410	5,687	5,407
Cystic kidney	634	718	830	842	814	862	895	911	932	918	957	970	1,007	1,057	1,086	1,117	1,067	1,151	1,250	1,265	1,257	1,258	1,333	1,248
Other urologic	340	494	616	704	673	812	840	943	938	987	862	1,000	1,030	872	896	1,281	1,560	1,550	1,619	1,891	1,754	1,837	1,949	1,900
Other cause	1,318	1,620	1,984	2,108	2,225	2,303	2,372	2,306	2,589	2,956	3,013	3,184	3,510	3,671	3,821	4,337	4,501	4,733	5,220	5,320	5,670	5,709	6,323	6,357
Missing cause	3,642	1,730	622	1,618	670	468	449	350	468	324	222	185	123	202	59	72	49	47	54	66	78	62	120	271
All	12,422	13,648	14,993	17,278	18,053	19,492	21,208	23,349	26,346	30,181	32,608	35,700	39,119	41,244	44,006	45,847	50,756	54,537	58,593	61,476	63,196	65,379	69,135	70,367

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90 day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, race, or primary cause of ESRD are excluded.

Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with 10 or fewer patients are suppressed.

Table I.16
90-day survival probabilities: incident hemodialysis patients

censored at transplant, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	91.5	100.0	100.0	100.0	100.0	92.3	100.0	100.0	100.0	100.0	94.1	100.0	100.0	100.0	100.0
5-9	100.0	100.0	100.0	95.7	100.0	100.0	100.0	100.0	100.0	100.0	100.0	96.3	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
10-14	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
15-19	100.0	100.0	100.0	100.0	100.0	100.0	99.6	100.0	100.0	99.6	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	99.6	100.0	99.6
20-29	99.8	99.8	99.8	99.8	99.8	99.9	99.8	99.9	99.9	99.9	99.9	99.6	99.8	99.7	99.7	99.6	99.7	99.8	99.9	99.7	99.8	99.7	99.8	99.8
30-39	99.5	99.7	99.4	99.7	99.6	99.5	99.3	99.4	99.9	99.6	99.7	99.5	99.6	99.4	99.2	99.6	99.4	99.5	99.5	99.6	99.5	99.5	99.6	99.4
40-49	99.3	99.1	99.5	99.1	99.5	99.5	99.6	99.3	99.5	99.3	99.3	99.6	99.7	99.6	99.1	99.3	99.5	99.3	99.0	99.3	99.5	99.4	99.3	99.2
50-59	98.9	98.8	99.0	98.8	99.1	99.1	99.0	99.3	99.2	99.2	98.8	99.3	99.0	99.2	99.0	99.1	99.0	99.1	98.8	98.9	99.0	98.9	98.9	98.8
60-64	98.1	98.2	98.2	98.0	98.4	98.2	98.3	98.3	98.3	98.6	98.1	98.4	98.5	98.6	98.2	98.3	98.3	98.2	98.0	98.4	98.3	98.3	98.3	98.4
65-69	96.6	96.7	96.7	96.3	95.7	95.9	96.4	96.0	96.9	96.5	96.6	96.6	96.7	96.8	97.0	96.7	96.8	96.6	96.6	96.7	96.4	96.6	96.9	96.8
70-79	95.5	95.9	95.7	95.5	94.5	94.4	94.6	95.0	94.3	94.6	95.2	94.8	95.0	95.3	95.2	95.3	95.1	94.8	95.0	95.0	94.9	94.8	95.0	94.8
80+	94.7	94.8	94.2	93.1	92.6	91.9	93.0	91.8	93.6	92.4	93.0	92.9	93.8	93.1	93.5	92.6	93.3	92.3	92.4	92.7	92.6	92.6	92.9	92.3
Male	98.1	98.2	98.0	97.6	97.6	97.5	97.3	97.3	97.2	97.1	97.2	97.3	97.2	97.4	97.1	97.1	97.0	96.7	96.8	96.9	96.8	96.6	96.8	96.6
Female	98.3	98.3	98.3	97.8	97.5	97.4	97.6	97.4	97.6	97.4	97.3	97.2	97.4	97.2	97.2	97.0	97.0	96.7	96.5	96.5	96.5	96.6	96.5	96.4
White	98.0	98.1	97.8	97.2	97.1	96.9	97.0	96.8	96.9	96.6	96.7	96.6	96.7	96.7	96.5	96.4	96.3	95.9	96.0	96.1	96.0	96.0	96.1	95.8
Black	98.6	98.6	98.9	98.6	98.4	98.4	98.5	98.5	98.4	98.3	98.2	98.3	98.3	98.4	98.1	98.2	98.1	98.0	97.8	98.0	97.8	97.6	97.7	97.7
Other race	97.6	98.2	98.3	98.1	98.4	98.5	98.5	98.5	98.3	98.3	98.6	98.2	98.2	98.1	98.3	97.8	98.6	98.0	98.0	97.8	98.0	98.0	98.0	98.0
†Hispanic																	98.2	97.8	97.7	97.8	97.3	97.3	97.6	97.5
†Non-Hispanic																	96.9	96.5	96.5	96.6	96.5	96.5	96.6	96.3
Diabetes	98.6	97.8	98.2	98.0	97.9	97.8	97.8	97.8	97.7	97.8	97.7	97.8	97.8	97.7	97.8	97.5	97.6	97.3	97.1	97.2	97.1	97.1	97.2	97.1
Hypertension	98.5	98.0	97.7	97.0	96.9	96.9	97.0	96.8	96.7	96.4	96.5	96.3	96.5	96.8	96.4	96.5	96.6	96.0	96.2	96.2	96.2	96.2	95.9	96.0
Glomerulonephritis	99.3	99.3	99.0	98.9	98.6	98.7	98.4	98.0	98.7	98.1	98.3	98.4	98.4	98.1	98.0	98.5	98.0	97.9	97.7	98.0	98.0	97.9	98.3	98.1
Other cause	97.6	98.1	98.0	97.4	97.1	96.9	97.0	97.2	97.2	97.0	96.9	96.7	96.7	96.7	96.3	96.0	95.8	95.5	95.9	95.7	95.7	95.7	95.6	94.9
All	98.2	98.2	98.1	97.7	97.5	97.4	97.5	97.4	97.4	97.2	97.2	97.2	97.3	97.3	97.1	97.1	97.0	96.7	96.7	96.7	96.7	96.6	96.7	96.5
ADJUSTED																								
0-19	100.0	100.0	100.0	99.1	100.0	100.0	99.0	100.0	100.0	97.6	99.1	100.0	100.0	100.0	99.0	100.0	100.0	98.8	100.0	99.1	100.0	98.9	100.0	99.1
20-44	99.6	99.6	99.6	99.6	99.6	99.6	99.6	99.5	99.8	99.6	99.6	99.6	99.7	99.6	99.2	99.5	99.5	99.6	99.4	99.6	99.6	99.5	99.6	99.5
45-64	98.9	98.7	98.8	98.6	98.9	98.8	98.9	98.9	98.9	99.0	98.6	99.0	98.9	99.0	98.7	98.9	98.8	98.6	98.7	98.9	98.8	98.8	98.8	98.7
65-74	96.8	96.8	96.5	96.3	95.5	95.6	95.9	96.1	96.0	95.9	96.2	96.0	96.2	96.3	96.5	96.1	96.0	96.1	96.3	96.1	96.0	96.0	96.2	96.3
75+	95.6	95.8	95.6	95.2	94.2	93.8	94.2	93.6	94.1	93.8	94.2	94.1	94.3	94.3	94.1	94.2	94.5	93.5	93.6	93.9	93.8	93.7	94.0	93.4
Male	97.5	97.4	97.3	97.1	97.0	96.9	96.9	97.0	96.9	96.9	97.0	97.1	97.1	97.3	97.0	97.1	97.1	96.9	97.0	97.2	97.1	96.9	97.2	96.9
Female	97.7	97.6	97.7	97.4	97.0	96.9	97.3	97.1	97.4	97.2	97.2	97.1	97.4	97.3	97.3	97.1	97.2	97.0	96.9	96.9	96.9	97.0	97.0	96.9
White	97.5	97.4	97.2	96.9	96.7	96.6	96.7	96.7	96.9	96.7	96.8	96.8	96.9	97.0	96.9	96.9	96.9	96.6	96.7	96.8	96.8	96.7	96.9	96.6
Black	98.0	97.7	98.3	98.1	97.7	97.7	97.9	97.8	97.8	97.7	97.8	97.9	98.0	97.7	97.7	97.7	97.7	97.5	97.6	97.4	97.3	97.4	97.4	
Other race	96.8	97.3	97.2	97.5	97.7	97.9	97.9	97.9	97.7	97.8	98.3	97.8	97.9	97.9	98.1	97.7	98.5	97.9	97.9	97.8	98.0	98.0	98.1	98.1
Diabetes	97.5	96.1	97.1	96.9	96.9	96.8	97.0	97.0	97.2	97.2	97.4	97.5	97.4	97.5	97.3	97.4	97.3	97.0	97.2	97.1	97.2	97.3	97.2	
Hypertension	97.9	97.5	97.3	96.7	96.7	96.8	97.1	97.0	97.0	96.8	96.9	96.9	97.1	97.4	97.0	97.2	97.3	96.9	97.1	97.1	97.1	96.9	97.1	97.1
Glomerulonephritis	98.4	98.6	98.1	98.0	97.8	97.9	97.7	97.1	98.2	97.6	97.9	98.1	98.0	97.7	97.7	98.3	97.7	97.6	97.5	97.9	97.7	97.6	98.1	97.8
Other cause	96.9	97.3	97.2	97.1	96.6	96.3	96.6	96.9	96.9	96.8	96.7	96.5	96.5	96.5	96.2	96.0	95.9	95.8	96.1	96.0	96.0	96.1	95.9	95.3
All	97.6	97.5	97.5	97.3	97.0	96.9	97.1	97.1	97.2	97.0	97.1	97.2	97.2	97.3	97.2	97.1	97.2	97.0	96.9	97.1	97.0	97.0	97.1	96.9

Reference cohort is 1996 incident ESRD patients.
 Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.
 Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.
 The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.
 The age of the incident patient is determined as of the date of ESRD initiation.
 Patients of unknown age or gender, or of age >110 are excluded.
 Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories; no unknown or foreign states.
 †CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.
 " " Zero values in this cell.

Table I.17

One-year survival probabilities: incident hemodialysis patients

censored at transplant, from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	100.0	88.9	87.5	90.0	87.5	94.1	84.0	81.8	55.3	70.8	64.3	81.0	80.8	58.3	64.9	59.3	100.0	82.6	64.0	82.5	100.0	81.3	84.4	93.8
5-9	88.8	92.4	100.0	93.8	100.0	100.0	100.0	100.0	100.0	100.0	87.8	100.0	100.0	92.9	100.0	95.0	87.5	100.0	100.0	100.0	100.0	91.1	80.7	87.5
10-14	96.5	97.6	98.4	95.8	96.5	96.4	100.0	97.6	94.6	98.1	95.8	97.4	90.5	92.2	96.5	100.0	100.0	92.4	95.6	90.2	96.9	97.2	95.5	100.0
15-19	96.0	94.7	95.4	95.5	97.5	93.5	95.3	95.7	96.9	99.0	95.9	94.9	96.5	95.3	96.2	98.0	95.4	97.7	94.4	98.2	95.5	96.5	96.6	96.7
20-29	90.7	92.6	92.5	92.8	92.3	90.4	92.8	90.4	91.2	91.1	91.7	91.4	92.0	92.3	93.0	92.0	94.2	95.1	95.0	94.6	93.0	94.4	93.2	93.3
30-39	90.2	89.8	88.6	89.9	87.4	88.6	88.3	87.6	88.6	87.9	88.7	87.5	89.2	88.0	89.1	88.7	89.5	91.2	90.4	90.6	90.6	91.0	91.2	91.5
40-49	88.0	88.0	86.8	88.1	87.5	87.6	87.5	87.2	87.7	87.4	88.2	86.2	87.6	88.5	88.7	88.5	89.2	89.6	88.5	89.3	89.5	88.7	89.4	88.8
50-59	84.0	84.0	84.4	81.8	82.1	82.8	82.5	83.0	83.5	82.9	83.6	83.4	85.0	85.0	85.8	85.9	85.3	85.4	85.4	85.6	85.3	85.6	85.6	85.4
60-64	79.4	78.3	78.3	78.3	75.8	76.3	77.4	76.3	76.3	77.3	77.7	78.3	79.1	81.6	81.3	80.3	81.9	81.8	80.3	81.4	80.9	81.6	80.5	81.8
65-69	73.9	74.2	74.8	72.4	73.9	71.7	73.5	73.6	72.9	74.2	75.3	75.1	75.3	77.0	76.5	77.2	77.7	76.8	75.8	76.3	76.5	76.5	76.2	76.7
70-79	68.7	68.7	69.5	65.9	67.4	67.0	66.7	65.7	66.0	67.2	68.7	68.3	68.8	70.5	70.5	70.2	70.6	69.9	69.8	69.3	69.1	69.2	69.2	69.4
80+	57.9	53.5	64.6	57.0	57.5	59.3	59.3	56.1	54.5	58.8	59.8	59.3	59.0	62.2	61.7	60.3	59.9	60.0	57.7	58.3	57.5	57.9	58.9	58.9
Male	80.7	81.0	80.0	77.5	77.3	77.0	76.4	76.3	75.6	76.5	77.4	76.7	77.2	78.7	78.4	77.9	78.2	77.7	77.1	77.3	76.9	77.1	76.7	76.8
Female	82.0	81.4	81.7	78.6	78.9	78.3	78.9	76.9	77.6	77.2	77.6	76.8	77.5	78.3	78.4	78.0	77.8	77.2	76.1	76.0	75.6	75.8	75.5	75.9
White	79.5	79.2	78.8	75.3	75.1	74.7	74.5	73.1	72.9	73.6	73.8	73.0	73.5	75.2	75.2	74.8	74.8	74.0	73.6	73.7	73.4	73.3	73.2	73.6
Black	85.4	85.5	84.9	83.2	84.0	83.0	83.1	83.0	82.9	82.4	83.6	82.7	83.7	83.9	83.7	83.0	83.7	83.4	81.9	81.9	81.5	82.0	81.4	81.0
Other race	79.9	80.7	84.2	79.9	80.6	81.4	83.9	80.0	83.2	83.2	85.7	86.1	85.0	85.5	85.0	83.0	81.4	82.9	81.2	82.2	81.8	83.1	82.0	83.5
†Hispanic																	82.1	81.7	81.7	81.0	81.8	82.1	81.5	81.8
†Non-Hispanic																	77.5	76.9	76.0	76.1	75.5	75.7	75.4	75.6
Diabetes	76.6	74.9	73.8	73.7	73.8	73.6	74.6	74.1	75.0	75.7	75.9	76.1	76.7	78.7	78.7	78.0	78.0	77.8	76.6	77.1	77.1	77.3	77.1	77.6
Hypertension	84.8	82.6	80.9	79.0	78.1	78.4	77.4	75.9	75.6	76.2	77.0	75.8	76.3	76.8	77.2	77.6	77.3	76.0	75.7	75.2	75.0	75.1	74.9	74.9
Glomerulonephritis	91.0	88.3	87.7	86.9	86.6	86.4	84.5	84.1	84.6	83.8	84.7	83.0	85.0	86.3	84.5	84.9	85.7	85.5	85.4	84.8	85.0	85.3	85.3	85.4
Other cause	78.5	80.1	81.7	75.8	76.9	75.7	77.1	75.9	75.1	75.3	76.6	75.6	75.6	76.3	76.2	74.3	74.5	74.5	73.8	73.6	72.1	72.5	71.5	71.9
All	81.2	81.2	80.8	78.0	78.1	77.6	77.5	76.5	76.5	76.8	77.5	76.7	77.3	78.5	78.4	77.9	78.0	77.5	76.6	76.7	76.3	76.5	76.1	76.4
ADJUSTED																								
0-19	92.0	90.4	92.7	90.5	94.2	89.4	91.5	91.5	89.6	94.9	88.4	90.2	90.4	87.1	91.4	92.9	92.3	92.2	89.0	93.8	92.8	91.6	90.6	94.1
20-44	88.1	89.2	88.5	88.9	87.6	87.9	87.9	87.1	88.2	87.3	88.6	87.0	88.3	87.8	89.0	88.5	89.6	90.5	90.0	90.3	90.1	90.4	90.4	90.6
45-64	81.6	81.1	81.3	80.3	79.6	80.2	80.9	80.5	80.8	81.4	82.0	81.8	83.2	84.5	84.9	84.6	85.0	85.3	84.6	85.2	85.0	85.2	85.0	85.1
65-74	71.9	71.3	73.3	69.8	71.2	69.4	70.6	70.8	70.7	71.6	73.2	72.9	73.4	75.4	74.6	75.2	75.7	75.0	74.6	74.8	74.7	74.7	74.4	74.9
75+	62.2	63.4	63.5	59.6	62.1	63.0	62.6	59.7	59.5	62.7	63.6	63.1	63.1	65.0	65.5	64.3	64.5	64.1	63.0	63.0	62.6	63.1	63.4	63.6
Male	75.2	75.5	75.1	73.3	73.3	73.2	73.3	73.4	72.9	74.4	75.7	75.3	76.0	77.8	77.8	77.4	78.3	78.2	77.8	78.2	78.0	78.2	78.1	78.3
Female	76.9	76.4	77.8	75.4	76.0	75.6	76.8	75.2	76.2	76.5	77.2	76.8	77.7	78.5	78.9	78.8	78.9	78.8	77.8	77.9	77.8	78.0	77.8	78.2
White	73.6	73.6	74.1	71.6	71.7	71.8	72.3	71.4	71.6	73.1	73.8	73.4	74.2	76.1	76.3	76.3	76.7	76.4	76.1	76.4	76.3	76.3	76.4	76.8
Black	81.3	80.6	80.5	79.7	80.1	79.1	79.8	79.8	79.7	79.4	81.0	80.4	81.4	81.8	81.7	81.2	82.1	82.1	80.5	80.6	80.3	80.9	80.4	80.0
Other race	73.4	75.5	78.4	75.5	75.7	78.0	81.2	76.8	80.7	81.2	84.5	85.1	84.2	85.0	84.7	83.3	82.1	83.8	82.1	83.2	83.1	83.9	83.2	84.7
Diabetes	71.6	70.0	69.3	69.5	69.9	69.8	71.4	71.1	72.3	73.4	73.9	74.4	75.3	77.4	77.7	77.0	77.4	77.5	76.3	77.1	77.3	77.5	77.4	78.0
Hypertension	81.5	79.9	79.2	77.7	77.1	78.0	77.7	76.6	76.5	77.5	78.6	77.7	78.2	79.1	79.3	80.0	80.1	79.3	79.1	78.9	78.8	78.9	79.1	79.0
Glomerulonephritis	86.3	83.4	83.4	82.7	82.9	83.1	81.3	80.8	81.4	81.2	82.4	80.9	83.1	84.4	83.1	83.2	84.5	84.3	84.3	84.0	83.9	83.8	84.3	84.2
Other cause	75.4	76.3	78.5	74.6	75.1	73.7	75.5	74.5	73.5	74.3	75.5	74.6	74.9	75.3	75.5	74.2	74.6	75.0	74.3	74.3	72.9	73.4	72.6	72.9
All	76.0	75.9	76.3	74.3	74.5	74.4	75.0	74.2	74.5	75.4	76.4	76.0	76.8	78.2	78.3	78.1	78.6	78.5	77.8	78.1	77.9	78.1	78.0	78.3

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age >110 are excluded.

Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

." Zero values in this cell.

Table I.18

Two-year survival probabilities: incident hemodialysis patients

censored at transplant, from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002
0-4	100.0	88.9	87.5	90.0	87.5	78.4	54.2	54.5	55.3	50.5	48.2	70.8	53.8	36.5	64.9	59.3	66.7	82.6	64.0	82.5	75.0	81.3	75.0
5-9	88.8	92.4	87.5	93.8	100.0	100.0	85.7	100.0	100.0	85.7	87.8	100.0	100.0	92.9	100.0	95.0	79.5	100.0	90.9	100.0	100.0	91.1	80.7
10-14	96.5	97.6	92.4	90.5	88.8	93.2	96.3	97.6	81.8	98.1	95.8	97.4	87.4	87.4	93.5	100.0	97.4	89.1	92.3	90.2	96.9	89.6	93.7
15-19	93.8	89.4	93.9	89.3	95.5	92.4	89.3	93.4	93.0	96.1	93.7	91.4	94.3	91.8	95.1	94.6	88.3	91.2	91.5	92.0	89.6	92.7	94.1
20-29	83.1	84.5	85.5	82.0	84.4	80.4	83.1	81.4	84.3	84.0	83.5	84.0	85.1	86.3	87.5	84.9	88.2	89.3	90.6	89.1	87.0	88.8	86.6
30-39	80.7	80.8	77.0	80.0	75.6	75.5	76.2	76.2	79.0	77.8	78.5	76.6	78.6	78.9	79.2	80.0	81.0	83.2	81.7	83.4	82.9	83.5	84.3
40-49	77.3	76.7	76.3	76.0	75.9	76.3	75.0	74.2	75.6	75.6	77.2	73.9	77.1	77.6	78.4	78.5	78.2	79.5	79.1	79.4	79.4	79.3	80.0
50-59	71.2	70.7	71.1	68.3	66.9	67.2	67.3	67.5	67.9	69.0	68.8	69.4	70.9	72.0	73.5	72.5	72.6	72.9	71.8	72.7	72.9	73.2	73.5
60-64	64.2	62.4	61.9	62.7	59.7	58.8	61.2	59.5	59.8	60.8	60.9	62.1	63.1	65.5	66.3	65.0	66.7	66.3	64.8	66.5	66.4	67.0	65.9
65-69	56.4	56.0	56.7	52.7	56.5	54.2	55.0	56.2	55.9	56.5	56.1	57.1	58.5	60.4	58.9	60.0	60.9	59.5	59.0	59.6	60.4	61.7	60.4
70-79	48.3	49.7	50.2	45.1	48.1	47.3	47.4	46.1	46.9	48.2	48.4	48.8	49.8	50.8	51.2	51.2	51.7	50.0	51.1	51.1	50.5	51.3	51.3
80+	31.9	34.2	40.3	30.9	37.5	36.0	36.1	33.5	33.2	38.7	36.8	36.4	37.9	38.9	39.6	38.9	38.2	37.5	37.0	37.3	37.2	37.4	38.6
Male	65.3	65.8	64.2	60.4	61.2	59.0	59.6	58.7	59.5	60.2	60.1	59.9	61.1	62.6	62.5	62.5	62.4	61.4	61.5	61.9	61.8	62.0	61.4
Female	68.7	67.6	67.3	62.6	63.2	62.8	62.1	61.0	61.3	61.4	60.7	60.2	61.6	62.0	62.4	61.7	61.9	60.7	60.1	60.1	59.6	60.7	60.3
White	64.2	63.8	62.5	57.4	57.9	56.6	56.3	55.2	54.7	55.6	54.9	54.6	55.8	56.9	57.1	57.0	56.8	55.7	56.2	56.5	56.4	56.6	56.4
Black	72.7	72.9	72.0	69.0	70.3	68.6	68.9	68.0	70.2	69.6	69.8	68.8	70.5	71.1	71.4	70.4	71.5	70.4	68.8	68.8	68.8	69.7	69.1
Other race	66.6	65.8	70.0	65.2	64.6	63.4	66.8	66.8	69.2	70.3	70.9	74.1	72.2	72.3	71.2	69.5	67.2	68.7	67.7	69.8	68.0	71.3	69.2
†Hispanic																	67.4	67.2	67.4	67.9	69.0	69.0	68.3
†Non-Hispanic																	61.4	60.3	60.0	60.2	59.6	60.4	60.0
Diabetes	58.4	55.8	53.7	54.9	53.3	53.3	53.7	54.2	55.6	57.2	56.5	57.6	58.9	60.7	60.9	60.5	60.5	59.9	59.4	60.4	60.5	61.1	60.6
Hypertension	72.1	68.6	66.3	63.1	63.9	61.9	61.2	59.6	60.1	60.8	60.0	59.4	60.8	60.9	61.7	62.0	61.9	59.9	60.0	59.6	59.6	59.9	59.6
Glomerulonephritis	80.7	77.6	76.1	74.2	75.1	72.5	71.1	70.8	73.0	70.6	71.5	70.0	72.3	73.5	72.7	73.2	73.1	73.1	74.1	72.9	73.4	74.7	74.6
Other cause	63.5	65.9	67.7	58.5	61.1	61.1	62.8	61.1	60.1	60.9	61.9	60.7	61.2	62.0	61.8	59.9	60.5	59.6	59.4	59.6	58.0	58.7	58.0
All	66.8	66.6	65.6	61.4	62.1	60.8	60.7	59.8	60.3	60.8	60.4	60.1	61.3	62.3	62.5	62.1	62.1	61.1	60.8	61.1	60.8	61.4	60.9
ADJUSTED																							
0-19	89.0	83.6	87.2	80.4	88.5	85.5	77.7	85.8	82.1	88.5	84.7	84.7	85.6	79.0	89.1	88.4	80.6	82.5	83.5	85.2	83.7	84.6	86.2
20-44	77.0	78.8	77.2	76.9	75.2	74.6	75.2	75.0	77.8	76.9	77.9	75.5	77.7	77.9	79.3	79.0	80.3	82.3	81.4	82.1	81.8	82.1	82.2
45-64	67.5	66.1	66.5	65.4	64.0	63.9	65.1	64.3	64.9	66.5	66.7	67.2	68.8	70.7	71.9	71.1	71.7	72.1	71.2	72.3	72.6	72.9	72.9
65-74	52.8	53.0	54.7	49.3	53.2	50.9	51.8	52.4	52.9	53.6	53.7	54.5	55.9	57.2	56.5	57.8	58.3	56.8	57.3	57.9	57.8	59.1	58.3
75+	40.3	43.1	41.7	36.8	41.4	41.4	41.2	38.7	39.0	42.7	41.6	41.9	42.8	43.9	44.6	43.6	44.1	43.0	43.3	43.5	43.2	43.6	44.1
Male	57.7	58.2	57.6	55.0	56.2	54.6	56.0	55.2	56.2	57.9	58.2	58.5	59.8	61.7	62.0	62.1	62.7	62.4	62.7	63.5	63.6	63.8	63.7
Female	61.6	60.7	61.8	58.4	59.5	59.5	59.6	59.2	59.7	60.9	60.6	60.7	62.3	62.9	63.6	63.3	63.9	63.3	62.8	63.1	63.0	64.1	64.0
White	56.2	56.3	56.5	53.0	54.2	53.6	54.2	53.7	53.8	55.8	55.6	55.9	57.4	58.9	59.4	59.7	60.1	59.7	60.3	60.9	60.9	61.2	61.4
Black	66.4	65.4	65.2	63.7	64.4	63.0	64.1	63.3	65.5	65.3	65.8	65.3	67.0	68.0	68.5	67.7	69.2	68.4	66.9	66.9	67.2	68.1	67.6
Other race	58.0	58.8	61.5	58.9	58.0	59.0	62.9	62.7	65.7	67.8	69.2	72.9	71.2	71.9	71.1	70.2	68.5	70.5	69.3	71.5	70.3	72.6	71.3
Diabetes	51.8	49.5	48.2	49.6	48.6	48.7	49.7	50.5	52.2	54.5	54.0	55.4	57.1	59.1	59.5	59.3	59.8	59.7	59.2	60.5	60.9	61.5	61.3
Hypertension	67.0	64.9	64.2	61.6	62.8	61.8	62.1	61.1	61.8	63.0	62.7	62.6	63.7	64.5	65.2	65.8	66.1	64.9	65.2	65.1	65.2	65.5	65.8
Glomerulonephritis	72.5	70.0	69.8	68.1	69.9	67.9	66.9	66.3	68.7	67.2	68.5	67.2	69.6	70.8	70.8	70.9	71.4	71.4	72.5	71.9	72.0	72.7	73.2
Other cause	59.5	60.9	63.5	57.2	59.3	58.9	61.1	59.6	58.4	60.1	60.9	59.8	60.5	61.2	61.3	60.1	60.8	60.6	60.4	60.8	59.3	60.1	59.6
All	59.5	59.4	59.5	56.6	57.7	56.9	57.7	57.1	57.9	59.3	59.3	59.5	61.0	62.3	62.8	62.7	63.3	62.9	62.8	63.4	63.3	63.9	63.8

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age >110 are excluded.

Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

." Zero values in this cell.

Table I.19

Three-year survival probabilities: incident hemodialysis patients

censored at transplant, from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
0-4	100.0	88.9	87.5	30.0	87.5	78.4	43.4	27.3	41.5	50.5	48.2	70.8	53.8	24.3	64.9	47.4	66.7	68.8	64.0	82.5	75.0	81.3
5-9	88.8	92.4	87.5	93.8	100.0	100.0	85.7	66.7	100.0	85.7	87.8	100.0	100.0	92.9	88.9	95.0	68.2	100.0	90.9	100.0	100.0	72.9
10-14	96.5	88.7	92.4	90.5	88.8	82.0	82.0	87.8	73.7	93.8	91.5	81.8	79.6	87.4	82.1	100.0	90.9	89.1	92.3	84.2	96.9	89.6
15-19	89.6	86.1	93.9	88.2	95.5	91.0	80.8	88.3	88.4	89.1	89.5	89.4	91.7	90.1	91.9	90.9	85.9	88.7	90.1	89.0	87.2	86.2
20-29	78.0	78.5	78.7	75.7	75.8	72.3	75.1	75.2	77.9	77.3	77.6	78.7	79.4	80.9	81.6	80.0	83.2	84.5	84.8	83.9	82.7	82.6
30-39	74.7	72.9	66.2	71.9	65.8	66.8	66.4	66.2	71.0	69.2	69.7	67.7	69.6	70.8	72.1	71.9	74.1	75.1	75.0	76.2	76.1	76.4
40-49	68.1	67.4	67.4	65.3	65.3	65.0	63.6	64.5	66.1	64.5	66.8	64.1	66.9	68.2	68.4	68.8	69.0	70.1	69.6	70.4	69.5	70.2
50-59	60.2	58.9	58.0	55.6	54.9	53.4	54.4	55.2	55.3	56.5	56.6	57.6	57.6	60.4	60.8	60.4	60.4	61.3	60.5	61.2	61.6	62.3
60-64	52.5	49.6	48.4	49.2	46.2	45.3	46.0	46.2	47.6	47.2	47.4	48.6	49.5	51.6	53.0	51.8	52.8	53.5	52.4	53.3	53.9	53.9
65-69	41.5	42.1	42.6	38.9	42.0	40.8	41.5	42.3	43.0	42.1	41.8	43.2	44.0	46.0	45.3	46.5	46.3	45.9	45.8	46.2	47.1	48.2
70-79	34.8	34.6	35.3	30.1	33.3	32.6	33.0	32.7	33.3	34.0	33.7	34.9	35.0	36.4	36.2	36.3	36.8	35.8	36.4	36.8	37.0	38.0
80+	18.9	22.5	20.1	18.3	21.3	22.2	20.7	21.8	19.9	23.5	22.2	22.3	23.6	23.9	24.5	23.7	24.4	23.4	22.4	23.1	23.7	23.7
Male	53.9	53.3	50.9	47.0	47.7	45.0	45.5	46.0	47.0	47.0	46.9	47.2	47.4	49.6	49.5	49.6	49.4	48.6	48.9	49.2	49.5	49.6
Female	57.5	55.9	54.1	49.9	49.8	50.0	48.8	48.3	49.0	47.9	47.4	47.3	48.3	48.8	49.0	48.2	48.5	48.0	47.0	47.2	47.3	48.4
White	52.6	51.0	48.9	44.0	44.2	42.4	41.8	41.8	41.4	41.3	40.6	40.7	41.1	42.9	42.8	42.8	42.6	41.9	42.4	42.7	43.0	43.4
Black	62.2	62.4	59.5	56.2	57.5	56.4	56.8	56.5	59.3	57.8	58.3	57.7	58.7	59.5	59.8	59.0	60.1	59.3	57.6	58.0	58.4	59.0
Other race	55.1	50.1	55.8	54.5	50.3	50.6	52.0	53.4	56.7	57.4	58.3	61.7	59.5	59.4	59.9	56.9	54.6	55.8	55.9	58.1	56.8	59.7
†Hispanic																	54.9	54.8	55.5	55.7	57.9	57.5
†Non-Hispanic																	48.2	47.5	47.1	47.3	47.0	47.9
Diabetes	43.9	41.9	39.0	39.4	38.3	38.0	38.5	39.9	41.0	41.7	42.1	43.1	43.8	46.0	46.4	45.8	46.0	45.8	45.5	46.3	46.8	48.0
Hypertension	61.5	57.1	53.0	50.9	49.9	49.1	48.1	47.2	48.3	48.3	47.2	46.9	47.9	48.1	48.5	49.4	49.2	47.5	47.4	47.4	47.5	47.5
Glomerulonephritis	72.8	67.0	65.0	64.3	63.8	58.6	58.7	59.3	62.0	58.5	59.5	59.4	60.2	63.0	62.0	62.0	61.7	63.3	63.4	61.7	63.9	64.9
Other cause	52.0	53.9	54.8	45.1	49.0	49.4	49.8	49.7	49.4	49.6	49.6	49.6	49.3	51.1	50.4	48.7	49.1	48.7	48.6	49.0	47.7	47.9
All	55.5	54.5	52.4	48.3	48.7	47.3	47.0	47.1	47.9	47.4	47.2	47.2	47.8	49.2	49.3	48.9	48.9	48.3	48.0	48.3	48.4	49.0
ADJUSTED																						
0-19	83.6	76.7	87.2	76.0	88.5	80.0	64.3	72.0	73.8	79.5	78.4	78.9	80.0	75.7	80.2	82.3	75.4	78.3	81.5	80.3	80.6	75.6
20-44	69.5	70.0	67.1	67.6	65.2	64.1	65.2	65.4	69.2	67.8	68.7	66.4	68.6	69.5	70.6	70.4	72.6	73.9	73.9	74.4	73.8	74.3
45-64	56.0	53.8	53.3	52.1	50.9	50.1	51.0	51.6	52.5	53.4	54.2	55.0	55.6	58.5	59.5	59.1	59.4	60.6	59.9	60.7	61.3	61.6
65-74	38.5	38.7	39.6	34.8	38.8	37.3	37.5	38.7	39.7	39.4	39.4	40.3	41.4	43.0	42.3	43.6	44.0	42.9	43.5	44.3	44.6	46.2
75+	26.9	28.7	26.5	23.0	25.4	26.3	27.2	26.1	25.4	28.1	26.7	28.3	28.0	29.1	29.6	28.7	29.3	28.9	28.6	29.1	29.7	29.7
Male	45.7	45.3	44.2	41.6	43.0	41.0	42.4	42.9	43.9	45.1	45.3	46.2	46.3	49.1	49.3	49.6	50.2	50.1	50.6	51.4	51.8	52.0
Female	49.7	48.5	48.2	45.7	46.2	46.8	46.7	46.9	47.7	47.9	47.7	48.3	49.6	50.3	50.8	50.6	51.2	51.3	50.6	51.1	51.5	52.6
White	44.1	43.3	42.9	39.9	41.1	40.2	40.5	41.2	41.2	42.5	42.2	43.0	43.8	45.9	46.1	46.5	47.0	47.1	47.6	48.2	48.6	49.1
Black	54.7	53.7	51.7	50.2	50.9	50.2	51.5	51.4	54.1	53.1	53.9	53.9	54.9	56.0	56.5	56.0	57.3	57.0	55.4	55.8	56.6	57.2
Other race	46.2	43.4	46.1	47.5	43.4	46.6	48.3	49.0	52.7	55.2	56.7	60.8	58.7	59.4	60.2	58.1	56.6	58.4	58.0	60.6	59.9	61.6
Diabetes	37.3	35.7	33.9	34.5	34.1	34.0	35.0	36.7	37.9	39.3	39.8	41.1	42.2	44.5	45.2	44.9	45.6	45.8	45.6	46.7	47.6	48.7
Hypertension	55.7	53.2	51.2	49.6	49.4	49.6	49.8	49.5	50.6	51.4	50.8	51.1	51.7	52.7	52.9	54.1	54.5	53.5	53.7	54.0	54.2	54.2
Glomerulonephritis	62.7	57.9	57.9	57.6	58.3	53.9	54.5	54.7	57.5	55.2	56.4	56.7	57.5	60.0	60.1	59.6	59.9	61.6	61.6	60.7	62.5	62.6
Other cause	47.9	48.7	50.3	44.2	47.6	47.5	48.6	48.6	48.1	49.2	48.8	49.2	49.1	50.6	50.3	49.2	49.8	50.1	49.9	50.5	49.5	49.6
All	47.5	46.8	46.0	43.5	44.5	43.8	44.4	44.8	45.7	46.4	46.4	47.2	47.9	49.7	50.0	50.1	50.7	50.7	50.6	51.3	51.7	52.3

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age >110 are excluded. Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

"." Zero values in this cell.

Table I.20

Five-year survival probabilities: incident hemodialysis patients

censored at transplant, from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-4	100.0	71.1	87.5	30.0	0.0	78.4	28.9	27.3	41.5	50.5	16.1	26.6	53.8	24.3	64.9	47.4	66.7	68.8	64.0	82.5
5-9	88.8	92.4	58.3	93.8	100.0	100.0	85.7	66.7	100.0	85.7	87.8	100.0	100.0	46.4	88.9	95.0	68.2	100.0	90.9	80.0
10-14	80.8	81.4	82.1	90.5	88.8	82.0	68.3	87.8	49.1	82.8	91.5	81.8	70.2	80.7	70.4	93.8	81.8	81.6	92.3	84.2
15-19	86.8	80.2	77.9	82.8	90.8	79.8	75.6	81.0	74.0	76.4	87.7	80.4	84.0	76.4	82.2	86.9	78.8	80.7	81.6	78.0
20-29	74.3	67.5	69.4	63.2	62.1	58.5	64.9	62.6	67.1	65.3	67.6	66.8	68.0	69.9	72.2	72.1	73.7	74.0	73.6	76.9
30-39	61.7	60.2	52.8	57.0	53.5	51.3	51.8	49.0	56.0	55.9	54.5	53.6	56.9	58.0	58.0	59.2	59.9	62.3	61.8	63.0
40-49	54.1	51.3	51.2	47.6	49.1	47.9	47.2	48.7	49.1	46.9	48.3	48.3	50.6	50.8	50.8	52.4	51.5	53.1	52.0	53.6
50-59	40.6	39.5	39.1	36.2	35.6	34.9	35.7	36.6	36.0	36.0	36.0	38.3	38.1	40.1	40.7	40.7	39.8	41.1	40.6	41.9
60-64	31.5	31.4	29.0	29.2	26.9	27.0	28.2	26.1	28.7	27.8	28.2	28.6	30.0	31.0	31.5	30.2	31.4	32.6	32.6	33.0
65-69	24.0	24.6	24.4	21.0	22.8	23.1	22.8	23.4	23.3	23.4	23.0	22.6	24.5	24.6	25.5	24.9	25.4	24.7	25.7	25.8
70-79	16.8	16.1	17.6	14.0	15.9	16.0	15.6	15.9	16.1	16.3	16.4	16.7	16.6	17.3	17.3	17.6	17.8	17.3	18.0	18.1
80+	7.6	7.1	6.6	6.2	7.5	8.3	7.5	7.8	6.8	9.1	8.9	8.1	7.9	8.4	8.7	8.9	8.7	8.4	8.3	8.3
Male	36.8	34.5	32.7	28.6	29.0	27.4	28.0	27.8	29.0	28.8	28.6	28.7	29.2	30.3	30.4	30.9	30.5	29.7	30.4	30.8
Female	39.2	38.8	35.9	31.6	31.6	31.6	30.4	29.8	30.1	29.0	28.7	28.4	29.1	29.1	29.5	28.8	28.4	28.6	28.4	28.4
White	35.2	32.5	30.3	25.9	25.6	24.8	24.1	23.3	23.1	22.8	22.4	22.2	22.6	23.4	23.6	23.3	23.0	22.5	23.5	23.5
Black	43.9	45.2	41.8	37.2	39.0	37.9	38.2	38.1	40.5	38.9	39.4	38.8	39.7	40.0	40.4	40.9	40.8	40.7	39.6	40.2
Other race	34.7	33.8	41.5	38.9	33.7	32.4	35.9	39.2	40.3	39.1	37.0	39.7	40.0	39.5	39.6	36.5	34.6	36.9	37.2	40.3
†Hispanic																	35.1	34.6	36.4	35.7
†Non-Hispanic																	28.8	28.5	28.6	28.9
Diabetes	26.9	23.0	20.0	20.4	19.6	18.7	20.7	20.8	22.1	21.7	22.3	23.0	24.2	24.8	25.4	25.0	24.9	25.0	25.5	26.3
Hypertension	45.4	38.8	34.7	32.4	31.7	31.7	29.8	29.2	30.6	30.2	29.7	28.6	29.4	29.2	30.0	31.0	30.6	29.8	29.5	29.6
Glomerulonephritis	57.6	51.9	48.1	44.4	43.9	39.3	40.1	40.5	43.2	40.7	41.4	41.9	41.6	44.6	43.6	44.5	44.0	44.1	45.3	44.7
Other cause	33.4	35.7	37.1	28.6	31.8	33.6	33.0	32.8	31.6	32.9	32.3	33.0	33.3	34.8	34.2	33.0	32.5	32.7	33.1	32.5
All	37.9	36.5	34.2	30.0	30.2	29.5	29.1	28.8	29.5	28.8	28.7	28.5	29.2	29.8	30.0	29.9	29.5	29.2	29.5	29.7
ADJUSTED																				
0-19	74.8	66.8	64.2	69.3	78.8	66.8	55.5	64.3	55.9	64.3	72.7	65.7	68.4	57.8	66.9	75.9	65.5	67.1	70.4	65.9
20-44	57.9	55.4	52.5	50.9	50.8	47.8	50.7	49.2	53.3	52.8	53.4	51.9	54.7	55.0	56.2	57.1	57.3	58.9	59.0	60.4
45-64	36.2	34.8	34.3	32.3	31.5	31.3	32.5	32.3	33.2	33.3	33.8	35.7	36.2	38.2	38.9	38.8	38.8	40.6	40.2	41.5
65-74	20.8	20.9	21.4	17.7	19.9	19.9	19.7	20.6	20.9	21.0	20.7	22.2	22.5	23.1	22.9	23.6	22.8	23.9	24.3	24.3
75+	11.6	11.4	11.3	9.0	10.9	11.5	11.2	10.9	10.4	11.9	11.4	11.8	11.0	11.7	11.7	12.3	12.3	12.1	12.4	12.5
Male	29.5	27.6	27.4	24.8	25.8	25.2	26.3	26.3	27.1	28.1	28.1	28.8	29.1	30.7	31.0	31.6	32.0	31.9	32.6	33.60
Female	31.8	31.9	31.0	28.6	29.3	29.7	29.5	29.6	30.0	29.9	30.0	30.4	31.4	31.6	32.3	32.0	32.2	32.8	32.9	33
White	27.7	26.1	26.0	23.5	24.2	24.2	24.4	24.2	24.4	25.5	25.3	25.7	26.5	27.5	28.0	28.0	28.6	28.5	29.6	30
Black	36.2	36.2	34.2	31.7	33.0	32.3	33.6	33.7	35.5	34.6	35.4	35.6	36.1	36.8	37.3	38.0	38.1	38.6	37.6	38.1
Other race	27.4	28.8	32.1	32.6	28.1	30.2	33.3	35.4	36.8	38.0	36.4	40.3	40.4	40.5	41.0	38.8	37.7	40.7	40.4	43.8
Diabetes	21.8	18.6	16.9	17.3	17.3	16.8	18.8	19.1	20.3	20.6	21.1	22.1	23.4	24.2	25.0	24.8	25.2	25.6	26.2	27.3
Hypertension	39.7	35.4	34.0	32.3	32.4	33.3	32.7	32.8	33.7	34.2	34.2	33.7	34.1	34.7	35.2	36.3	36.6	36.5	36.5	36.8
Glomerulonephritis	45.9	42.3	41.3	38.4	39.2	35.8	37.1	36.9	39.7	38.5	38.9	40.2	39.9	42.1	42.3	42.3	42.5	42.8	43.9	44
Other cause	30.0	31.4	33.5	28.4	31.5	32.6	32.8	32.5	31.2	33.4	32.5	33.4	33.8	34.8	34.8	34.0	33.8	34.6	34.9	34.6
All	30.5	29.6	29.1	26.6	27.5	27.3	27.8	27.8	28.5	29.0	29.0	29.5	30.2	31.1	31.6	31.8	32.1	32.3	32.7	33.4

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age >110 are excluded. Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

" " Zero values in this cell.

Table I.21

Ten-year survival probabilities: incident hemodialysis patients*censored at transplant, from day 91 to ten years + 90 days, by age, gender, race, & primary diagnosis*

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994
0-4	0.0	71.1	0.0	0.0	0.0	0.0	28.9	0.0	20.7	50.5	16.1	26.6	53.8	24.3	64.9
5-9	88.8	46.2	58.3	93.8	100.0	100.0	85.7	66.7	100.0	85.7	87.8	50.0	100.0	46.4	0.0
10-14	65.1	55.5	27.4	77.5	55.5	82.0	68.3	87.8	24.6	74.5	78.4	81.8	55.3	67.2	40.6
15-19	77.3	62.9	60.4	65.4	74.8	64.4	60.0	49.9	59.4	65.5	69.9	67.2	65.4	59.7	71.4
20-29	53.2	46.2	46.4	44.1	43.7	41.3	43.0	40.8	45.5	43.2	45.6	43.9	44.6	52.5	50.8
30-39	39.9	36.2	30.6	34.1	31.4	30.7	28.7	28.6	30.6	32.0	31.5	31.5	34.3	32.8	32.0
40-49	26.5	23.6	24.5	21.3	23.1	21.8	21.2	21.6	23.0	19.5	20.2	20.3	22.0	21.9	22.0
50-59	13.1	13.4	13.6	11.2	11.4	11.9	11.1	11.5	10.9	10.8	10.6	11.8	11.0	10.9	11.8
60-64	7.9	7.1	5.8	7.4	6.9	7.7	7.2	6.2	7.0	5.9	5.7	6.1	6.6	6.9	7.1
65-69	4.8	5.2	4.3	5.0	4.9	5.9	5.0	4.6	4.6	4.2	4.6	4.1	4.3	4.7	4.2
70-79	2.6	2.1	2.8	2.1	3.1	2.8	2.3	2.5	2.4	1.9	2.0	1.8	2.0	2.2	2.1
80+	1.3	0.9	1.5	0.3	1.2	0.8	0.7	0.7	0.5	0.5	0.2	0.6	0.5	0.5	0.5
Male	13.5	11.8	10.5	9.3	9.9	9.7	9.3	9.0	9.2	8.4	9.0	8.4	8.8	8.9	8.9
Female	15.6	14.6	12.6	10.9	10.7	10.8	9.4	8.8	9.4	8.3	7.7	7.9	7.9	7.9	7.7
White	13.4	10.9	9.6	7.9	8.2	7.9	6.9	6.6	6.3	5.3	5.5	5.3	5.3	5.5	5.3
Black	16.9	17.6	15.2	13.8	14.0	14.4	13.5	12.9	14.3	13.5	13.1	13.0	13.4	13.3	13.4
Other race	12.0	14.1	15.2	13.5	14.9	11.7	15.8	13.4	14.1	11.1	12.5	12.2	12.5	11.7	11.7
Diabetes	7.8	5.6	4.9	4.1	4.3	4.4	4.1	4.4	4.4	4.0	4.3	4.1	4.3	4.6	4.9
Hypertension	18.3	14.3	10.6	11.1	10.7	10.5	9.6	8.4	9.3	9.1	8.6	8.4	9.0	8.5	9.0
Glomerulonephritis	31.3	24.2	18.9	18.2	18.1	17.5	17.0	16.2	17.4	15.2	16.9	16.6	17.6	17.9	16.3
Other cause	11.2	11.9	13.8	10.2	11.9	13.0	12.1	12.5	12.7	11.6	11.8	12.7	12.4	13.2	12.5
All	14.5	13.1	11.5	10.1	10.3	10.2	9.3	8.9	9.3	8.3	8.3	8.2	8.4	8.4	8.3
ADJUSTED															
0-19	58.6	44.1	35.7	47.3	50.4	48.6	41.1	36.4	39.5	52.0	53.8	49.7	48.2	40.9	45.7
20-44	35.0	30.3	28.5	28.2	28.1	27.0	27.0	26.1	28.2	28.2	28.5	28.1	29.8	29.9	29.4
45-64	11.1	10.3	10.4	9.1	9.5	10.0	9.7	9.6	9.7	9.1	9.4	10.2	10.2	10.6	11.5
65-74	4.0	3.9	3.7	3.7	4.2	4.7	3.9	3.8	3.7	3.4	3.7	3.2	3.7	3.9	3.7
75+	1.7	1.5	1.9	0.9	1.9	1.4	1.2	1.5	1.3	1.0	0.8	1.1	0.9	1.1	1.0
Male	10.5	9.2	9.3	8.5	9.5	9.9	9.8	9.6	9.2	9.1	9.6	9.5	9.7	10.1	10.3
Female	12.2	11.7	11.3	10.5	11.0	11.1	10.2	10.2	10.7	10.0	9.8	10.2	10.4	10.6	10.5
White	10.2	8.8	8.9	8.1	9.0	9.2	8.6	8.6	8.3	8.0	8.2	8.3	8.7	8.9	8.9
Black	12.5	12.7	11.7	11.3	11.6	12.1	11.6	11.6	12.2	11.6	11.7	11.8	11.9	12.2	12.4
Other race	8.6	11.7	12.6	11.3	12.9	12.1	15.3	12.7	13.4	12.9	13.3	14.5	14.9	14.2	14.4
Diabetes	6.0	4.6	4.4	3.7	4.3	4.6	4.2	4.5	4.5	4.1	4.6	4.5	4.7	5.1	5.4
Hypertension	15.8	13.7	12.2	12.6	12.8	13.1	12.8	12.4	12.4	12.6	12.4	12.3	12.9	12.9	13.1
Glomerulonephritis	21.5	17.7	16.5	15.5	16.7	16.8	16.4	15.5	16.9	15.2	16.0	16.6	17.2	17.1	16.4
Other cause	10.6	11.0	12.9	11.1	13.0	13.6	13.0	13.3	13.1	12.7	12.7	13.9	13.5	14.0	13.6
All	11.2	10.4	10.3	9.4	10.2	10.5	10.0	9.9	9.9	9.5	9.6	9.8	10.0	10.3	10.4

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age >110 are excluded. Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories.

"." Zero values in this cell.

Table I.22
Incident patient counts: CAPD/CCPD patients, unknowns dropped

dialysis patients alive on day 91, by age, gender, race, ethnicity, & primary diagnosis

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	*	20	33	48	52	70	59	51	58	50	39	60	60	60	47	60	78	61	63	55	77	61	73	63
5-9	*	*	26	30	45	31	41	34	28	34	36	25	25	29	46	35	38	36	33	38	34	39	41	29
10-14	*	20	48	57	71	46	49	51	48	35	56	58	45	54	60	61	79	62	52	55	59	42	75	58
15-19	*	18	50	59	60	65	60	69	60	80	75	57	94	77	70	80	82	73	61	61	68	66	53	54
20-29	53	102	169	186	223	209	254	248	281	278	326	294	303	313	297	279	262	225	199	191	179	174	136	144
30-39	101	185	316	388	378	428	429	477	535	602	657	706	735	714	760	701	615	514	475	488	438	379	392	356
40-49	108	171	343	393	411	463	526	543	594	739	839	981	943	1,055	988	1,126	1,044	858	772	766	766	717	631	686
50-59	147	315	492	535	598	625	633	663	714	868	949	984	1,121	1,111	1,233	1,282	1,219	1,178	1,124	1,099	1,012	1,124	1,045	1,019
60-64	57	188	267	330	323	394	375	418	466	506	605	623	662	661	679	755	664	628	564	546	553	546	529	562
65-69	44	143	234	214	224	270	292	340	341	417	535	502	459	613	561	616	536	502	520	497	500	503	473	494
70-79	43	125	306	265	258	324	284	380	392	478	590	610	637	696	779	742	787	753	725	721	714	735	698	680
80+	*	25	59	52	47	60	62	67	90	114	117	96	132	145	164	161	190	199	170	189	193	235	215	229
Male	311	659	1,215	1,371	1,479	1,582	1,682	1,785	1,955	2,265	2,595	2,793	2,788	2,975	3,040	3,155	2,987	2,694	2,496	2,477	2,457	2,435	2,338	2,331
Female	278	662	1,128	1,186	1,211	1,403	1,382	1,556	1,652	1,936	2,229	2,203	2,428	2,553	2,644	2,743	2,607	2,395	2,262	2,229	2,136	2,186	2,023	2,043
White	476	1,007	1,708	1,880	1,997	2,302	2,323	2,508	2,708	3,119	3,602	3,699	3,826	3,980	4,101	4,204	4,077	3,759	3,447	3,495	3,349	3,337	3,096	3,041
Black	100	297	598	628	623	621	667	747	795	970	1,092	1,150	1,201	1,322	1,309	1,365	1,198	1,065	1,031	986	970	992	968	1,034
Other race	13	17	37	49	70	62	74	86	104	112	130	147	189	226	274	329	319	265	280	225	274	292	297	299
†Hispanic																	570	484	468	492	552	457	481	458
†Non-Hispanic																	5,024	4,605	4,290	4,214	4,041	4,164	3,880	3,916
Diabetes	167	416	769	821	890	1,003	1,104	1,236	1,284	1,626	1,908	2,043	2,202	2,276	2,413	2,645	2,630	2,351	2,215	2,224	2,153	2,095	2,012	1,976
Hypertension	116	295	615	569	561	647	662	694	848	957	1,202	1,142	1,161	1,301	1,295	1,176	1,013	1,015	947	929	917	936	926	975
Glomerulonephritis	155	270	450	490	562	595	606	664	733	812	866	905	944	958	1,013	1,052	997	881	807	729	750	721	627	633
Cystic kidney	38	82	109	115	149	146	160	171	173	195	235	273	265	294	306	295	270	245	218	256	227	257	205	256
Other urologic	13	53	89	86	80	104	84	86	87	87	97	94	113	115	101	140	132	132	110	122	127	133	131	105
Other cause	88	160	284	347	365	405	372	409	381	452	487	515	513	559	543	583	541	459	458	440	417	476	450	410
Missing cause	12	45	27	129	83	85	76	81	101	72	29	24	18	25	13	*	11	*	*	*	*	*	10	19
All	589	1,321	2,343	2,557	2,690	2,985	3,064	3,341	3,607	4,201	4,824	4,996	5,216	5,528	5,684	5,898	5,594	5,089	4,758	4,706	4,593	4,621	4,361	4,374

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90 day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, race, or primary cause of ESRD are excluded.

Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

*Values for cells with 10 or fewer patients are suppressed.

Table I.23
90-day survival probabilities: incident CAPD/CCPD patients

censored at transplant, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	100.0	100.0	100.0	100.0	98.3	100.0	100.0	98.4	100.0	100.0	94.7	98.8	98.6	100.0	98.7	97.7	99.1	96.9	97.3	97.0	98.3	100.0	99.1	99.1
5-9	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	97.7	100.0	100.0	100.0	100.0	100.0	98.4	100.0	100.0	98.5	100.0	98.3	100.0	100.0
10-14	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	98.6	100.0	100.0	98.4	98.8	98.8	100.0	99.0	100.0	100.0	100.0	100.0	100.0	100.0
15-19	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	98.9	100.0	100.0	100.0	100.0	100.0	99.1	100.0	100.0	100.0	98.0	98.9	100.0	98.8
20-29	100.0	99.2	99.5	99.5	99.6	99.2	99.6	98.6	100.0	99.4	99.2	99.4	98.9	99.7	99.7	100.0	99.4	100.0	99.7	98.8	100.0	99.6	100.0	100.0
30-39	99.1	98.6	98.8	99.3	99.0	98.9	98.2	98.9	98.5	98.8	99.1	99.0	98.9	99.2	99.1	99.4	99.6	99.3	99.8	99.2	99.6	99.8	99.2	99.6
40-49	100.0	99.0	99.2	98.9	98.7	98.8	98.8	98.8	99.5	99.6	99.2	99.5	99.2	98.8	99.4	99.3	99.1	99.0	99.5	99.3	99.5	99.7	99.6	99.9
50-59	98.9	98.1	98.3	98.5	98.8	97.9	98.9	98.8	98.5	98.7	99.1	98.5	99.0	98.9	98.9	99.1	99.0	99.5	98.8	99.4	99.0	99.2	99.2	99.2
60-64	98.6	99.5	98.7	98.6	98.1	95.5	96.8	97.3	97.7	99.3	98.4	98.3	98.6	98.8	98.4	98.4	98.8	98.8	98.7	99.1	98.8	99.0	99.1	99.7
65-69	96.4	97.6	94.6	94.8	94.6	97.1	97.5	96.0	96.8	96.3	97.6	98.3	97.8	99.1	98.5	98.0	97.3	98.9	98.0	98.1	98.9	99.3	99.4	98.9
70-79	96.1	95.3	92.7	93.4	94.9	95.5	94.4	95.9	94.7	96.2	95.7	97.1	97.1	96.2	98.2	97.4	96.9	97.7	97.3	97.1	97.1	97.5	97.6	97.4
80+	100.0	97.5	94.2	88.4	93.4	87.8	87.7	87.6	93.6	96.1	94.8	90.7	93.5	92.9	92.1	94.3	92.8	96.3	93.4	96.7	95.4	97.4	95.2	96.2
Male	99.4	98.4	97.2	97.7	98.1	97.3	97.6	97.9	98.2	98.6	98.3	98.7	98.4	98.4	98.8	98.7	98.5	98.9	98.5	98.8	98.7	99.0	98.7	99.1
Female	98.2	98.2	97.7	97.8	97.8	97.8	98.0	97.7	97.9	98.4	98.3	98.3	98.7	98.6	98.5	98.7	98.5	98.9	98.8	98.7	98.8	99.1	99.2	98.9
White	98.8	98.2	97.0	97.6	97.9	97.3	97.5	97.7	97.9	98.3	98.2	98.5	98.5	98.5	98.7	98.6	98.5	98.8	98.5	98.8	98.6	99.0	98.8	98.9
Black	99.1	98.5	98.7	98.3	98.3	98.6	98.7	97.9	98.3	99.0	98.6	98.4	98.4	98.7	98.5	98.8	98.5	99.2	98.9	98.9	99.2	99.3	99.3	99.4
Other race	100.0	100.0	100.0	95.5	98.8	96.4	97.8	100.0	99.2	98.6	98.2	99.5	99.6	98.9	99.2	98.9	98.4	99.2	99.0	98.3	98.5	99.1	99.5	99.5
†Hispanic																	99.5	98.4	98.3	99.7	99.0	99.5	99.1	99.1
†Non-Hispanic																	98.4	99.0	98.7	98.6	98.7	99.0	98.9	99.0
Diabetes	97.8	99.1	97.1	97.6	98.3	97.7	97.6	98.0	97.7	98.5	98.5	98.2	98.6	98.5	98.9	98.9	98.5	99.0	98.7	98.9	98.8	99.0	99.0	99.1
Hypertension	100.0	97.5	96.5	96.7	96.4	97.6	97.1	96.6	97.9	97.3	97.3	98.6	97.9	97.9	98.3	98.2	97.8	98.5	98.1	98.9	98.1	98.7	98.5	98.3
Glomerulonephritis	99.4	99.3	98.3	98.7	99.2	98.0	98.5	98.9	99.1	99.5	99.2	99.5	99.5	99.2	99.3	99.2	99.6	99.6	99.4	99.3	99.9	99.7	99.5	99.8
Other cause	98.6	97.5	98.1	98.0	98.0	97.0	98.2	97.5	97.7	98.8	98.4	98.2	98.2	98.7	98.2	98.4	98.1	98.4	98.4	98.1	98.2	99.0	98.7	99.0
All	98.8	98.3	97.4	97.7	98.0	97.5	97.8	97.8	98.1	98.5	98.3	98.5	98.5	98.5	98.7	98.7	98.5	98.9	98.6	98.8	98.8	99.0	98.9	99.0
ADJUSTED																								
0-19	100.0	100.0	100.0	100.0	99.6	100.0	100.0	99.6	100.0	100.0	97.9	99.7	99.7	99.7	99.4	99.2	99.3	99.0	99.2	99.0	99.1	99.6	99.8	99.5
20-44	99.5	98.6	99.0	99.3	99.1	99.0	98.6	98.6	99.2	99.2	99.1	99.3	99.0	99.1	99.3	99.6	99.4	99.5	99.8	99.2	99.7	99.6	99.5	99.8
45-64	99.0	98.8	98.6	98.6	98.6	97.2	98.3	98.4	98.4	99.1	99.0	98.7	99.0	98.9	98.9	98.9	99.0	99.2	98.9	99.3	99.1	99.3	99.2	99.5
65-74	95.9	96.4	94.6	95.4	94.9	96.2	96.6	96.7	95.6	96.6	96.9	98.1	98.1	98.3	98.3	98.0	97.5	98.3	98.1	97.5	98.3	98.4	98.7	98.9
75+	100.0	97.9	91.9	89.6	95.0	94.2	91.9	92.0	95.7	95.9	95.8	94.7	94.8	94.2	96.2	95.8	94.7	97.5	95.3	97.5	96.2	97.7	96.7	95.9
Male	99.1	97.8	96.3	96.8	97.3	96.2	96.6	97.0	97.5	98.0	97.6	98.1	97.8	97.8	98.4	98.2	97.9	98.5	98.0	98.4	98.4	98.7	98.4	98.9
Female	96.9	97.3	96.9	96.6	96.6	96.6	96.9	96.6	96.8	97.6	97.6	97.5	98.0	98.0	97.9	98.1	97.8	98.4	98.3	98.2	98.3	98.7	98.9	98.6
White	97.7	97.2	95.8	96.4	96.7	95.9	96.2	96.6	97.0	97.7	97.5	97.9	97.9	97.9	98.3	98.1	98.0	98.4	98.0	98.4	98.3	98.7	98.5	98.6
Black	98.5	97.8	98.0	97.6	97.4	97.8	97.9	96.5	97.1	98.2	97.6	97.4	97.2	97.6	97.5	98.0	97.3	98.6	98.1	98.1	98.6	98.7	98.8	99.0
Other race	100.0	100.0	100.0	93.8	97.9	94.4	96.5	100.0	98.7	98.0	97.1	99.1	99.3	98.3	98.6	98.3	97.7	98.9	98.3	97.6	97.9	98.7	99.4	99.4
Diabetes	96.2	98.4	95.5	96.1	97.2	96.2	96.1	97.0	96.6	97.8	97.9	97.4	98.0	97.9	98.4	98.4	97.9	98.7	98.3	98.5	98.5	98.7	98.8	98.9
Hypertension	100.0	97.1	96.2	96.1	95.6	97.3	96.7	96.3	97.7	97.1	97.2	98.4	97.7	97.8	98.3	98.1	97.7	98.5	98.1	98.9	98.2	98.8	98.6	98.4
Glomerulonephritis	98.7	98.8	97.3	97.6	98.4	96.5	97.1	97.9	98.4	99.2	98.5	99.1	99.1	98.6	98.7	98.5	99.3	99.3	98.9	98.6	99.8	99.4	99.1	99.5
Other cause	97.3	96.3	97.3	97.0	96.9	95.3	97.1	96.1	96.4	98.1	97.3	97.0	97.1	97.8	97.0	97.3	96.9	97.3	97.2	96.9	97.1	98.3	97.9	98.3
All	98.1	97.6	96.5	96.7	97.0	96.4	96.7	96.8	97.2	97.8	97.6	97.8	97.9	97.9	98.1	98.1	97.9	98.5	98.1	98.3	98.3	98.7	98.6	98.8

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age >110 are excluded.

Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

." Zero values in this cell.

Table I.24

One-year survival probabilities: incident CAPD/CCPD patients

censored at transplant, from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	85.7	100.0	85.5	85.8	81.7	82.5	93.2	96.3	80.5	90.4	80.6	76.1	86.9	86.3	89.8	88.6	85.8	85.2	85.6	83.2	84.3	88.6	90.4	92.5
5-9	80.0	100.0	90.0	100.0	84.7	83.3	100.0	100.0	100.0	100.0	96.8	100.0	90.7	92.7	100.0	98.1	94.9	96.0	100.0	98.4	98.0	98.1	97.7	97.6
10-14	75.0	100.0	98.0	100.0	96.2	98.1	97.6	100.0	94.5	94.9	96.5	96.4	95.6	96.7	100.0	96.5	94.3	98.6	98.8	100.0	96.2	98.7	98.7	100.0
15-19	100.0	100.0	91.0	93.3	93.8	92.6	96.3	94.9	100.0	97.1	100.0	95.2	96.5	96.8	93.5	97.4	98.1	99.0	97.6	98.9	98.6	98.7	98.6	100.0
20-29	95.8	90.9	90.6	88.5	91.1	91.8	94.8	89.0	92.4	91.1	90.0	93.0	94.0	93.7	94.3	93.9	93.9	98.9	96.3	98.3	95.5	95.7	95.5	96.0
30-39	81.5	87.6	84.4	88.4	86.7	86.0	84.0	87.4	88.4	88.7	90.3	92.3	90.6	91.3	92.0	90.4	92.7	93.5	93.9	95.6	95.9	96.6	94.8	94.8
40-49	85.4	83.5	83.7	85.1	84.8	85.0	83.5	87.5	87.4	87.5	89.5	89.7	89.7	90.7	90.5	92.0	92.3	92.3	93.1	92.9	93.4	95.4	92.1	94.3
50-59	80.0	81.2	80.3	79.9	81.2	78.3	79.5	82.4	83.0	82.8	85.5	84.8	87.0	86.6	88.6	87.5	87.4	89.5	87.4	90.2	89.2	91.0	91.3	91.0
60-64	78.3	73.6	75.3	73.9	72.0	76.8	76.3	74.6	78.0	77.8	78.7	82.5	81.0	82.9	82.0	81.3	82.2	83.0	83.9	81.2	84.4	84.1	87.9	87.7
65-69	67.9	68.9	67.8	71.8	67.0	68.4	68.2	67.8	74.4	74.0	75.6	77.3	81.1	80.0	78.3	80.3	80.6	78.0	80.8	80.3	79.6	79.5	81.1	82.9
70-79	51.0	64.6	63.2	60.2	63.2	71.0	64.6	65.2	65.1	66.9	64.6	69.2	68.7	70.0	70.2	74.7	73.6	73.1	74.5	73.0	72.2	78.0	76.0	78.2
80+	55.6	61.5	50.8	41.0	44.1	48.5	49.3	44.8	50.0	46.3	59.8	61.3	60.4	57.7	58.9	65.6	60.7	57.0	60.0	60.2	61.8	63.2	58.5	65.4
Male	79.1	78.8	79.3	78.1	78.7	79.5	79.6	80.8	80.3	80.5	82.3	83.8	84.1	84.2	84.5	85.2	85.2	86.3	85.8	86.4	86.1	88.0	86.3	88.4
Female	79.1	79.4	75.4	78.8	78.4	78.5	78.2	77.9	81.9	81.5	82.1	84.1	84.6	84.9	84.9	85.8	85.8	85.3	86.3	86.1	86.0	86.9	87.8	87.8
White	78.3	77.8	76.5	77.8	77.4	78.1	77.8	78.2	79.8	79.6	81.0	82.6	83.5	83.5	83.7	84.5	84.0	84.2	84.2	84.8	84.3	85.8	85.1	86.8
Black	81.1	82.2	80.1	79.7	81.8	81.9	81.8	82.3	83.5	83.8	84.9	86.5	85.7	86.3	86.2	86.5	88.9	89.6	90.1	90.5	90.5	91.0	91.4	90.6
Other race	89.7	94.7	76.7	85.1	81.3	81.2	86.9	87.1	90.5	88.7	88.2	92.2	88.6	90.9	90.5	91.8	89.4	90.9	91.1	88.1	89.9	92.8	91.0	91.6
†Hispanic																	89.6	88.6	90.8	91.3	90.4	92.2	88.6	90.3
†Non-Hispanic																	84.9	85.5	85.4	85.6	85.4	86.9	86.7	87.8
Diabetes	62.6	68.3	69.9	72.8	70.8	72.9	71.5	74.2	77.7	76.7	78.4	80.4	80.9	82.1	81.5	82.2	82.1	81.6	82.6	83.2	82.8	85.1	83.3	85.7
Hypertension	81.5	80.1	75.8	75.3	75.8	78.8	79.3	77.3	79.5	78.2	81.0	83.5	83.7	82.6	82.4	85.9	85.7	85.3	84.3	84.4	84.8	85.9	86.8	86.2
Glomerulonephritis	88.9	88.5	85.9	89.9	87.2	90.2	88.8	89.6	90.2	90.8	91.9	90.1	91.7	93.1	93.3	93.1	92.8	93.6	94.9	95.4	95.3	93.7	96.1	95.7
Other cause	83.8	82.3	82.3	79.9	83.1	78.9	81.8	81.4	80.1	83.3	82.6	86.4	85.8	84.9	86.7	86.0	86.6	89.2	88.3	88.1	87.0	89.4	88.8	89.8
All	79.1	79.1	77.4	78.5	78.6	79.0	79.0	79.4	81.1	81.0	82.2	83.9	84.3	84.6	84.7	85.5	85.5	85.8	86.0	86.3	86.0	87.5	87.0	88.1
ADJUSTED																								
0-19	84.0	100.0	83.4	88.6	80.3	79.2	92.5	95.0	85.4	89.5	87.7	83.7	87.4	88.5	92.8	89.8	90.6	89.7	93.1	93.8	88.8	94.0	92.1	95.1
20-44	85.3	86.7	85.8	87.1	86.3	87.6	87.5	88.3	88.5	89.0	90.7	91.8	91.8	91.9	92.4	92.3	93.8	94.8	94.8	95.3	95.9	96.3	95.2	94.6
45-64	77.7	76.5	77.9	77.5	79.0	78.0	79.1	80.0	82.1	83.1	85.0	86.1	86.9	87.7	88.0	88.3	87.6	89.3	89.3	89.4	90.8	90.7	90.9	90.9
65-74	59.3	66.2	65.3	65.1	65.0	67.8	67.3	67.4	70.4	72.9	73.5	75.1	77.3	78.8	76.6	78.7	79.2	78.7	81.4	79.2	78.6	81.7	79.2	82.3
75+	52.7	53.8	52.6	47.3	52.2	62.6	57.0	54.9	55.2	53.4	58.0	64.1	61.9	60.1	63.4	70.9	65.6	64.1	64.5	66.9	66.2	67.9	68.9	70.7
Male	68.7	69.9	71.5	69.5	70.5	72.9	73.2	74.0	73.5	75.1	77.3	79.2	80.4	80.9	81.3	82.4	81.8	83.7	83.1	84.3	83.8	86.0	83.8	86.2
Female	67.6	70.1	67.8	69.5	69.8	69.8	70.6	71.2	74.9	75.6	77.9	79.6	80.0	81.0	80.7	82.6	82.2	81.5	83.0	82.3	82.3	83.8	84.5	84.3
White	65.8	67.1	67.9	68.2	68.1	70.0	69.9	71.0	72.4	73.7	75.9	77.7	79.1	79.6	80.2	81.3	80.4	81.4	81.2	81.8	81.4	83.2	82.6	84.3
Black	68.6	73.1	71.6	69.3	73.3	72.5	74.5	72.4	74.9	77.0	79.0	80.7	80.8	81.3	80.0	82.5	84.3	84.3	86.7	86.6	87.2	87.7	87.1	86.7
Other race	87.0	91.3	60.9	78.1	65.8	63.9	80.2	79.2	85.4	82.3	83.7	93.3	83.7	88.6	89.1	91.3	88.0	86.9	88.4	86.8	85.6	92.1	88.5	88.6
Diabetes	52.8	58.8	62.3	64.5	63.3	65.2	64.7	67.6	71.7	71.0	74.2	76.0	76.5	78.9	77.9	79.2	78.6	79.0	79.9	80.5	80.0	82.8	80.5	83.1
Hypertension	77.2	76.2	73.1	70.9	71.7	76.3	77.7	75.1	76.4	77.1	79.8	81.7	82.4	81.7	81.5	85.0	84.9	84.7	84.1	83.9	84.2	85.7	87.0	86.0
Glomerulonephritis	80.2	81.4	77.6	83.0	79.2	85.6	82.7	83.6	84.4	86.0	86.3	85.2	87.7	89.6	90.0	90.1	89.6	89.6	91.8	91.9	92.2	89.3	93.8	93.2
Other cause	76.9	76.7	77.0	73.2	77.6	72.5	75.4	75.1	72.9	77.2	77.4	81.1	81.5	79.0	82.3	81.2	80.4	83.9	82.6	83.3	82.3	85.6	82.6	84.4
All	68.3	69.9	69.6	69.4	70.1	71.5	72.0	72.6	74.1	75.4	77.5	79.4	80.2	80.9	81.1	82.5	82.0	82.7	83.1	83.4	83.2	85.0	84.2	85.4

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age >110 are excluded.

Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

." Zero values in this cell.

Table I.25

Two-year survival probabilities: incident CAPD/CCPD patients

censored at transplant, from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002
0-4	42.9	95.5	80.5	75.9	78.3	75.6	90.1	91.7	71.6	90.4	69.9	76.1	84.4	84.5	83.5	78.4	81.3	77.1	81.4	81.6	74.3	83.3	79.2
5-9	80.0	100.0	90.0	91.7	77.0	83.3	84.4	100.0	100.0	100.0	86.9	100.0	90.7	92.7	91.1	93.4	94.9	96.0	95.2	95.4	98.0	91.0	86.2
10-14	75.0	78.8	98.0	100.0	89.5	98.1	93.3	100.0	94.5	91.9	87.2	96.4	85.7	93.0	100.0	93.6	89.8	92.1	97.0	100.0	94.0	94.8	97.1
15-19	100.0	100.0	88.0	89.8	87.0	87.7	90.2	92.3	97.0	95.1	97.9	95.2	94.8	87.0	91.4	93.5	91.2	95.6	89.5	96.8	93.4	95.1	98.6
20-29	80.8	78.4	81.1	81.7	76.6	80.1	87.2	78.6	86.2	83.0	81.5	84.3	87.8	88.0	88.1	89.5	87.8	91.8	92.1	93.3	92.8	88.9	90.0
30-39	66.4	76.7	74.4	80.5	74.9	73.2	71.1	76.1	79.1	78.4	79.5	81.9	80.2	82.1	81.4	84.2	84.4	84.7	85.6	88.7	90.6	88.8	90.7
40-49	72.7	70.1	68.5	70.1	69.6	72.8	70.0	75.1	75.4	74.1	80.0	75.0	79.1	78.3	78.2	80.6	82.4	82.2	82.8	82.5	84.3	87.1	84.8
50-59	65.0	67.1	64.3	64.3	65.9	61.4	61.7	62.5	66.5	67.4	69.2	67.3	71.3	72.7	73.2	72.4	73.2	74.7	73.2	76.8	76.6	77.1	80.4
60-64	66.7	52.5	52.8	54.8	51.9	55.8	55.4	57.7	60.5	59.3	57.6	61.4	61.0	66.3	64.7	62.8	63.6	67.1	64.9	65.9	69.9	69.5	73.4
65-69	39.6	54.9	47.3	51.3	51.2	47.8	42.8	46.4	52.9	52.4	56.0	54.5	59.0	60.9	61.6	61.4	61.2	56.0	62.7	59.8	60.6	66.2	63.4
70-79	46.9	42.1	43.1	37.9	37.7	47.2	38.2	43.1	42.4	42.2	40.9	48.5	47.6	48.2	48.1	51.1	50.8	52.1	52.5	51.0	48.8	58.5	53.6
80+	11.1	35.9	21.5	23.0	25.2	32.9	25.4	17.1	23.5	30.1	35.4	35.8	33.3	33.3	33.1	34.4	38.0	32.9	40.0	36.4	39.6	40.6	34.9
Male	64.9	64.0	63.5	61.8	61.7	60.0	61.0	63.4	63.9	63.6	64.6	65.4	67.3	69.5	68.6	69.7	69.6	70.6	70.3	71.7	72.3	73.3	73.8
Female	63.0	62.7	57.2	63.1	61.9	63.6	59.8	60.9	66.2	66.0	66.9	68.5	69.8	69.6	69.9	70.2	71.5	70.7	72.0	72.0	71.8	74.8	73.8
White	61.8	62.1	58.6	61.1	59.5	60.1	57.7	59.8	62.7	62.1	61.9	64.0	66.0	66.6	66.7	66.7	67.8	67.0	67.7	68.7	68.9	70.4	69.6
Black	71.4	67.0	65.4	65.5	67.5	67.2	67.6	69.2	71.3	70.3	74.1	72.8	73.6	74.9	72.9	76.0	76.7	79.4	78.5	79.8	79.4	81.6	83.0
Other race	79.2	68.0	63.2	68.8	68.8	63.6	67.6	61.2	67.7	75.4	83.0	78.4	77.1	81.5	82.3	78.7	76.3	79.3	81.0	79.2	80.4	84.6	82.5
†Hispanic																	77.7	75.3	81.3	78.6	79.8	81.7	79.7
†Non-Hispanic																	69.6	70.1	69.9	71.0	70.9	73.1	72.9
Diabetes	39.2	47.8	48.3	53.6	47.7	49.8	47.9	51.8	56.1	56.3	56.2	57.5	59.9	61.7	61.7	61.8	62.9	62.1	63.1	64.3	65.8	68.2	67.9
Hypertension	64.6	64.3	60.6	57.9	61.9	63.3	62.5	60.6	66.0	62.1	64.8	68.2	69.0	67.4	67.9	71.4	70.9	71.5	71.0	71.0	69.8	72.6	73.6
Glomerulonephritis	83.0	76.7	74.1	79.2	76.9	76.3	76.8	79.0	77.9	78.2	83.4	78.9	82.2	86.2	83.3	84.3	85.3	85.8	86.2	88.4	88.5	86.5	88.6
Other cause	70.7	68.5	66.1	65.8	67.2	64.9	64.4	67.2	66.6	71.6	71.1	74.7	74.9	75.5	75.4	75.5	75.9	77.3	78.6	78.1	76.0	79.4	77.4
All	64.0	63.3	60.5	62.5	61.8	61.8	60.4	62.2	65.0	64.7	65.7	66.8	68.5	69.5	69.2	69.9	70.5	70.6	71.1	71.8	72.1	74.0	73.8
ADJUSTED																							
0-19	59.7	87.1	79.3	79.9	70.1	73.4	80.1	90.7	77.3	87.8	75.6	83.7	83.1	81.5	85.6	82.9	82.3	82.4	85.3	89.4	82.0	87.3	86.4
20-44	68.6	74.6	74.4	76.6	75.0	74.9	76.3	76.9	78.6	78.4	80.7	80.3	81.7	82.3	82.6	84.7	84.9	85.3	85.7	87.4	90.2	87.4	88.7
45-64	63.5	58.4	59.4	60.6	60.4	60.7	60.0	62.2	66.0	66.9	68.3	68.5	71.3	73.8	72.9	73.1	73.9	75.4	74.6	76.0	76.3	78.1	80.0
65-74	39.5	48.2	44.5	44.2	44.4	47.2	41.1	46.5	49.3	49.9	52.1	54.5	56.6	58.3	58.2	59.7	59.1	59.1	61.6	59.1	59.1	65.7	60.3
75+	30.1	31.7	30.0	26.6	28.5	39.1	31.0	29.5	28.4	32.8	34.8	39.9	37.7	38.7	38.3	40.1	42.7	39.6	44.2	43.2	42.3	47.5	44.9
Male	51.8	52.5	53.0	50.8	50.9	51.9	52.1	53.9	54.8	56.0	56.9	58.3	60.9	64.1	63.4	64.4	64.3	66.3	65.9	67.2	68.1	69.9	69.4
Female	46.7	50.1	48.3	51.7	50.5	53.3	49.0	52.2	56.2	57.4	60.3	61.5	62.6	63.1	63.0	64.4	65.7	64.0	66.9	65.9	65.3	69.6	68.5
White	45.7	48.6	47.5	49.0	47.5	50.2	47.2	50.4	52.9	54.0	54.9	56.9	59.3	60.8	61.3	61.4	62.5	62.5	63.6	63.8	64.3	66.7	65.7
Black	54.4	53.1	54.7	52.2	55.6	55.4	56.6	56.2	58.8	59.6	64.0	62.8	64.4	66.6	62.7	69.0	68.5	70.1	71.3	71.3	71.7	74.7	76.0
Other race	63.2	48.6	49.7	60.4	49.9	43.5	57.4	47.7	54.3	65.2	75.6	76.3	69.8	77.5	77.7	73.8	71.5	72.9	73.9	76.6	71.9	81.3	77.5
Diabetes	30.0	37.3	39.5	44.5	39.4	42.4	40.0	43.8	48.1	48.7	50.1	51.2	53.1	56.3	56.4	56.4	57.6	58.0	59.0	59.6	61.0	64.5	63.4
Hypertension	58.1	59.3	57.4	52.0	56.9	60.9	59.5	58.1	62.3	60.6	62.9	65.5	67.1	66.0	66.5	69.4	70.0	70.4	70.5	69.8	68.3	71.8	73.5
Glomerulonephritis	71.1	65.1	62.8	67.7	64.7	68.4	67.1	69.1	67.1	69.2	73.8	70.3	73.8	80.2	75.3	78.2	78.8	77.4	79.0	80.9	82.3	79.7	81.9
Other cause	60.3	61.1	58.8	57.5	58.7	56.5	55.0	58.2	57.4	63.1	63.3	66.1	67.9	67.4	67.4	67.7	66.2	67.7	69.7	69.9	67.3	72.0	66.9
All	49.6	51.2	50.5	51.2	50.6	52.6	50.7	53.0	55.4	56.6	58.5	59.7	61.7	63.6	63.3	64.4	64.9	65.3	66.4	66.6	67.0	69.8	69.0

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age >110 are excluded. Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

." Zero values in this cell.

Table I.26

Three-year survival probabilities: incident CAPD/CCPD patients

censored at transplant, from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
0-4	42.9	95.5	80.5	75.9	78.3	75.6	90.1	85.6	71.6	84.0	65.7	71.3	84.4	77.8	81.0	78.4	71.5	70.6	81.4	81.6	71.2	78.9
5-9	80.0	100.0	90.0	91.7	77.0	69.4	84.4	100.0	83.3	100.0	79.7	100.0	90.7	85.0	85.0	93.4	94.9	96.0	89.6	95.4	93.5	91.0
10-14	75.0	52.5	98.0	93.8	89.5	98.1	93.3	94.1	94.5	91.9	87.2	96.4	85.7	79.7	94.7	86.3	85.7	88.5	97.0	100.0	90.6	94.8
15-19	100.0	100.0	88.0	85.7	82.6	77.5	86.6	89.5	92.8	87.3	91.6	91.2	92.6	83.5	91.4	91.2	89.4	90.8	84.5	85.5	87.2	92.8
20-29	74.9	70.6	71.5	76.5	72.1	74.5	79.0	72.1	81.3	77.0	72.4	77.6	80.6	82.2	84.6	84.2	82.6	86.8	87.4	85.2	85.8	81.4
30-39	58.1	65.4	63.5	69.9	68.4	63.0	62.3	65.7	69.0	69.0	71.7	73.0	68.4	70.8	71.7	76.0	77.3	78.9	78.7	81.8	83.4	84.0
40-49	57.0	61.0	56.4	57.3	57.5	62.8	60.5	62.3	62.1	60.9	64.7	63.3	64.5	65.9	67.4	70.1	71.1	72.1	72.0	74.1	72.3	77.3
50-59	54.4	56.4	52.5	51.0	53.2	48.4	47.7	48.0	52.4	53.3	56.1	51.6	57.9	56.8	58.1	59.2	59.4	59.2	61.6	63.5	65.4	64.9
60-64	49.2	39.7	38.7	42.9	38.5	42.0	43.9	43.9	42.3	46.0	42.8	47.8	46.3	49.9	50.7	47.2	49.2	53.5	51.5	49.4	54.3	54.3
65-69	30.2	43.9	36.2	35.3	36.2	35.4	30.2	32.4	38.6	35.9	39.4	38.2	42.9	43.3	42.7	46.8	46.2	40.1	43.4	41.6	45.0	46.8
70-79	38.8	28.0	29.2	26.2	23.5	31.8	21.1	26.2	29.4	26.9	24.4	32.1	28.8	34.1	31.2	36.1	35.6	34.4	36.5	34.1	34.4	41.2
80+	0.0	15.4	10.8	13.1	19.4	12.5	16.6	10.5	13.7	13.8	22.8	23.6	20.1	18.6	15.4	15.8	20.3	17.9	20.0	20.4	24.6	26.1
Male	51.8	51.8	51.6	49.6	48.6	47.1	47.4	47.8	49.4	49.9	49.7	51.4	51.9	54.2	53.4	56.0	55.7	55.2	55.6	57.6	57.3	58.8
Female	53.6	51.6	44.8	50.6	51.1	50.8	49.0	49.3	53.7	52.3	53.6	54.9	56.4	55.8	56.7	57.7	59.3	59.0	60.3	58.8	61.5	62.5
White	49.4	49.2	46.2	47.0	47.5	46.5	44.4	44.9	47.5	47.1	46.7	48.9	49.7	50.5	50.6	52.4	53.2	52.3	53.9	54.1	55.0	56.2
Black	64.1	59.4	53.7	57.5	55.1	56.2	57.5	58.3	61.6	59.9	61.9	61.6	62.6	63.8	62.2	65.2	66.8	68.7	67.3	68.1	68.7	70.0
Other race	73.1	56.1	51.0	55.3	60.5	48.8	61.5	55.4	56.4	61.3	74.0	68.9	69.3	68.8	72.4	67.5	65.1	65.4	66.7	67.7	70.9	72.0
†Hispanic																	64.2	65.4	68.1	66.6	69.2	71.1
†Non-Hispanic																	56.5	56.0	56.7	57.1	57.8	59.4
Diabetes	26.3	33.8	33.1	36.4	33.5	35.1	35.4	36.2	39.0	39.6	39.4	41.0	43.5	43.8	44.1	45.5	46.4	46.2	47.0	48.0	51.0	52.5
Hypertension	56.7	51.5	48.6	48.4	48.9	52.0	50.7	47.0	52.4	48.8	51.5	55.1	53.3	53.9	53.7	58.5	58.6	57.4	60.1	57.3	58.3	60.0
Glomerulonephritis	72.8	69.6	64.9	70.7	67.5	62.9	65.2	68.1	68.0	68.1	72.0	69.3	74.0	74.1	73.9	75.9	76.3	76.2	75.7	80.3	80.3	74.9
Other cause	57.9	57.3	55.9	54.3	57.2	53.1	52.0	55.3	56.0	60.7	59.6	63.2	62.4	66.0	65.8	67.3	67.8	67.2	69.0	68.1	64.0	70.0
All	52.6	51.7	48.3	50.0	49.8	48.9	48.2	48.6	51.4	51.0	51.6	53.0	54.0	55.0	55.0	56.8	57.4	57.0	57.9	58.2	59.3	60.7
ADJUSTED																						
0-19	59.7	79.3	79.3	76.2	67.5	63.0	77.5	83.7	71.4	82.9	66.7	77.7	83.1	69.0	81.3	76.3	78.1	71.9	80.7	82.0	75.5	81.9
20-44	58.9	64.7	63.5	67.4	67.3	65.9	67.8	66.1	67.3	68.0	70.5	71.4	69.8	70.9	73.5	76.5	76.6	79.0	78.3	78.8	79.8	80.2
45-64	48.8	46.7	46.1	46.8	46.6	47.7	47.4	48.3	50.6	53.1	53.8	53.8	56.8	58.3	58.8	59.2	60.5	61.2	62.5	62.8	64.3	66.0
65-74	29.7	35.1	31.5	30.6	30.2	33.3	27.1	30.3	35.7	33.1	35.0	38.5	39.7	41.7	40.0	45.1	44.1	41.3	43.6	41.7	44.0	48.4
75+	21.2	18.7	19.0	15.3	17.9	23.5	15.8	17.7	18.3	19.5	20.7	24.4	20.5	25.6	21.2	23.6	27.0	24.6	27.5	27.3	27.5	31.1
Male	38.1	40.2	40.6	38.8	37.6	39.2	38.4	38.0	39.8	42.2	41.5	43.9	44.7	48.1	47.3	49.8	49.7	50.0	50.4	52.6	52.6	54.9
Female	36.5	38.9	36.1	38.4	39.3	40.9	38.1	40.5	43.3	42.7	46.3	47.0	48.0	48.3	48.8	50.8	52.6	51.2	54.3	51.5	54.1	57.0
White	32.9	36.0	35.2	35.1	35.7	37.4	34.1	35.8	38.1	39.1	39.7	42.0	42.7	44.6	44.9	46.8	47.9	47.5	49.4	49.1	50.6	52.9
Black	46.2	44.1	41.9	43.3	41.2	43.2	45.8	43.6	46.9	47.7	49.6	49.4	51.1	53.1	50.4	55.8	56.2	56.8	57.8	56.5	57.9	60.7
Other race	52.3	34.5	35.5	44.4	39.0	29.6	50.2	41.1	43.6	48.2	65.2	61.8	59.7	62.2	63.9	59.5	60.2	55.8	56.8	63.8	58.1	65.4
Diabetes	18.9	25.1	25.4	28.1	26.2	29.5	28.0	28.8	31.8	32.4	33.8	35.0	36.9	38.2	38.8	39.9	41.0	42.0	42.7	42.9	45.8	48.6
Hypertension	50.3	46.1	45.4	42.8	43.5	50.3	47.8	45.2	48.9	47.2	49.5	52.2	50.7	52.7	51.9	55.7	57.5	56.1	59.6	56.6	56.6	59.7
Glomerulonephritis	57.6	57.3	52.7	57.6	53.9	53.7	53.4	56.0	54.8	56.9	59.5	59.5	62.9	64.2	62.9	67.1	67.7	64.0	64.8	69.0	72.0	65.3
Other cause	45.9	49.7	48.2	45.5	48.2	43.9	42.1	45.4	46.1	51.5	50.4	52.3	52.9	56.5	55.7	57.9	56.9	55.3	57.4	57.9	52.8	60.6
All	37.5	39.4	38.2	38.5	38.3	40.0	38.3	39.2	41.4	42.4	43.7	45.3	46.2	48.2	48.0	50.3	51.1	50.6	52.3	52.1	53.4	56.0

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age >110 are excluded.

Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

"." Zero values in this cell.

Table I.27

Five-year survival probabilities: incident CAPD/CCPD patients

censored at transplant, from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-4	42.9	95.5	80.5	75.9	78.3	61.8	90.1	85.6	71.6	84.0	65.7	71.3	67.2	64.0	72.6	64.7	65.3	66.9	70.7	81.6
5-9	80.0	100.0	90.0	91.7	77.0	52.1	70.3	100.0	83.3	81.8	79.7	100.0	90.7	85.0	79.0	65.4	94.9	96.0	80.7	95.4
10-14	75.0	26.3	87.1	93.8	79.5	98.1	93.3	87.4	85.1	73.5	80.5	72.3	85.7	63.8	83.6	86.3	85.7	88.5	69.3	88.9
15-19	100.0	100.0	78.2	85.7	67.6	64.0	76.7	85.0	83.9	78.7	77.8	81.3	88.9	83.5	81.1	88.0	82.2	87.8	77.9	78.4
20-29	70.8	54.8	57.4	65.9	52.4	61.2	64.3	59.8	69.8	60.0	55.8	67.0	70.2	72.2	75.8	71.4	74.4	82.1	75.7	75.4
30-39	47.6	49.4	46.1	49.7	51.0	47.4	46.2	47.2	54.1	54.6	54.0	53.3	51.7	54.9	58.9	58.5	62.0	64.2	62.8	65.8
40-49	40.0	43.1	42.3	39.8	40.2	46.7	44.1	41.0	46.3	43.4	45.2	45.9	42.4	49.7	48.9	52.1	50.9	50.5	52.5	55.8
50-59	35.1	38.9	34.6	34.3	33.6	30.0	32.4	31.3	30.5	33.4	32.1	30.3	36.9	38.0	35.9	37.1	38.0	37.4	41.5	39.8
60-64	35.8	21.6	21.8	22.6	18.9	22.1	26.8	24.9	24.4	24.2	21.9	25.9	26.0	28.9	29.5	26.5	27.3	30.8	27.3	30.4
65-69	18.9	21.3	17.1	16.4	19.1	21.1	16.6	17.1	19.3	16.4	21.8	16.7	23.0	23.4	21.8	23.3	23.1	20.7	22.5	21.1
70-79	18.4	12.2	11.6	10.4	8.1	16.0	7.1	14.0	11.3	12.8	9.9	13.6	13.5	13.3	12.2	16.8	15.6	14.7	16.1	16.1
80+	0.0	2.6	3.1	0.0	7.8	1.6	9.1	1.3	4.9	6.5	7.1	6.6	6.9	4.5	6.9	4.9	5.4	6.3	5.4	8.7
Male	35.9	31.2	31.6	30.3	29.0	30.9	31.3	30.6	30.3	31.5	29.7	30.7	32.2	34.9	33.5	35.5	34.1	34.0	34.5	36.9
Female	39.1	35.8	29.7	33.1	33.3	31.6	33.3	31.9	35.7	33.5	33.5	34.5	37.0	36.8	37.0	37.3	39.7	39.5	39.9	39.8
White	32.9	30.0	28.4	28.4	28.9	28.2	28.1	27.3	27.9	27.9	25.8	27.7	29.5	30.4	29.6	31.0	31.1	30.6	31.7	32.6
Black	56.0	43.3	36.5	39.8	36.1	40.2	41.5	41.3	45.7	42.7	44.1	42.8	44.8	46.4	44.9	47.4	50.1	49.8	48.4	51.4
Other race	53.1	56.1	35.1	33.0	40.1	32.5	51.3	41.4	38.0	41.0	50.8	44.9	46.5	49.1	54.1	43.9	43.0	50.5	51.1	49.4
†Hispanic																				
†Non-Hispanic																	44.0	44.1	43.3	45.8
Diabetes																	36.0	35.8	36.4	37.3
Hypertension	16.3	18.4	16.4	18.4	16.9	18.0	18.1	17.0	20.4	19.1	17.6	19.3	21.4	23.7	24.5	23.1	24.5	24.7	24.8	26.0
Glomerulonephritis	41.9	31.6	32.7	34.1	31.3	35.6	35.6	32.4	34.5	31.7	34.0	35.3	36.5	36.9	34.3	40.0	39.4	37.5	37.5	38.9
Other cause	53.3	48.4	46.8	47.1	46.4	46.0	49.2	52.9	48.7	52.9	53.6	51.2	58.0	54.4	53.2	58.8	56.8	58.8	60.2	62.6
	41.3	39.7	36.3	35.4	37.2	33.6	38.2	38.2	38.3	42.2	40.0	43.3	43.7	47.9	47.8	48.8	50.7	49.4	53.4	52.5
All	37.4	33.5	30.7	31.7	31.1	31.3	32.2	31.3	32.9	32.4	31.6	32.5	34.5	35.8	35.2	36.4	36.9	36.6	37.2	38.3
ADJUSTED																				
0-19	59.7	71.3	64.3	76.2	63.4	46.1	67.5	76.8	62.8	74.0	56.0	65.5	73.5	60.9	61.8	65.1	69.9	71.9	61.8	72.4
20-44	46.8	48.2	48.0	47.9	49.2	50.4	52.5	49.5	51.2	51.4	51.9	53.5	52.6	56.6	59.3	58.4	59.8	61.1	61.1	61.9
45-64	31.9	28.4	28.9	29.2	27.2	28.4	31.3	29.1	31.0	32.7	31.2	32.8	35.7	38.6	37.5	38.2	39.4	38.5	41.3	41.4
65-74	14.7	16.1	13.7	13.7	14.0	19.2	13.1	16.1	17.0	15.3	18.5	17.5	21.4	21.3	19.3	22.9	21.3	20.5	21.7	21.9
75+	8.8	5.0	7.0	2.5	6.6	7.9	5.8	7.6	5.4	9.3	6.4	8.3	6.8	7.6	7.3	8.8	10.7	9.5	10.9	11.7
Male	23.9	22.3	23.3	22.0	21.0	24.7	24.1	22.4	22.9	25.2	23.1	24.8	26.6	29.5	28.3	30.2	28.9	29.0	29.7	32.70
Female	23.8	24.2	23.0	23.1	23.8	23.9	24.2	25.4	26.4	25.8	28.2	28.3	29.7	30.7	30.2	31.3	33.8	32.2	34.9	32.8
White	19.2	19.5	20.4	19.6	20.3	21.8	20.6	20.7	21.3	22.4	21.6	23.2	24.9	26.6	25.7	27.2	27.7	27.4	29.1	29.2
Black	38.2	29.1	25.9	27.0	23.6	27.4	30.0	28.0	30.3	30.6	32.2	31.0	33.0	35.0	33.0	37.2	38.3	35.9	37.5	39
Other race	33.1	34.5	24.0	21.5	22.9	18.7	39.5	28.2	25.5	31.3	39.3	35.3	34.6	41.6	45.0	35.4	37.2	40.0	39.1	44.9
Diabetes	11.5	13.1	12.3	13.6	12.7	15.5	13.8	13.3	15.6	15.2	15.2	16.4	17.7	20.4	20.9	19.9	21.3	21.6	22.4	22.6
Hypertension	36.7	26.3	31.0	28.9	27.5	33.9	33.1	31.1	32.2	30.6	33.1	33.5	34.9	35.8	33.1	37.7	38.4	36.3	38.4	38.3
Glomerulonephritis	36.6	36.4	35.3	34.3	34.0	37.2	37.3	39.6	34.7	41.3	39.9	40.3	44.9	41.9	40.4	46.9	45.1	43.2	45.5	49.1
Other cause	28.8	32.6	29.6	27.7	29.2	25.6	29.4	29.4	29.1	33.5	31.0	32.6	34.4	38.5	36.3	38.3	38.2	36.4	39.6	40.8
All	24.0	23.2	23.0	22.5	22.3	24.4	24.2	23.8	24.5	25.5	25.5	26.3	28.1	30.0	29.2	30.7	31.2	30.6	32.2	32.8

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age >110 are excluded.

Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

"." Zero values in this cell.

Table I.28

Ten-year survival probabilities: incident CAPD/CCPD patients*censored at transplant, from day 91 to ten years + 90 days, by age, gender, race, & primary diagnosis*

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994
0-4	42.9	95.5	80.5	75.9	67.1	49.5	90.1	85.6	44.8	84.0	41.1	62.4	52.3	54.8	66.0
5-9	80.0	80.0	67.5	91.7	77.0	34.7	70.3	100.0	83.3	65.5	59.8	100.0	75.6	34.0	79.0
10-14	0.0	26.3	56.5	82.0	79.5	65.4	35.0	87.4	70.9	36.7	40.2	72.3	85.7	63.8	58.5
15-19	100.0	58.3	68.4	71.4	25.4	38.5	57.2	78.9	83.9	62.9	46.9	44.8	55.7	46.4	57.9
20-29	56.6	34.8	33.0	48.1	39.7	38.1	41.4	36.1	43.8	38.7	38.2	38.3	46.3	50.3	55.8
30-39	25.0	26.4	23.3	27.5	28.6	24.6	28.2	24.1	28.4	29.2	31.7	28.4	22.8	31.3	29.3
40-49	19.9	19.7	15.2	21.4	20.0	18.4	17.1	19.5	21.6	19.5	18.1	19.2	16.7	21.6	22.2
50-59	14.4	13.6	9.7	11.0	9.6	10.7	8.3	9.5	9.0	9.6	10.0	8.3	9.9	9.2	10.8
60-64	7.5	7.4	4.6	4.8	4.8	5.1	6.9	4.5	6.0	4.5	3.3	4.2	5.4	5.6	6.3
65-69	5.7	4.3	2.7	3.8	4.6	7.8	4.0	1.7	2.6	3.4	3.9	2.5	4.1	3.6	4.1
70-79	6.1	1.2	1.7	1.9	0.7	3.3	1.9	1.9	0.9	1.4	1.3	1.7	1.8	1.3	1.3
80+	0.0	2.6	0.0	0.0	3.9	0.0	0.0	0.0	0.0	0.8	0.8	0.9	1.4	0.0	0.6
Male	15.4	12.8	10.5	12.7	10.7	10.9	11.3	10.6	10.0	10.6	10.1	9.6	10.3	11.2	10.4
Female	18.3	13.6	9.7	13.6	14.3	12.6	12.5	11.7	14.8	13.2	12.1	12.2	12.2	12.7	14.8
White	14.9	11.9	9.6	11.3	10.6	9.9	9.8	8.7	7.8	8.3	8.0	7.5	8.3	8.7	8.8
Black	24.4	16.5	11.4	17.5	16.8	16.9	16.9	16.9	22.6	19.4	17.8	17.6	17.4	18.1	19.7
Other race	23.9	24.9	12.8	17.6	17.4	13.3	17.6	23.1	21.0	19.8	20.3	18.9	15.2	19.6	20.6
Diabetes	5.7	4.5	2.0	5.3	5.6	4.5	3.5	4.0	5.6	3.8	3.3	3.6	3.7	4.1	5.6
Hypertension	13.5	12.8	10.5	14.4	12.4	12.1	13.4	10.3	13.8	11.4	11.4	13.2	11.3	13.9	13.5
Glomerulonephritis	28.4	18.0	21.2	21.2	24.5	20.9	24.8	22.5	20.8	25.8	24.4	19.5	26.5	25.6	25.1
Other cause	21.0	18.2	13.6	16.4	13.2	14.8	15.3	16.6	14.9	17.4	17.5	17.8	18.8	18.8	19.2
All	16.8	13.2	10.2	13.1	12.5	11.7	11.9	11.2	12.3	11.8	11.0	10.8	11.2	11.9	12.5
ADJUSTED															
0-19	41.4	45.4	45.8	59.3	44.7	22.6	43.2	72.2	47.8	51.7	28.8	39.0	40.6	37.7	39.4
20-44	28.6	26.5	22.2	26.6	29.0	25.3	28.7	27.7	27.6	26.2	27.0	25.4	25.2	29.4	31.3
45-64	10.8	9.4	7.8	9.0	8.3	8.6	9.0	8.7	9.5	9.7	8.7	9.2	10.1	11.2	11.9
65-74	4.1	2.5	2.6	3.2	2.9	5.6	3.4	2.2	2.4	3.1	3.5	3.1	3.7	3.3	3.5
75+	4.5	1.6	0.6	0.0	1.3	3.0	0.9	1.2	0.8	0.2	0.6	0.3	1.1	0.0	1.0
Male	10.0	9.0	7.7	8.3	7.2	9.5	8.8	7.6	6.9	7.8	7.4	7.6	8.4	9.5	9.1
Female	10.1	9.2	7.9	9.0	10.5	9.9	9.2	10.1	10.9	10.0	10.4	9.8	10.2	10.4	11.9
White	8.2	7.7	7.3	7.3	7.6	8.7	7.7	7.4	6.5	6.9	7.4	6.8	7.9	8.4	8.8
Black	13.2	9.3	6.9	10.2	9.3	10.0	9.9	9.9	12.5	11.7	10.3	10.7	10.9	11.4	12.1
Other race	17.7	14.9	9.8	10.8	7.9	7.1	16.2	10.9	11.9	15.9	13.8	14.1	8.3	16.8	17.3
Diabetes	4.3	3.4	1.7	3.9	4.6	5.4	3.3	3.8	4.3	3.3	3.5	3.5	3.9	4.1	5.4
Hypertension	16.2	11.3	12.1	12.1	10.7	13.9	12.8	11.6	13.1	11.8	11.4	12.1	11.3	13.9	14.2
Glomerulonephritis	16.0	13.5	14.2	13.4	16.7	16.3	16.5	14.4	11.8	17.9	15.7	14.3	17.1	16.5	15.6
Other cause	12.0	13.9	10.5	11.4	9.5	9.9	11.4	11.5	9.8	11.8	12.4	11.2	13.5	13.1	11.0
All	10.1	8.9	7.8	8.6	8.7	9.7	8.9	8.7	8.7	8.8	8.8	8.5	9.2	9.9	10.4

Reference cohort is 1996 incident ESRD patients.

Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables are adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age >110 are excluded.

Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories.

"." Zero values in this cell.

Table I.29

90-day patient survival probabilities: first transplants, deceased donors*by age, gender, race/ethnicity, primary diagnosis, & transplant number*

UNADJUSTED	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	100.0	100.0	96.7	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
5-9	100.0	100.0	100.0	100.0	97.5	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
10-14	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
15-19	100.0	99.5	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
20-29	100.0	99.8	99.7	99.8	99.9	100.0	99.7	99.9	100.0	99.9	99.9	99.6	100.0
30-39	99.4	99.8	99.9	99.6	99.7	99.9	99.9	99.7	99.7	99.9	99.8	99.6	99.8
40-49	99.6	99.5	99.6	99.8	99.8	99.5	99.7	99.8	99.6	99.7	99.7	99.5	99.8
50-59	99.1	99.5	99.0	99.5	99.0	99.4	99.5	99.6	99.5	99.5	99.5	99.9	99.6
60-64	99.4	98.8	99.2	99.3	99.3	98.9	99.6	99.8	99.3	98.5	99.5	99.5	98.7
65+	98.0	99.5	99.5	100.0	98.5	99.3	99.7	99.2	99.7	99.0	99.6	99.4	99.7
Male	99.5	99.6	99.5	99.7	99.6	99.6	99.8	99.9	99.7	99.5	99.6	99.6	99.6
Female	99.5	99.6	99.6	99.6	99.5	99.7	99.5	99.5	99.6	99.8	99.8	99.7	99.8
White	99.5	99.5	99.6	99.7	99.5	99.6	99.7	99.7	99.6	99.5	99.6	99.6	99.6
Black	99.8	100.0	99.4	99.6	99.8	99.8	99.6	99.7	99.7	99.7	99.7	99.8	99.8
Other race	99.2	99.6	100.0	100.0	99.7	99.4	99.7	100.0	99.5	99.8	99.7	99.8	99.4
†Hispanic						99.7	99.7	99.9	99.9	99.4	99.8	99.8	99.6
†Non-Hispanic						99.6	99.7	99.7	99.6	99.6	99.6	99.6	99.7
Diabetes	99.1	99.2	99.3	99.7	99.6	99.7	99.8	99.6	99.6	99.6	99.5	99.4	99.6
Hypertension	99.7	99.8	99.7	99.8	99.6	99.7	99.5	99.7	99.5	99.4	99.8	99.9	99.9
Glomerulonephritis	99.8	99.7	99.7	99.7	99.5	99.7	99.8	99.9	99.9	99.8	100.0	99.8	99.7
Other cause	99.4	99.7	99.5	99.5	99.5	99.5	99.6	99.6	99.6	99.5	99.5	99.8	99.6
All	99.5	99.6	99.5	99.7	99.6	99.6	99.7	99.7	99.6	99.6	99.7	99.7	99.6
ADJUSTED													
0-19	100.0	99.3	99.4	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
20-44	99.5	99.6	99.7	99.8	99.8	99.9	99.9	99.7	99.7	99.9	99.7	99.6	99.8
45-64	99.3	99.5	99.3	99.5	99.3	99.5	99.5	99.7	99.5	99.5	99.6	99.7	99.6
65+	98.7	98.9	99.3	99.2	99.0	98.6	99.8	99.3	99.5	98.6	99.3	99.4	99.2
Male	99.0	99.0	98.9	99.4	99.2	99.2	99.7	99.8	99.4	99.1	99.3	99.3	99.3
Female	98.8	99.2	99.2	99.2	99.0	99.4	99.1	99.0	99.2	99.6	99.6	99.6	99.6
White	98.8	98.8	99.0	99.3	98.9	99.2	99.5	99.5	99.3	99.2	99.4	99.3	99.4
Black	99.5	100.0	98.9	99.3	99.6	99.6	99.3	99.4	99.5	99.5	99.6	99.7	99.7
Other race	98.0	99.2	100.0	100.0	99.2	98.9	99.4	100.0	99.1	99.6	99.5	99.6	99.0
Diabetes	98.4	98.6	98.9	99.5	99.3	99.5	99.8	99.4	99.4	99.4	99.2	99.1	99.4
Hypertension	99.5	99.7	99.6	99.8	99.4	99.5	99.3	99.6	99.3	99.2	99.7	99.8	99.8
Glomerulonephritis	99.6	99.3	99.4	99.4	99.0	99.4	99.6	99.9	99.7	99.6	100.0	99.6	99.4
Other cause	98.8	99.5	98.9	98.9	99.0	98.9	99.2	99.3	99.3	99.2	99.2	99.6	99.3
All	98.9	99.1	99.0	99.3	99.1	99.3	99.4	99.5	99.3	99.3	99.4	99.4	99.4

Patients of unknown age, gender, race, or primary diagnosis are excluded.

Age is calculated as of the day of transplant.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have been left blank.

"." Zero values in this cell.

Table I.30

One-year patient survival probabilities: first transplants, deceased donors*by age, gender, race/ethnicity, primary diagnosis, & transplant number*

UNADJUSTED	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	93.9	97.1	96.7	96.9	100.0	100.0	100.0	100.0	97.3	100.0	96.3	97.0	96.9
5-9	100.0	100.0	100.0	97.9	95.0	100.0	100.0	100.0	100.0	97.1	100.0	100.0	100.0
10-14	98.7	100.0	100.0	97.7	100.0	98.8	100.0	100.0	100.0	100.0	100.0	100.0	99.1
15-19	99.0	98.9	99.4	98.1	99.5	99.3	99.3	98.6	99.5	99.4	99.3	99.2	100.0
20-29	98.7	99.0	98.6	98.9	99.5	99.0	99.2	98.9	99.1	99.2	99.2	99.0	99.5
30-39	98.4	98.8	98.7	98.4	98.4	98.6	98.7	99.2	98.6	98.9	99.3	99.0	98.8
40-49	98.4	98.4	98.3	98.2	97.7	98.1	98.3	98.6	98.0	98.2	98.2	98.2	98.1
50-59	97.1	96.4	96.8	96.6	96.8	97.2	97.0	97.6	97.4	96.8	96.7	97.7	97.4
60-64	96.7	97.4	93.8	96.6	96.7	96.1	95.9	96.2	96.0	95.1	97.2	96.7	95.5
65+	94.0	97.9	94.1	96.6	95.2	96.4	95.0	94.5	96.7	94.4	95.1	95.5	96.3
Male	98.1	98.1	97.9	97.7	97.7	97.9	97.9	98.2	98.1	97.4	97.8	97.9	97.6
Female	97.9	98.4	97.7	98.1	98.0	98.0	97.9	98.1	97.8	98.1	98.0	98.2	98.2
White	98.0	98.1	97.8	97.8	97.5	97.7	98.0	98.1	98.0	97.5	98.1	97.9	97.7
Black	97.9	98.2	97.9	97.9	98.4	98.6	97.6	98.3	97.8	98.0	97.5	98.3	98.3
Other race	98.3	99.3	98.0	98.8	98.7	97.7	98.5	98.5	98.2	97.8	97.7	98.6	97.9
†Hispanic						97.4	99.4	98.6	98.1	97.3	98.2	98.7	97.9
†Non-Hispanic						98.0	97.8	98.1	97.9	97.7	97.8	97.9	97.9
Diabetes	96.9	97.6	96.6	97.3	97.3	97.4	97.6	97.7	97.6	96.6	97.3	97.5	97.2
Hypertension	98.3	97.7	98.1	98.2	98.1	98.7	97.1	98.1	97.4	97.0	97.3	98.4	97.9
Glomerulonephritis	98.4	98.6	99.1	98.7	98.3	98.4	98.6	98.7	98.6	99.2	99.0	98.5	98.3
Other cause	98.4	98.7	97.8	97.4	97.8	97.6	98.2	98.3	98.2	98.0	98.2	98.0	98.4
All	98.0	98.2	97.8	97.9	97.8	97.9	97.9	98.2	97.9	97.6	97.9	98.0	97.9
ADJUSTED													
0-19	97.5	98.7	99.4	97.0	100.0	100.0	100.0	99.3	98.9	100.0	99.3	99.3	98.9
20-44	98.1	98.5	98.4	98.6	98.6	98.5	98.7	99.0	98.7	98.8	98.9	98.9	99.2
45-64	97.3	97.3	96.9	97.0	96.8	97.3	97.1	97.8	97.3	97.2	97.3	97.7	97.3
65+	95.3	96.7	93.4	95.2	95.0	95.3	95.3	94.5	96.0	93.9	95.7	95.9	96.1
Male	95.7	95.8	95.6	95.4	95.5	95.9	96.1	96.7	96.5	95.5	96.3	96.6	96.3
Female	95.2	96.5	95.1	96.1	95.9	96.2	96.1	96.5	95.9	96.6	96.6	97.0	97.1
White	95.6	96.0	95.3	95.4	95.1	95.7	96.2	96.6	96.3	95.8	96.8	96.5	96.4
Black	95.7	96.3	96.0	96.1	97.1	97.4	95.9	97.1	96.3	96.6	95.9	97.2	97.3
Other race	95.9	98.4	95.6	97.5	96.8	95.5	97.1	97.1	97.0	96.2	96.0	97.6	96.8
Diabetes	94.5	95.9	94.1	95.6	95.5	95.9	96.3	96.6	96.5	95.3	96.2	96.5	96.3
Hypertension	97.3	96.5	97.2	97.3	97.2	98.1	96.0	97.4	96.4	95.9	96.5	97.9	97.2
Glomerulonephritis	96.5	96.9	98.0	97.3	96.6	96.8	97.3	97.4	97.3	98.5	98.1	97.4	97.1
Other cause	96.6	97.3	95.4	94.8	95.6	95.5	96.6	97.0	96.6	96.5	96.8	96.5	97.4
All	95.5	96.1	95.4	95.7	95.7	96.1	96.1	96.7	96.3	96.0	96.5	96.8	96.6

Patients of unknown age, gender, race, or primary diagnosis are excluded.

Age is calculated as of the day of transplant.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

"." Zero values in this cell.

Table I.31

Two-year patient survival probabilities: first transplants, deceased donors*by age, gender, race/ethnicity, primary diagnosis, & transplant number*

UNADJUSTED	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002
0-4	92.7	90.9	97.1	96.7	93.8	100.0	97.1	97.2	100.0	97.3	100.0	96.3	97.0
5-9	93.3	100.0	100.0	100.0	97.9	92.5	98.0	100.0	100.0	100.0	97.1	100.0	97.5
10-14	96.5	98.7	97.1	98.8	94.7	98.9	96.4	98.9	98.6	100.0	100.0	98.6	100.0
15-19	96.9	98.0	97.8	97.8	97.6	99.5	98.0	97.8	97.9	98.4	99.4	98.6	97.7
20-29	97.6	97.0	97.1	97.4	98.2	98.6	97.7	98.0	97.8	97.7	97.8	97.6	98.6
30-39	96.2	96.4	96.3	96.8	95.9	96.5	96.4	96.5	97.6	96.8	96.6	96.7	96.8
40-49	93.4	95.9	95.5	94.8	94.8	95.6	95.0	96.1	96.2	95.7	96.0	94.7	95.3
50-59	93.5	94.6	92.6	93.3	92.5	92.9	93.6	93.4	94.1	94.0	93.1	92.2	93.2
60-64	92.9	91.3	91.6	89.5	91.1	91.9	91.6	91.8	91.5	90.9	89.6	92.5	91.1
65+	87.9	90.1	93.6	86.8	90.6	88.9	90.4	89.0	87.7	92.8	88.3	89.9	90.4
Male	94.6	95.5	95.1	95.0	94.4	95.0	95.1	95.1	95.2	95.4	94.4	94.1	94.4
Female	95.4	95.9	95.4	95.0	95.5	95.8	94.9	95.5	95.8	95.3	95.1	94.9	95.4
White	94.8	95.6	95.4	94.9	94.7	95.1	94.7	95.3	95.7	95.7	95.0	94.6	94.4
Black	95.1	95.5	94.6	94.8	94.6	95.6	95.4	95.2	94.8	94.4	94.1	93.9	95.5
Other race	94.8	96.7	95.4	97.0	96.7	96.7	96.8	95.3	95.8	95.4	94.3	95.3	95.8
†Hispanic							95.2	96.9	97.4	96.7	95.4	95.6	96.1
†Non-Hispanic							95.0	95.1	95.2	95.2	94.6	94.2	94.6
Diabetes	92.9	93.4	92.9	92.7	93.4	93.5	93.2	93.5	93.8	94.0	92.8	92.3	92.6
Hypertension	94.9	95.4	94.5	94.3	95.6	95.3	95.4	94.9	95.2	94.3	92.8	93.9	95.6
Glomerulonephritis	97.1	97.0	96.8	97.4	96.5	96.6	96.1	96.5	97.1	96.8	97.3	96.6	96.5
Other cause	94.4	96.6	96.5	95.9	94.1	96.1	95.8	96.4	96.2	96.4	96.2	95.6	95.7
All	94.9	95.6	95.2	95.0	94.8	95.3	95.0	95.3	95.4	95.3	94.7	94.4	94.8
ADJUSTED													
0-19	93.9	96.2	97.4	98.1	94.4	98.9	97.0	98.6	98.6	98.9	100.0	97.8	98.6
20-44	95.5	96.1	95.7	96.4	96.5	96.9	96.5	96.9	97.3	96.5	96.6	96.6	97.2
45-64	92.5	93.9	93.3	92.7	92.5	93.4	93.3	93.8	94.4	94.4	93.9	92.9	93.7
65+	88.5	89.3	90.2	87.1	88.8	88.2	89.2	88.8	88.1	89.8	87.1	90.1	89.6
Male	87.9	90.1	89.7	89.7	88.7	90.3	90.7	91.0	91.5	91.8	90.6	90.2	91.0
Female	89.3	90.9	90.1	89.6	90.9	91.6	90.3	91.5	92.3	91.5	91.6	91.4	92.3
White	88.2	90.3	90.4	89.5	89.4	90.5	90.1	91.2	92.3	92.3	91.6	91.0	91.1
Black	90.1	91.0	89.3	90.4	90.0	91.9	91.8	91.8	91.1	90.7	90.2	90.2	92.8
Other race	88.2	92.0	89.7	93.4	93.4	92.2	93.8	90.8	91.8	92.3	90.5	92.0	92.8
Diabetes	87.3	88.5	87.9	87.7	89.1	89.6	89.4	90.2	90.8	91.2	89.9	89.3	89.9
Hypertension	92.0	92.7	91.5	91.4	93.3	92.9	93.3	92.9	93.4	92.1	90.3	92.1	94.2
Glomerulonephritis	93.7	93.4	93.2	94.3	92.8	93.3	92.5	93.3	94.3	94.0	95.0	93.9	93.9
Other cause	88.1	92.9	92.8	91.6	88.5	92.4	92.0	93.3	93.0	93.4	93.3	92.4	92.6
All	88.5	90.4	89.9	89.8	89.6	90.8	90.6	91.3	91.9	91.7	91.0	90.7	91.6

Patients of unknown age, gender, race, or primary diagnosis are excluded.

Age is calculated as of the day of transplant.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

"." Zero values in this cell.

Table I.32

Three-year patient survival probabilities: first transplants, deceased donors*by age, gender, race/ethnicity, primary diagnosis, & transplant number*

UNADJUSTED	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
0-4	97.4	90.2	90.9	97.1	96.7	93.8	100.0	97.1	94.4	96.8	94.6	95.5	96.3
5-9	98.1	93.3	97.4	100.0	100.0	97.9	92.5	94.0	100.0	100.0	100.0	97.1	100.0
10-14	90.4	96.5	97.4	94.2	97.5	94.7	98.9	96.4	98.9	98.6	99.0	98.6	98.6
15-19	95.4	94.2	97.0	95.7	96.1	97.6	98.5	95.9	97.1	97.9	97.9	98.7	97.1
20-29	96.0	95.6	95.2	96.0	95.5	96.5	97.1	96.0	96.4	97.1	96.5	96.5	96.0
30-39	94.1	94.4	94.1	93.7	94.3	94.0	94.2	94.8	94.7	95.9	94.6	94.6	94.4
40-49	89.3	89.8	93.0	92.4	91.5	91.8	92.8	92.0	93.3	92.7	93.2	93.8	91.8
50-59	87.7	90.0	89.4	87.9	89.3	88.9	88.0	89.5	89.0	89.5	89.7	89.6	87.6
60-64	84.6	86.5	86.2	87.8	81.7	85.7	87.2	86.1	86.0	85.7	84.5	84.5	87.1
65+	81.7	79.5	83.4	84.0	79.9	83.0	80.8	84.4	79.7	81.5	85.4	83.3	83.4
Male	91.1	91.1	92.0	91.9	91.5	91.5	91.7	92.2	91.8	91.7	92.1	91.9	90.3
Female	92.3	93.0	93.5	92.4	91.9	92.7	92.9	91.7	92.3	93.0	92.2	91.9	92.0
White	91.8	91.5	92.8	92.3	91.6	92.1	92.0	91.8	92.2	92.2	92.5	92.4	91.4
Black	90.2	92.8	91.8	91.3	91.5	91.2	91.8	92.4	91.4	92.0	91.2	90.6	89.5
Other race	94.1	93.2	92.9	92.9	94.3	94.6	95.3	92.2	92.7	92.8	92.3	92.6	94.3
†Hispanic								93.0	95.3	95.4	93.7	94.0	92.6
†Non-Hispanic								91.9	91.7	91.8	91.9	91.7	90.8
Diabetes	88.5	88.4	90.1	87.9	88.0	90.0	89.7	89.3	89.0	89.1	89.3	88.7	88.0
Hypertension	90.4	91.9	92.2	90.9	91.3	92.6	91.4	91.5	91.9	92.1	91.4	89.7	89.9
Glomerulonephritis	94.9	95.0	94.3	95.1	95.1	93.9	94.5	94.1	94.3	94.4	94.5	95.8	94.6
Other cause	91.6	91.7	93.4	94.0	93.0	91.9	93.3	93.7	93.5	94.1	94.0	94.1	92.7
All	91.5	91.9	92.5	92.1	91.7	92.0	92.1	92.0	92.0	92.2	92.1	91.9	91.0
ADJUSTED													
0-19	95.2	92.3	95.0	95.4	96.8	94.4	98.4	94.6	97.9	97.9	97.8	98.5	97.1
20-44	92.8	93.2	93.9	93.4	93.8	94.1	94.6	94.6	94.9	95.4	94.8	94.8	94.4
45-64	86.5	87.7	88.9	88.7	88.1	88.9	89.1	89.3	89.6	90.0	90.4	90.6	88.7
65+	78.2	79.8	81.3	81.5	79.3	81.0	80.7	82.2	80.1	81.1	81.0	81.9	84.2
Male	80.0	80.9	82.9	83.3	83.0	83.3	84.1	85.5	85.2	85.5	86.2	86.5	84.3
Female	82.4	84.1	85.7	84.0	83.7	85.6	86.0	84.5	85.8	87.3	86.1	86.3	86.7
White	81.1	81.3	84.4	84.1	82.9	84.4	84.8	85.0	85.8	86.5	86.7	87.6	86.1
Black	80.8	85.5	83.9	83.0	84.7	84.0	85.3	86.6	85.4	86.7	85.5	84.6	83.5
Other race	86.2	84.7	83.8	84.5	87.8	89.3	89.2	85.3	85.9	86.1	87.4	87.8	90.2
Diabetes	79.3	79.9	83.0	79.8	80.2	83.9	83.6	83.5	83.4	84.1	84.5	84.4	83.5
Hypertension	84.8	87.3	87.7	86.2	87.0	88.9	87.2	87.9	88.7	89.2	88.2	86.3	86.9
Glomerulonephritis	88.3	89.1	87.6	89.6	89.6	87.6	89.3	88.7	89.1	89.3	89.6	92.4	90.3
Other cause	82.4	82.8	86.5	88.1	86.1	84.2	87.1	88.1	88.1	89.4	89.1	89.8	87.6
All	81.0	82.2	84.1	83.6	83.4	84.3	85.0	85.2	85.5	86.3	86.2	86.6	85.4

Patients of unknown age, gender, race, or primary diagnosis are excluded.

Age is calculated as of the day of transplant.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

" " Zero values in this cell.

Table I.33

Five-year patient survival probabilities: first transplants, deceased donors*by age, gender, race/ethnicity, primary diagnosis, & transplant number*

UNADJUSTED	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-4	91.5	88.6	94.7	90.2	90.9	94.1	93.3	93.8	97.1	97.1	91.7	90.3	89.2
5-9	95.3	93.3	96.3	93.3	94.9	97.5	94.7	95.8	90.0	92.0	100.0	97.4	100.0
10-14	96.2	97.9	89.0	95.3	93.5	92.8	95.0	93.9	97.8	95.2	96.8	95.8	99.0
15-19	93.5	92.4	94.0	92.9	93.5	94.0	93.3	95.2	95.5	92.5	91.2	97.2	95.8
20-29	89.1	89.7	90.3	91.9	91.6	91.3	91.2	92.9	93.2	91.0	92.8	94.1	93.2
30-39	81.1	85.1	88.0	89.0	87.1	87.3	88.2	88.5	89.1	90.0	89.9	92.2	90.1
40-49	75.7	81.1	81.7	82.2	85.1	83.0	85.0	83.8	84.9	84.3	86.3	86.4	86.7
50-59	70.4	74.5	76.5	79.1	77.6	76.9	77.5	79.1	78.5	80.0	78.4	79.9	79.2
60-64	65.2	67.9	72.7	75.1	71.0	76.2	66.3	69.2	73.5	74.8	75.3	73.3	72.1
65+	60.5	71.4	72.0	61.4	65.6	66.3	62.7	68.5	62.0	67.2	65.3	70.0	68.9
Male	78.3	81.4	83.1	83.6	82.8	83.4	83.1	83.4	83.9	84.4	84.5	84.9	84.1
Female	83.6	84.5	86.2	86.9	86.9	84.6	85.1	86.1	85.8	84.6	84.9	86.5	85.6
White	81.0	83.2	84.5	84.7	84.9	84.1	84.1	85.1	84.7	84.4	84.9	85.8	84.9
Black	76.7	79.9	82.7	84.6	83.0	82.5	82.0	82.1	83.2	83.8	83.2	84.0	83.7
Other race	86.8	87.4	89.7	88.4	83.8	87.6	90.2	86.4	91.0	87.8	87.7	88.9	87.2
†Hispanic										87.9	88.1	90.4	87.2
†Non-Hispanic										84.1	84.3	84.9	84.4
Diabetes	70.4	74.9	78.0	78.1	79.3	75.9	77.2	78.5	79.9	78.4	78.6	79.9	79.2
Hypertension	77.1	80.7	82.1	84.6	83.2	82.1	82.1	84.4	82.1	83.1	85.3	84.5	83.0
Glomerulonephritis	86.5	87.1	89.9	89.5	87.3	89.0	89.6	88.5	88.6	89.0	88.7	89.9	88.5
Other cause	83.3	85.0	85.5	86.3	87.2	87.8	87.5	87.3	88.2	88.6	87.5	89.3	88.9
All	80.3	82.6	84.3	84.9	84.4	83.9	83.9	84.4	84.6	84.5	84.6	85.5	84.7
ADJUSTED													
0-19	93.3	92.1	92.5	90.7	90.7	92.1	93.1	92.7	95.8	92.3	95.2	93.6	95.7
20-44	80.9	83.7	86.1	87.6	87.3	86.6	88.2	88.4	89.6	89.2	89.6	91.5	90.1
45-64	68.1	73.6	75.3	76.7	76.8	76.9	76.7	78.4	78.4	79.3	80.0	80.8	80.8
65+	54.9	61.3	65.8	62.0	63.9	63.9	61.6	64.4	64.3	66.7	65.5	69.2	65.4
Male	54.8	62.0	64.8	66.8	66.2	67.9	68.2	69.3	70.8	72.3	73.0	74.5	73.4
Female	63.8	66.8	70.3	72.0	73.0	69.5	71.3	73.7	73.3	72.6	73.5	76.4	75.1
White	58.4	64.0	66.8	68.5	69.7	69.1	69.5	72.1	72.2	72.5	73.7	76.0	74.3
Black	57.8	63.9	67.6	70.7	68.5	67.9	69.0	69.1	71.1	72.8	72.7	74.1	73.9
Other race	65.4	69.1	76.7	74.8	66.0	73.8	79.8	74.7	79.9	77.7	77.1	78.9	79.4
Diabetes	52.1	59.0	62.6	64.0	66.4	61.9	64.2	66.9	69.4	68.0	69.0	71.4	70.9
Hypertension	62.7	70.1	72.5	76.6	74.5	73.8	74.0	77.2	74.1	76.5	79.8	79.0	77.3
Glomerulonephritis	69.5	72.4	77.9	77.9	73.8	77.6	78.6	77.4	78.5	79.5	79.0	81.1	79.0
Other cause	65.8	70.4	71.3	72.6	75.0	76.5	76.0	76.0	77.9	79.2	77.7	81.1	80.4
All	58.3	63.9	67.1	68.9	68.9	68.6	69.5	71.1	72.0	72.5	73.3	75.4	74.2

Patients of unknown age, gender, race, or primary diagnosis are excluded.

Age is calculated as of the day of transplant.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

"." Zero values in this cell.

Table I.34

Ten-year patient survival probabilities: first transplants, deceased donors*by age, gender, race/ethnicity, primary diagnosis, & transplant number*

UNADJUSTED	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994
0-4	82.4	87.5	85.0	85.7	90.2	87.2	80.0	92.1	85.4	87.9	91.2	83.3	90.6
5-9	71.4	92.3	77.8	87.3	86.5	85.9	86.7	90.7	77.8	89.7	95.0	89.5	85.4
10-14	75.0	81.1	82.2	77.2	74.6	88.7	86.2	79.5	88.2	83.1	91.3	85.0	84.0
15-19	82.6	87.5	84.2	76.2	82.4	85.0	85.4	86.2	84.5	85.0	85.9	83.9	85.2
20-29	70.7	72.1	71.7	75.0	72.4	75.9	77.5	77.4	79.0	79.0	75.6	79.3	80.7
30-39	59.9	60.5	58.6	61.4	61.2	62.9	67.8	68.0	69.4	67.3	69.5	71.1	70.5
40-49	48.7	47.9	48.8	48.9	49.4	53.6	56.8	58.4	59.5	58.8	59.4	62.7	63.1
50-59	33.8	36.3	35.8	34.2	37.0	42.2	45.0	47.3	49.3	47.9	46.3	50.7	48.1
60-64	33.3	23.7	19.6	28.8	26.1	32.9	29.9	37.9	35.9	37.4	36.0	34.0	36.0
65+	0.0	20.0	23.5	8.7	12.5	39.5	33.3	33.3	24.2	25.8	27.8	23.5	28.9
Male	56.3	58.5	56.1	57.8	56.3	58.6	59.6	61.0	61.0	59.5	59.6	61.5	60.7
Female	65.1	64.3	63.0	61.6	62.1	65.2	64.7	66.2	66.4	65.3	63.6	65.5	66.0
White	60.7	62.9	59.9	61.3	59.4	62.4	63.1	64.2	63.2	61.8	61.3	63.7	63.5
Black	54.6	51.3	54.2	52.2	53.0	55.3	55.6	58.0	60.9	60.7	58.6	58.1	59.1
Other race	69.8	72.5	62.8	62.4	73.3	69.7	69.2	69.0	72.3	67.2	72.0	76.8	70.7
Diabetes	43.8	39.5	39.6	41.9	41.8	44.6	46.0	48.9	49.3	47.3	45.5	50.2	48.6
Hypertension	59.4	55.4	56.7	53.2	51.2	54.9	55.1	57.9	59.6	58.8	56.6	58.9	60.6
Glomerulonephritis	68.0	72.1	68.0	70.5	70.7	71.0	71.6	73.2	73.3	70.6	70.3	73.1	72.4
Other cause	59.1	62.5	61.4	62.4	62.1	67.0	67.4	68.2	67.3	68.3	70.6	71.2	71.4
All	59.6	60.6	58.7	59.2	58.4	61.1	61.6	63.0	63.1	61.7	61.2	63.1	62.7
ADJUSTED													
0-19	73.0	82.0	80.0	75.1	78.5	81.7	83.0	82.9	81.3	82.4	87.0	80.5	80.9
20-44	57.3	57.7	56.6	59.8	59.9	61.9	65.3	66.5	68.2	67.0	67.5	71.0	70.9
45-64	31.2	33.9	33.8	33.5	34.5	40.8	42.6	45.2	45.8	46.0	45.1	49.1	49.6
65+	10.0	8.0	16.2	9.5	17.8	25.5	22.7	26.9	25.4	23.4	24.2	22.5	25.7
Male	33.6	34.8	35.0	34.5	37.1	40.5	42.4	44.5	45.6	44.5	45.5	47.9	48.1
Female	22.4	24.8	24.1	25.8	25.9	29.3	32.3	33.8	35.1	34.2	35.1	38.1	38.0
White	31.1	30.7	30.5	30.2	31.8	36.4	37.5	39.9	40.4	40.4	38.9	42.5	44.1
Black	25.4	28.0	26.7	28.4	28.4	32.4	35.0	37.0	37.3	36.8	37.2	40.4	41.3
Other race	25.4	23.9	26.1	25.6	27.0	30.9	32.5	34.1	37.0	37.4	34.9	37.2	37.5
Diabetes	34.4	32.5	30.2	27.5	41.8	37.0	38.7	41.7	47.5	40.3	47.3	56.8	50.8
Hypertension	19.6	17.5	17.5	19.6	19.7	24.1	25.8	27.5	29.2	28.1	26.7	31.6	31.1
Glomerulonephritis	37.5	34.4	37.6	33.5	32.7	35.5	38.2	41.8	44.5	43.5	42.2	44.9	47.1
Other cause	35.8	40.4	36.6	40.5	42.1	43.5	46.7	48.8	50.3	46.8	46.9	50.8	51.2
All	28.3	32.6	32.3	33.4	34.4	41.0	43.8	45.2	43.7	46.1	49.8	50.5	51.0
All	25.4	27.0	26.5	27.5	28.1	32.0	34.4	36.2	37.2	36.7	36.7	39.9	40.4

Patients of unknown age, gender, race, or primary diagnosis are excluded.

Age is calculated as of the day of transplant.

"." Zero values in this cell.

Table I.35

90-day patient survival probabilities: first transplants, living donors

by age, gender, race/ethnicity, primary diagnosis, & transplant number

UNADJUSTED	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	96.6	98.1	100.0	100.0	100.0	100.0	100.0	100.0	100.0	97.9	100.0	100.0	100.0
5-9	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
10-14	97.8	99.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
15-19	100.0	100.0	100.0	100.0	100.0	100.0	100.0	99.3	100.0	100.0	100.0	100.0	100.0
20-29	100.0	100.0	99.8	100.0	100.0	100.0	99.8	100.0	100.0	100.0	100.0	100.0	100.0
30-39	100.0	99.6	100.0	100.0	100.0	99.8	99.7	99.9	100.0	99.9	100.0	100.0	100.0
40-49	99.7	100.0	100.0	99.8	99.8	100.0	99.8	100.0	100.0	99.9	99.8	100.0	100.0
50-59	98.5	99.2	99.3	100.0	99.3	99.6	99.6	99.8	99.8	99.9	99.5	99.6	99.7
60-64	95.3	95.9	100.0	98.8	100.0	100.0	99.5	100.0	100.0	99.7	99.7	99.5	100.0
65+	100.0	100.0	100.0	100.0	98.5	98.9	99.1	99.3	100.0	99.2	99.6	99.0	99.2
Male	99.4	99.6	99.9	99.9	99.7	99.8	99.8	99.8	100.0	99.8	99.8	99.6	99.9
Female	99.6	99.6	99.9	100.0	99.9	99.9	99.7	99.9	99.9	99.9	99.7	100.0	99.8
White	99.5	99.6	99.9	99.9	99.8	99.9	99.8	99.9	100.0	99.8	99.8	99.7	99.9
Black	99.6	99.6	99.7	100.0	99.7	99.8	99.6	99.8	100.0	99.8	99.9	99.9	99.9
Other race	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	99.6	100.0	100.0
†Hispanic						100.0	100.0	99.8	100.0	99.6	100.0	100.0	99.8
†Non-Hispanic						99.8	99.7	99.9	100.0	99.9	99.8	99.7	99.9
Diabetes	99.6	99.5	99.8	99.6	99.5	99.8	99.5	99.9	99.9	99.7	99.4	99.8	99.7
Hypertension	100.0	100.0	100.0	100.0	99.7	99.8	99.8	100.0	100.0	99.8	99.8	100.0	99.7
Glomerulonephritis	99.8	99.7	100.0	100.0	100.0	100.0	100.0	99.8	100.0	99.8	100.0	99.8	100.0
Other cause	99.0	99.3	99.8	100.0	99.9	99.8	99.6	99.9	100.0	99.9	99.9	99.7	99.9
All	99.5	99.6	99.9	99.9	99.8	99.9	99.7	99.9	100.0	99.8	99.8	99.8	99.9
ADJUSTED													
0-19	98.0	98.9	100.0	100.0	100.0	100.0	100.0	99.5	100.0	99.5	100.0	100.0	100.0
20-44	100.0	99.8	99.9	100.0	99.9	99.9	99.6	99.9	100.0	99.8	100.0	100.0	100.0
45-64	98.5	99.6	99.6	99.7	99.6	99.8	99.8	99.9	99.9	99.9	99.5	99.7	99.8
65+	100.0	91.8	100.0	100.0	98.9	99.0	98.3	99.4	100.0	99.0	99.7	98.9	99.3
Male	97.9	98.6	99.5	99.6	99.3	99.5	99.4	99.6	100.0	99.5	99.6	99.2	99.8
Female	99.0	98.8	99.7	100.0	99.8	99.8	99.2	99.8	99.8	99.7	99.4	100.0	99.6
White	98.2	98.6	99.7	99.7	99.5	99.7	99.3	99.7	99.9	99.6	99.6	99.5	99.7
Black	99.0	99.1	99.3	100.0	99.4	99.5	99.1	99.6	100.0	99.7	99.7	99.7	99.7
Other race	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	99.3	100.0	100.0
Diabetes	99.1	99.1	99.6	99.3	99.1	99.7	99.2	99.8	99.8	99.5	99.2	99.8	99.6
Hypertension	100.0	100.0	100.0	100.0	99.5	99.6	99.6	100.0	100.0	99.7	99.7	100.0	99.5
Glomerulonephritis	99.5	99.1	100.0	100.0	100.0	100.0	100.0	99.5	100.0	99.6	100.0	99.5	100.0
Other cause	96.6	98.0	99.3	100.0	99.7	99.4	99.0	99.8	100.0	99.8	99.7	99.3	99.9
All	98.4	98.7	99.6	99.8	99.5	99.6	99.3	99.7	99.9	99.6	99.5	99.5	99.7

Patients of unknown age, gender, race, or primary diagnosis are excluded.

Age is calculated as of the day of transplant.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

"." Zero values in this cell.

Table I.36

One-year patient survival probabilities: first transplants, living donors*by age, gender, race/ethnicity, primary diagnosis, & transplant number*

UNADJUSTED	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
0-4	96.6	98.1	98.7	100.0	98.3	98.4	100.0	100.0	100.0	97.9	100.0	98.5	97.1
5-9	100.0	100.0	100.0	98.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	98.4	98.1
10-14	96.7	96.9	100.0	100.0	100.0	98.9	100.0	100.0	100.0	100.0	98.9	100.0	100.0
15-19	99.3	98.6	100.0	100.0	99.4	100.0	99.4	99.3	100.0	100.0	100.0	99.4	100.0
20-29	99.6	99.8	99.4	99.8	99.8	100.0	99.6	99.4	99.6	99.6	99.7	100.0	99.1
30-39	99.6	99.3	99.5	99.3	99.5	99.4	99.1	99.6	99.5	99.3	99.1	99.7	100.0
40-49	99.0	99.3	98.7	98.9	99.1	99.5	98.5	99.1	99.1	99.0	98.8	98.9	99.1
50-59	98.0	97.3	97.7	98.5	97.5	98.3	98.1	98.8	98.6	98.2	98.7	98.1	99.1
60-64	93.0	90.5	98.7	97.6	97.4	97.3	97.9	98.6	98.4	99.0	98.0	97.8	99.0
65+	100.0	96.2	91.9	100.0	94.1	97.8	97.2	93.7	96.9	98.4	97.8	97.7	97.2
Male	98.7	98.8	98.9	99.0	98.9	99.2	99.1	98.8	98.9	98.9	99.0	98.9	99.1
Female	99.3	98.5	99.1	99.5	99.0	99.3	98.3	99.3	99.4	99.2	98.8	98.8	99.1
White	98.9	98.7	99.0	99.2	98.9	99.3	98.9	99.1	99.1	99.1	98.9	98.8	99.0
Black	98.9	98.2	98.9	99.4	99.2	98.4	98.0	98.6	99.0	98.7	98.9	98.7	99.3
Other race	100.0	98.7	98.8	98.3	100.0	100.0	100.0	98.6	100.0	99.0	99.2	99.1	99.2
†Hispanic						99.4	99.7	99.3	99.5	98.3	98.9	99.3	99.6
†Non-Hispanic						99.2	98.7	99.0	99.1	99.1	98.9	98.8	99.0
Diabetes	98.3	98.4	98.2	98.7	98.4	99.1	97.9	98.6	98.0	98.8	97.9	98.2	98.9
Hypertension	99.2	99.3	98.5	98.6	98.4	98.5	98.5	99.3	99.4	98.3	99.0	99.4	98.9
Glomerulonephritis	99.7	99.0	99.7	99.5	99.3	99.8	99.5	99.4	99.5	99.2	99.7	99.1	99.3
Other cause	98.7	98.2	99.0	99.6	99.2	99.1	98.8	98.9	99.4	99.3	99.0	98.8	99.1
All	99.0	98.6	99.0	99.2	99.0	99.2	98.8	99.0	99.1	99.0	98.9	98.8	99.1
ADJUSTED													
0-19	97.1	96.8	99.6	100.0	99.1	99.1	99.5	99.5	100.0	99.5	100.0	99.1	98.7
20-44	99.3	99.1	99.2	99.2	99.5	99.5	99.0	99.4	99.0	99.3	98.8	99.4	99.5
45-64	97.7	98.3	98.0	98.2	97.8	98.6	97.8	98.5	98.8	98.4	98.5	98.2	98.8
65+	100.0	81.2	90.6	100.0	94.4	97.1	96.6	94.3	97.5	97.9	97.9	97.3	97.5
Male	95.6	95.9	96.5	96.9	96.9	97.8	97.7	96.9	97.4	97.6	97.7	97.7	98.1
Female	97.9	95.8	97.4	98.7	97.5	98.2	95.9	98.5	98.7	98.2	97.6	97.5	98.1
White	96.5	95.9	96.9	97.7	96.8	98.2	97.1	97.8	97.9	98.0	97.6	97.7	98.0
Black	96.9	95.5	97.2	98.6	98.2	96.5	95.8	97.0	97.8	97.4	97.8	97.6	98.6
Other race	100.0	96.4	97.0	96.3	100.0	100.0	100.0	97.3	100.0	97.9	98.6	98.5	98.5
Diabetes	96.6	96.9	96.5	97.6	97.3	98.5	96.6	97.7	97.0	98.2	97.0	97.5	98.5
Hypertension	98.2	98.6	97.1	97.3	97.2	97.4	97.5	98.9	99.0	97.4	98.5	99.2	98.4
Glomerulonephritis	99.0	96.9	99.1	98.4	98.0	99.4	98.6	98.4	98.8	98.0	99.2	98.0	98.5
Other cause	95.6	94.8	97.2	98.9	97.9	97.5	97.1	97.3	98.6	98.5	97.8	97.5	98.1
All	96.6	95.8	96.9	97.7	97.1	97.9	96.9	97.6	97.9	97.8	97.7	97.6	98.1

Patients of unknown age, gender, race, or primary diagnosis are excluded.

Age is calculated as of the day of transplant.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

"." Zero values in this cell.

Table I.37

Two-year patient survival probabilities: first transplants, living donors*by age, gender, race/ethnicity, primary diagnosis, & transplant number*

UNADJUSTED	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002
0-4	95.0	96.6	98.1	98.7	100.0	98.3	96.8	97.1	98.3	98.3	97.9	98.7	97.0
5-9	94.0	100.0	100.0	95.8	98.0	100.0	100.0	97.3	100.0	100.0	100.0	100.0	98.4
10-14	89.4	96.7	95.8	100.0	100.0	100.0	97.9	100.0	100.0	100.0	100.0	96.8	98.8
15-19	94.8	99.3	97.1	99.4	99.4	98.2	100.0	98.3	99.3	98.8	98.8	99.5	99.4
20-29	98.5	98.5	99.1	99.2	99.1	98.4	99.1	99.0	98.5	99.1	98.5	98.1	98.6
30-39	97.4	97.7	98.5	98.2	98.6	98.3	97.7	98.6	98.0	98.4	98.8	98.3	98.6
40-49	98.3	96.9	98.1	97.9	96.2	97.8	97.6	97.3	97.6	97.6	97.4	97.4	97.8
50-59	93.5	96.0	95.8	96.3	95.9	94.6	95.6	97.0	96.8	97.4	95.2	96.4	96.3
60-64	96.6	93.0	89.2	96.2	93.9	94.0	96.0	96.3	97.6	95.6	95.8	95.5	94.1
65+	84.2	93.8	92.3	89.2	90.2	88.2	94.6	93.5	91.6	93.1	93.9	93.0	92.4
Male	96.7	97.3	97.9	98.1	97.7	97.3	97.6	98.1	97.4	97.2	96.7	97.3	96.9
Female	96.3	97.9	97.4	97.9	97.5	97.3	97.5	97.3	97.9	98.5	97.7	96.8	97.1
White	96.3	97.5	97.8	98.1	97.9	97.3	97.8	97.8	97.7	97.7	97.2	97.1	96.9
Black	97.8	97.3	96.8	97.5	96.4	97.3	95.6	96.7	96.8	97.2	96.8	96.9	96.7
Other race	100.0	100.0	97.4	98.8	96.6	97.6	100.0	100.0	98.6	100.0	97.4	98.3	98.2
†Hispanic							98.5	98.9	98.1	98.6	96.8	97.8	97.5
†Non-Hispanic							97.4	97.6	97.5	97.6	97.2	97.0	96.9
Diabetes	97.2	94.9	96.3	96.3	96.6	94.8	96.7	96.0	95.8	95.5	94.6	95.3	95.5
Hypertension	95.3	98.4	98.0	96.9	97.0	97.2	95.8	97.8	97.6	98.4	97.0	97.2	96.7
Glomerulonephritis	97.4	98.7	98.4	99.3	98.4	98.1	98.8	99.2	98.8	98.4	98.3	98.2	97.9
Other cause	95.6	98.1	97.7	98.4	97.9	98.2	97.8	97.4	97.9	98.5	98.1	97.6	97.4
All	96.5	97.6	97.7	98.1	97.6	97.3	97.6	97.7	97.6	97.8	97.2	97.1	97.0
ADJUSTED													
0-19	88.5	97.1	95.2	98.2	99.5	98.2	98.1	97.5	99.0	98.5	98.9	98.5	98.1
20-44	97.5	97.3	98.1	98.3	98.1	97.9	97.5	98.0	97.9	97.6	98.1	97.4	97.9
45-64	94.7	95.4	96.6	96.5	94.5	95.2	96.2	96.4	96.4	97.0	95.6	95.9	96.1
65+	84.1	94.1	78.6	85.9	91.4	86.5	93.3	93.1	91.8	93.9	92.3	93.6	91.8
Male	88.6	91.0	93.0	94.0	93.0	92.4	93.6	94.8	93.7	93.6	93.0	94.3	93.7
Female	89.1	94.0	92.8	94.3	93.5	93.1	94.1	93.5	95.1	96.5	95.1	93.5	94.3
White	87.9	92.0	93.2	94.2	93.9	92.5	94.3	94.3	94.5	94.8	94.0	93.8	94.0
Black	93.2	93.0	92.0	93.7	91.4	94.0	90.7	93.0	93.2	94.3	93.9	94.1	93.8
Other race	100.0	100.0	92.9	97.0	92.7	94.3	100.0	100.0	97.3	100.0	94.9	97.1	97.0
Diabetes	94.1	90.0	92.9	93.1	93.9	91.3	94.5	93.6	93.4	93.3	92.1	93.3	93.9
Hypertension	90.0	96.4	95.9	94.2	94.1	94.9	92.8	96.3	95.9	97.4	95.3	95.7	95.3
Glomerulonephritis	91.4	95.9	95.2	97.9	95.3	94.7	96.7	97.8	97.0	96.1	96.1	96.0	95.5
Other cause	87.1	93.7	93.3	95.4	93.9	94.9	94.3	93.8	94.9	96.4	95.9	94.8	94.6
All	88.7	92.3	92.8	94.1	93.2	92.6	93.8	94.2	94.3	94.8	93.8	93.9	93.9

Patients of unknown age, gender, race, or primary diagnosis are excluded.

Age is calculated as of the day of transplant.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

"." Zero values in this cell.

Table I.38

Three-year patient survival probabilities: first transplants, living donors*by age, gender, race/ethnicity, primary diagnosis, & transplant number*

UNADJUSTED	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
0-4	96.1	95.0	96.6	96.2	98.7	100.0	98.3	96.8	97.1	98.3	98.3	95.7	98.7
5-9	98.0	94.0	100.0	98.4	95.8	98.0	98.3	98.2	97.3	100.0	100.0	97.8	100.0
10-14	100.0	89.4	96.7	93.8	100.0	100.0	100.0	97.9	100.0	99.0	99.0	100.0	95.8
15-19	98.4	94.2	98.6	95.7	98.8	99.4	98.2	98.8	97.2	99.3	98.1	98.8	97.9
20-29	96.3	98.1	97.4	98.0	97.3	97.6	97.3	97.0	98.4	97.6	97.8	98.2	97.2
30-39	97.9	95.2	95.4	97.3	96.5	97.4	97.7	96.9	97.2	96.2	97.2	98.2	97.0
40-49	94.2	96.0	94.8	96.5	95.9	94.7	96.2	95.8	95.3	96.1	95.9	95.9	95.5
50-59	90.8	92.9	93.0	93.5	91.6	90.8	91.6	93.9	95.0	94.6	93.9	92.3	94.4
60-64	96.9	96.6	90.7	85.1	89.7	86.6	90.5	92.6	93.1	94.2	87.1	92.9	90.6
65+	100.0	78.9	93.8	92.3	81.1	82.9	83.8	90.2	88.0	86.7	90.0	89.3	90.4
Male	96.0	95.1	95.5	96.2	95.8	95.9	95.9	95.9	96.3	95.5	95.0	94.9	95.5
Female	96.6	95.5	96.4	95.9	96.0	95.2	95.8	96.0	95.7	96.5	96.1	96.1	95.0
White	96.1	94.9	96.0	96.5	95.8	96.0	95.8	96.1	96.2	95.9	95.5	95.2	95.3
Black	96.2	96.7	94.7	93.5	96.1	94.5	95.7	94.2	95.0	95.4	94.1	96.1	94.4
Other race	100.0	100.0	98.6	96.1	96.5	92.2	97.6	99.2	97.7	97.1	99.4	96.9	97.5
†Hispanic								96.7	97.8	96.7	97.0	95.8	96.7
†Non-Hispanic								95.8	95.8	95.8	95.2	95.4	95.1
Diabetes	94.3	94.1	90.4	93.5	92.7	92.8	91.9	93.5	92.4	92.6	91.8	92.1	92.6
Hypertension	95.6	94.2	97.1	96.3	93.9	94.5	95.3	93.6	95.4	95.4	95.7	94.9	96.0
Glomerulonephritis	97.6	96.6	97.9	96.9	97.9	97.1	97.2	97.6	98.5	98.0	97.0	97.2	96.5
Other cause	96.5	95.1	97.5	96.7	96.7	96.6	97.3	97.0	96.3	96.6	96.4	96.6	96.0
All	96.3	95.3	95.9	96.1	95.9	95.6	95.9	95.9	96.1	95.9	95.5	95.4	95.3
ADJUSTED													
0-19	98.3	88.5	96.6	92.7	97.8	99.5	97.7	96.7	97.0	98.5	98.1	97.8	98.0
20-44	95.2	95.5	95.4	96.5	95.9	96.4	96.7	95.6	96.2	96.0	96.0	97.2	95.4
45-64	91.9	93.2	91.9	93.6	91.9	90.1	92.4	93.8	93.9	94.0	92.8	92.9	93.3
65+	100.0	79.0	94.1	76.1	79.0	82.8	80.9	89.5	87.1	86.8	89.4	87.4	90.9
Male	85.9	83.5	85.6	87.7	86.9	87.9	88.6	89.3	90.5	89.2	88.7	89.2	90.5
Female	89.8	86.9	89.8	89.1	89.2	87.8	89.5	90.5	89.8	91.9	91.1	91.7	89.9
White	87.0	84.0	87.5	89.2	87.4	88.6	88.5	90.0	90.2	90.3	89.9	89.8	90.3
Black	89.0	90.0	86.3	84.7	90.4	87.0	90.6	87.9	89.5	90.3	88.1	92.6	89.4
Other race	100.0	100.0	96.7	89.3	91.0	84.0	94.3	98.3	95.5	94.7	98.6	93.9	95.7
Diabetes	88.3	87.8	81.8	87.8	86.5	87.3	86.6	89.5	87.8	88.3	87.9	88.6	89.6
Hypertension	89.9	87.7	93.7	92.6	88.6	89.4	91.8	89.0	92.2	92.3	93.1	92.2	93.9
Glomerulonephritis	92.2	88.8	93.5	91.0	93.7	91.6	92.2	93.7	96.2	94.8	93.0	93.5	92.2
Other cause	88.6	85.7	91.9	90.6	90.7	90.4	92.6	92.3	91.2	92.1	91.6	92.8	91.4
All	87.5	84.9	87.4	88.2	87.8	87.7	88.9	89.8	90.1	90.3	89.7	90.2	90.2

Patients of unknown age, gender, race, or primary diagnosis are excluded.

Age is calculated as of the day of transplant.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

"." Zero values in this cell.

Table I.39

Five-year patient survival probabilities: first transplants, living donors*by age, gender, race/ethnicity, primary diagnosis, & transplant number*

UNADJUSTED	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-4	89.1	91.7	96.1	95.0	96.6	94.3	97.4	100.0	96.6	96.8	97.1	98.3	98.3
5-9	97.3	93.9	98.0	92.0	98.5	98.4	93.7	98.0	98.3	98.2	97.3	100.0	100.0
10-14	97.6	94.8	98.9	85.9	94.5	92.7	98.0	98.9	98.0	95.8	96.5	98.0	98.1
15-19	94.5	93.7	97.6	92.9	98.0	95.7	96.4	99.4	96.5	96.5	92.0	97.8	96.3
20-29	92.3	95.3	93.8	96.3	96.2	96.0	95.6	95.0	93.7	95.3	95.6	95.1	95.8
30-39	92.2	89.6	94.3	91.7	91.7	94.1	93.1	93.3	95.1	93.9	92.1	92.5	94.5
40-49	92.3	89.0	88.7	91.3	88.7	89.5	90.6	90.4	91.8	90.9	91.5	91.2	92.3
50-59	87.7	87.2	82.4	82.7	85.1	88.6	82.6	83.7	85.0	86.9	87.0	85.8	87.7
60-64	84.2	68.4	84.4	79.3	83.7	74.3	76.9	70.7	81.0	87.9	81.9	82.7	76.3
65+	80.0	85.7	100.0	68.4	87.5	84.6	70.3	70.7	75.0	80.4	76.9	69.2	78.8
Male	91.4	91.8	92.9	91.8	92.2	92.7	91.7	91.2	91.9	91.9	90.8	89.7	90.6
Female	92.0	91.0	92.2	91.0	92.3	91.8	91.4	91.6	91.7	92.0	90.6	91.2	92.0
White	91.7	92.7	92.7	90.9	92.6	92.7	91.7	91.9	91.6	92.3	90.8	90.5	91.3
Black	90.8	85.1	90.2	94.6	90.1	89.5	91.0	89.0	92.0	90.0	89.3	89.1	89.1
Other race	94.1	84.3	98.2	95.2	93.1	93.4	89.4	89.7	95.2	92.4	94.7	92.9	95.2
†Hispanic										93.2	93.5	93.3	93.7
†Non-Hispanic										91.8	90.3	89.9	90.8
Diabetes	84.1	84.1	88.6	87.9	83.1	85.5	84.1	84.4	84.9	86.3	83.8	82.9	82.8
Hypertension	94.0	86.6	89.6	87.7	91.4	92.3	89.6	88.4	89.4	88.5	89.5	88.9	91.0
Glomerulonephritis	95.0	96.0	95.5	94.3	95.2	94.4	95.4	95.5	95.3	94.5	94.8	94.6	94.4
Other cause	92.2	93.3	93.3	91.9	96.3	94.3	93.4	93.5	93.8	95.1	91.7	92.6	93.9
All	91.7	91.5	92.6	91.5	92.3	92.3	91.5	91.4	91.8	92.0	90.7	90.4	91.2
ADJUSTED													
0-19	91.7	90.0	97.3	85.5	95.1	91.6	94.7	98.9	96.3	93.9	92.0	98.0	97.1
20-44	89.8	90.6	90.8	91.9	91.5	92.4	92.2	91.7	92.0	91.7	90.6	91.5	92.3
45-64	87.3	81.5	83.3	82.8	83.4	85.9	82.6	82.2	85.6	87.4	85.8	84.8	86.1
65+	78.4	76.4	100.0	68.9	88.2	63.5	63.1	70.1	70.8	80.0	76.2	70.3	77.3
Male	75.2	72.7	76.3	73.6	76.2	77.8	75.8	75.5	78.5	79.9	77.6	76.8	79.5
Female	78.9	74.0	77.7	75.5	79.4	78.9	78.0	79.4	80.0	81.9	78.9	80.8	82.5
White	76.5	76.4	77.0	73.2	78.0	78.7	76.6	78.1	78.2	81.2	77.8	78.6	81.2
Black	78.4	62.0	73.5	83.8	75.9	76.3	79.1	75.3	82.9	79.6	78.5	78.0	78.7
Other race	84.7	58.4	95.7	88.6	84.0	82.2	75.2	79.1	88.6	85.2	89.7	87.0	89.2
Diabetes	70.5	68.5	77.5	76.2	69.5	74.2	72.0	73.6	75.7	78.4	75.0	74.2	75.4
Hypertension	88.2	72.4	77.4	75.2	82.0	84.8	81.1	78.5	81.9	80.7	82.9	82.2	85.9
Glomerulonephritis	86.1	87.3	86.0	82.0	85.4	84.2	86.6	87.2	87.2	85.9	87.1	86.5	87.0
Other cause	81.2	78.4	79.3	77.4	88.2	84.0	81.8	82.2	83.6	87.7	80.9	83.3	86.2
All	76.7	73.1	76.8	74.2	77.4	78.1	76.6	77.1	79.0	80.7	78.0	78.4	80.6

Patients of unknown age, gender, race, or primary diagnosis are excluded.

Age is calculated as of the day of transplant.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

"." Zero values in this cell.

Table I.40
Ten-year patient survival probabilities: first transplants, living donors

by age, gender, race/ethnicity, primary diagnosis, & transplant number

UNADJUSTED	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994
0-4	68.4	70.4	94.3	90.3	90.7	87.5	85.4	94.1	95.0	91.5	90.6	94.7	97.1
5-9	75.0	88.0	95.5	96.2	89.2	83.8	90.9	96.1	90.0	95.5	93.4	91.7	92.0
10-14	90.3	84.1	86.5	94.9	85.6	89.4	90.6	89.1	81.2	87.9	88.5	90.1	93.1
15-19	89.0	89.6	85.0	87.7	84.8	85.5	90.9	91.3	85.8	91.2	83.5	88.1	89.8
20-29	80.4	78.9	83.6	82.0	82.0	81.5	90.5	85.9	88.1	87.9	84.4	87.2	88.2
30-39	71.6	74.3	75.6	73.6	78.8	78.6	75.6	82.2	80.3	79.7	81.2	80.6	81.7
40-49	64.9	66.8	65.9	68.7	70.1	69.7	66.5	73.4	72.7	70.6	72.7	72.6	71.1
50-59	42.3	63.8	66.2	61.7	60.3	66.9	63.2	56.2	53.0	55.2	59.7	57.0	56.2
60-64	55.6	50.0	65.0	58.1	67.9	47.4	52.6	46.9	37.9	58.1	41.9	47.4	51.2
65+	.	33.3	33.3	12.5	34.6	52.0	28.6	0.0	47.4	68.8	53.8	24.3	34.1
Male	72.5	74.7	76.8	73.7	74.2	74.8	80.0	79.7	79.1	79.4	77.6	77.1	76.7
Female	75.9	77.1	78.5	78.9	78.4	77.6	79.7	81.3	77.9	78.3	75.9	77.2	77.2
White	73.4	76.3	78.0	76.5	76.0	76.3	80.9	80.3	78.8	79.7	77.4	78.0	77.8
Black	75.1	71.4	72.4	70.6	72.0	73.2	73.9	77.6	75.0	73.8	73.3	73.1	71.3
Other race	76.2	77.8	83.3	80.0	85.3	78.4	76.5	90.9	82.3	79.2	77.6	76.5	79.3
Diabetes	52.2	51.8	54.4	54.4	57.7	59.7	63.2	67.8	64.9	58.5	58.7	57.7	59.3
Hypertension	70.0	76.8	82.5	72.8	74.6	75.3	72.6	77.6	72.5	76.2	73.7	73.9	71.3
Glomerulonephritis	83.8	82.8	81.7	83.6	83.4	82.3	87.2	86.4	84.5	84.2	82.0	84.8	84.8
Other cause	74.8	79.7	83.4	81.9	80.7	79.9	85.8	83.3	83.1	89.2	84.1	83.4	83.7
All	73.7	75.6	77.4	75.8	75.9	75.9	79.9	80.4	78.6	78.9	76.9	77.2	76.9
ADJUSTED													
0-19	79.9	77.3	84.8	88.3	82.3	80.6	84.1	89.3	79.8	86.3	83.2	86.2	88.2
20-44	66.7	67.9	71.2	71.2	72.6	73.6	76.6	77.7	79.1	76.8	75.2	77.2	77.6
45-64	47.7	58.8	58.1	57.5	60.1	59.3	57.4	56.5	50.1	57.6	57.0	56.7	56.1
65+	0.0	52.2	48.3	27.0	36.2	38.6	27.7	32.5	40.7	59.8	42.4	22.0	35.5
Male	33.8	37.4	41.1	40.9	41.9	42.9	45.8	46.1	45.7	48.0	46.1	45.8	46.4
Female	41.1	44.6	47.1	50.2	51.3	50.7	50.1	54.2	49.0	51.2	48.3	50.4	52.0
White	36.0	39.9	44.2	44.9	45.5	46.1	49.2	49.3	47.8	50.0	47.0	48.1	49.6
Black	42.1	42.3	40.2	42.5	45.0	47.4	42.1	48.2	43.2	46.4	48.3	47.0	45.3
Other race	43.2	47.6	56.9	55.1	64.1	53.3	44.8	78.4	61.4	56.9	49.5	51.8	60.3
Diabetes	26.3	25.8	28.6	31.5	34.0	37.0	38.1	45.1	41.3	36.5	37.9	36.4	40.2
Hypertension	41.5	59.2	65.6	52.5	56.1	56.6	49.2	55.9	50.7	55.8	53.7	56.2	51.7
Glomerulonephritis	55.3	53.2	53.3	58.2	60.8	58.2	63.9	62.3	56.8	59.1	56.3	61.5	61.5
Other cause	43.7	51.1	58.1	58.8	57.1	56.8	59.5	55.5	57.8	69.2	60.7	59.1	60.0
All	36.4	40.1	43.3	44.2	45.4	45.8	47.4	49.3	46.8	48.9	46.7	47.4	48.5

Patients of unknown age, gender, race, or primary diagnosis are excluded.

Age is calculated as of the day of transplant.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

." Zero values in this cell.